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OVERVIEW 
 
Cardiovascular disease (CVD) is the leading cause of death in most developed 
countries. In addition to environmental risk factors, such as diet and physical activity, 
genetic risk factors contribute to the CVD risk. Risk of CVD is not uniformly distributed 
across populations, as African Americans and Hispanics have more risk factors for CVD 
compared with European Americans, yet prevalence remins higher in Europeans. 
Although the genetics of CVD are well-studied in European Americans, few studies have 
been performed in minority populations.  
CVD is common and complex, and while there has been progress determining the 
genetic risk factors, there is inconsistency across studies. One likely contributor to this 
discrepancy in the literature is probably due to phenotypic heterogeneity across studies.  
The use of quantitative traits to identify genetic risk factors is a potentially more 
powerful, informative and uniform approach compared with the use of binary or 
qualitative traits (such as CVD case status). The primary objective of this work is to 
identify genetic risk factors associated with the regulation of fibrinogen/hematological 
and electrocardiogram (ECG) traits in African Americans. Both fibrinogen/hematological 
and ECG traits are common clinical characteristics of CVD and have a strong genetic 
component. Using three approaches: candidate gene, genome-wide association studies 
(GWAS), and testing for genetic interactions (gene-gene and gene-environment), we 
identify novel and previously identified genetic associations with ECG traits and 
fibrinogen/hematological traits in African Americans and other global populations. 
xvii 
 
Chapter I gives an in-depth description of the biology and epidemiology of ECG 
and fibrinogen/hematological traits. The advantages of using quantitative traits compared 
to disease outcomes, as well as their role in CVD risk are highlighted. Additional 
background information about what is known concerning the genetics of ECG and 
fibrinogen/hematological traits and what has yet to be determined is also discussed. 
Lastly, the current state of genetics for ECG and fibrinogen/hematological traits in 
diverse populations is described, highlighting the potential advantages and obstacles.   
Chapter II focuses on ECG traits in African Americans. In section A, we 
performed a candidate gene study with 65 variants in a sodium channel gene, SCN5A, in 
>3,000 African Americans from the Jackson Heart Study. In this section we also tested 
for replication of significant associations in an independent study population of non-
Hispanic blacks from the Third National Health and Nutrition Examination Survey 
(NHANES III). In section B, we conducted a genome-wide association study (GWAS) in 
455 African Americans from the Vanderbilt Genome-Electronic Records Project and 
Northwestern University NUgene Project. We identified novel associations, as well as 
determined the generalizability of previous GWAS findings, originally identified in 
European and/or Asian populations, in African Americans. In the last section of this 
Chapter, we tested for gene-gene interactions between variants in the SCN5A gene. Then 
we tested for gene-environment interactions with environmental risk factors age and sex 
with variants in the SCN5A gene. 
Chapter III focuses on identifying genetic variants associated with fibrinogen and 
hematological traits in African Americans. In section A we tested 25 variants in the three 
genes that encoded the fibrinogen polypeptide, FGA, FGB, and FGG for an association 
xviii 
 
with fibrinogen levels in non-Hispanic blacks from NHANES III.  We also tested these 
variants for pleiotropic effects with hematological traits: platelet count, platelet 
distribution width, mean platelet volume, white blood cell counts and serum triglycerides 
also recorded in NHANES III.  Section B focuses on the generalization of previously 
identified GWAS associations for fibrinogen and hematological traits in the combined 
NHANES dataset of non-Hispanic blacks. In the last section of this chapter we 
investigate the role genetic modifiers (gene-gene and gene-environment interactions) 
have on fibrinogen levels. This section was limited to variants in the fibrinogen gene 
cluster in non-Hispanic blacks from NHANES III. 
Replication and generalization of significant genetic associations is important in 
confirming genetic disease risk. In Chapter IV, we replicate and generalize findings in 
Chapter II and III in non-Hispanic whites and Mexican Americans from NHANES. In 
section A, we focus on the ECG traits. We tested SCN5A significant associations for 
generalization in non-Hispanic whites and Mexican Americans from NHANES III. In this 
section we also replicate previously identified GWAS variants for ECG traits in non-
Hispanic whites and generalize these variants in Mexican Americans. Using the same 
approach in section B of this chapter, we performed all tests in non-Hispanic blacks 
(from Chapter III) with fibrinogen and hematological traits in non-Hispanic whites and 
Mexican Americans in NHANES III and 99-02.  
Chapter V summarizes Chapters II-IV, specifically discussing the limitations and 
strengths of our findings. In this chapter we describe how these results contribute to the 
little known about the quantitative traits of cardiovascular disease in African Americans. 
xix 
 
Additionally, we discuss future analyses using alternative approaches not described here 
for identifying genetic risk variants in African Americans.  
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CHAPTER I 
 
INTRODUCTION 
 
Cardiovascular Disease 
 Cardiovascular disease (CVD) is a class of diseases that involve the heart and/or 
blood vessels (Arking and Chakravarti, 2009; Mendis et al., 2011). Cardiovascular 
disease is not a single disease nor is it limited to diseases that affect the heart. Some of 
the most common CVDs include atherosclerosis, cerebrovascular disease (commonly 
referred to as stroke), diseases of the aorta and arteries (arterial thrombosis), 
hypertension, coronary heart disease, and myocardial infarction (MI, commonly referred 
to as a heart attack). Cardiovascular disease also includes aneurysms, angina (chest 
pains), peripheral vascular disease, cardiac arrhythmias, rheumatic heart disease, 
cardiomyopathies, pericarditis, cardiac tumors, myocarditis, and congenital heart disease 
(Mendis et al., 2011).  
Clinicians often diagnosis patients with heart disease if the patient has recently 
had a heart attack, stroke, or has been previously diagnosed with hypertension or 
atherosclerosis. There are several clinical procedures to confirm cardiovascular disease in 
patients. Some of the most common procedures include an electrocardiogram, complete 
blood exam, coronary angiographs, echocardiographs, and nuclear scans(2009a). 
 Cardiovascular disease is the leading cause of death worldwide and is responsible 
for over 17.3 million deaths per year (2011). Greater than 80% of these deaths are in 
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middle to low income countries (2009b). While the highest rates for CVDs are in low and 
middle income countries, it is also the leading cause of death in the United States and 
most developed countries (Figure 1.1) (Lloyd-Jones et al., 2009; 2009b). The correlation 
with income and CVD status is also observed in the United States (US), particularly in 
the southeastern states which have the highest prevalence of CVD in the US (Lloyd-Jones 
et al., 2009). In developed countries, the majority of CVD cases in Americans are in 
relatively young individuals. Over 80 million Americans have one or more CVDs, but 
only 38 million are ≥ 60 years of age (Lloyd-Jones et al., 2009). In addition to age, there 
is a difference in CVD disease incidence between men and women. In previous years, 
CVD was higher in males compared to females, but recent data suggest that females have 
a slightly higher prevalence of CVD (Lloyd-Jones et al., 2009).  Racial disparities also 
exist in the United States for cardiovascular diseases. Europeans have higher prevalence 
of CVD compared to other race/ethnicities in the US but African Americans have the 
highest mortality rates (Thom et al., 2006; Lloyd-Jones et al., 2009). 
 There are several reasons that explain the increased  CVD prevalence in recent 
years. Cardiovascular diseases have a complex etiology and are likely caused by a 
combination of several risk factors. Increased age has been consistently associated with 
CVD risk, and being male increases this risk among middle-aged individuals (Mendis et 
al., 2011; Mendis, 2005; Lloyd-Jones et al., 2009; Thom et al., 2006). Modifiable risk 
factors include diet, exercise, stress, and tobacco use, all of which are directly impacted 
by an individual’s lifestyle (Yusuf et al., 1998; Grundy, 1980; Grundy et al., 1999). These 
risk factors can subsequently lead to elevated lipid levels, high blood pressure, and high 
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blood glucose, all of which are associated with CVD and affect over 34% of American 
adults (Lloyd-Jones et al., 2009; Kannel and McGee, 1979; Wilson et al., 1998).  
In addition to these risk factors, CVD has a large genetic component.  Heritability 
studies of CVD risk factors and other CVD related phenotypes report that anywhere from 
20-80% of the phenotypic variance is explained by genetic factors (Rose et al., 1998; 
Hunt et al., 2002; Tholin et al., 2005; Hunt et al., 1989; Nelson et al., 2000; Poulsen et al., 
1999; Feinleib et al., 1977). CVD outcome variables and traits have been described in 
familial studies and are said to “run in families” (Bhagavatula et al., 2004; Mjos et al., 
1977; Thelle and Forde, 1979; Snowden et al., 1982). Additionally, linkage studies and 
small sequencing studies have identified rare genetic mutations associated with 
cardiovascular disease and related phenotypes (Benson et al., 1996; London et al., 2007; 
Best et al., 2008). More often than not, these mutations are rare and family-specific and 
are usually not observed at the population level. The work contained herein is focused on 
identifying the common genetic factors underlying cardiovascular disease risk in the 
general population. 
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Figure 1.1 Major causes of death among Americans. Causes of deaths among both 
sexes in the United States in 2005. (Obtained from the National Center for Health 
Statistics (NCHS) and the National Heart, Lung, and Blood Institute (NHLBI) (Lloyd-
Jones et al., 2009). Abbreviations: Cardiovascular Disease (CVD), Chronic Lower 
Respiratiry Disease (CLRD) 
 
 
Quantitative Traits Associated with Cardiovascular Disease  
More often than not, patients are diagnosed with CVD based on a clinical 
outcome event, such as myocardial infarction or stroke. Individuals diagnosed with CVD 
usually have other diseases that may have contributed to the development of CVD over 
time. Identifying and treating these diseases or conditions before diagnosis of CVD may 
reduce the likelihood of life threatening cardiovascular events such as myocardial 
infarction and stroke. The use of quantitative measurements or intermediate phenotypes is 
an accurate method of identifying patients at high-risk for CVD (Vasan, 2006). There are 
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several quantifiable biological parameters that are often used by clinicians to identify 
high-risk CVD patients. As previously mentioned, electrocardiographic (ECG) 
measurements, echocardiograms, inflammation markers, blood glucose measurements, 
and lipid levels are common procedures/measurements used to asses CVD status. An 
electrocardiogram measures and records the electrical activity of the heart, while an 
echocardiogram is a test that uses sound waves to create a visual image of the heart. Both 
tests provide information about the physical condition of the heart including: damage to 
the heart, heart rhythm, size and position of the heart chambers, abnormal heart valves, 
heart murmurs, infections around the heart or on the heart valves, and the source of blood 
clots. Recently, inflammation markers such as fibrinogen levels, white blood cell count, 
and C-reactive protein have been associated with CVD (Pearson et al., 2003). Elevated 
levels of inflammatory markers can lead to arterial thrombosis that is caused by a clot in 
the arteries thereby limiting the blood supply to the heart.  
Using intermediate or quantitative traits is an excellent alternative to using 
clinical outcomes for complex diseases such as CVDs. Given the complexity of CVD, it 
is likely that different genetic etiologies explain several traits or intermediate phenotypes 
of CVD. Quantitative measurements are more robust to phenotypic heterogeneity and are 
often more uniform and informative compared to disease outcomes. Additionally, 
quantitative traits also have more statistical power compared to disease outcome 
variables. The research reported in succeeding chapters will focus on two groups of 
quantitative phenotypes associated with cardiovascular disease: electrocardiographic 
(ECG) traits and fibrinogen levels (and/or other hematological traits).    
Electrocardiographic Traits 
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An electrocardiogram (ECG) is a common clinical procedure usually performed on 
patients who are at high risk for CVD or experience chest pain or dizziness (Micheal A 
Chizner, 2004). An ECG measures the electrical activity of the heart and is a useful tool 
in assessing cardiac arrhythmias, myocardial infarction, pericarditis, and other cardiac 
abnormalities (Micheal A Chizner, 2004). The ECG records electrical depolarization and 
repolarization of the heart and provides information about the electrical activity of the 
cardiac cycle. An ECG records the duration, amplitude, and direction of electrical activity 
during the cardiac cycle. The most commonly used ECG has twelve leads (a record of 
electrical activity between two electrodes), which provides measurements for both the 
frontal and horizontal planes and captures views of the left ventricle from twelve 
different angles (Aehlert, 2006). ECG duration measurements (P, PR, QRS, QT, ST and 
T durations) reflect the time spent for depolarization or repolarization in each phase of 
cardiac conduction (Micheal A Chizner, 2004).  ECG axes (P, QRS and T) values 
represent the direction and position of myocardial cell depolarization. Usually the P 
wave, a QRS complex, and a T wave  are visible on the ECG (Figure 1.2A). The ECG 
begins with the P wave which occurs during atrial depolarization, and represents the 
electrical impulse from the sinoatrial (SA) node towards the atrioventricular (AV) node 
that then spreads to the left and right atrium.  The PR interval is the time the electrical 
impulse takes to go to the sinus node to the AV node then to the ventricles (lower 
chambers of the heart). It is measured from the P wave to the start of the QRS complex 
(Figure 1.2). The QRS marks the start of depolarization of the ventricles, and the ST 
segment represents the ventricle once they have fully depolarized (Figure 1.2). After 
depolarization, the left and right ventricles repolarize, represented as the T wave on the 
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ECG. The QT interval represents the time it takes the ventricles to depolarize and 
repolarize and is measured in the ECG from the start of the QRS complex to the end of 
the T wave (Figure 1.2). 
A.  
B.  
Figure 1.2 An example of a normal electrocardiograph. (A. Obtained from 
http://www.dentalarticles.com/visual/d/index.php B. http://www.meditech.cn/meditech-
edu/ecg-2.asp ) 
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The risk profile of an individual with an abnormal ECG is consistent with 
individuals diagnosed with other CVD outcomes such as myocardial infarction. In 
addition to traditional risk factors such as age and sex,  hyperlipidemia, 
hyperinsulinaemia, and hypertension are also associated with ECG traits (Lind et al., 
1997).  As with other CVD outcome variables, a considerable amount of ECG traits are 
variability can be explained by genetics. Several twin studies report heritability estimates 
as much as 30-60% of the variability in ECG traits attributable to genetic factors 
(MATHERS et al., 1961; Perez and Keith, 1978; Havlik et al., 1980; Hanson et al., 1989; 
Kupper et al., 2004; Moller et al., 1982; Russell et al., 1998).  These twin studies 
established the framework for subsequent studies designed to discover the genetic 
variants underlying the reported heritability. 
Several genetic association studies of ECG traits have been focused on genes that 
encode for proteins in voltage-gated ion channels(George, Jr. et al., 1995; Gouas et al., 
2005b; Newton-Cheh et al., 2009; George, Jr., 2005; Lai et al., 1994; Gellens et al., 1992; 
Abriel and Kass, 2005). Voltage-gated ion channels are integral membrane proteins that 
allow the certain ions to pass across the cell membrane. Ion channels play an important 
role in generating electrical impulses thereby producing action potentials in myocytes 
(heart cells). Candidate gene studies have identified several genes throughout the genome 
that have an effect on heart depolarization and conduction measured by ECG traits. 
Several candidate gene and genome-wide association studies (GWAS) have identified 
polymorphisms in sodium and potassium channel genes that affect ECG measurements 
(Gouas et al., 2005b; Newton-Cheh et al., 2009; Schott et al., 1999; Wang et al., 1995a; 
Plant et al., 2006; Bezzina et al., 2006; Sotoodehnia et al., 2010; Baroudi et al., 2002; 
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Chambers et al., 2010; Smith et al., 2009b; Pfeufer et al., 2010; Rook et al., 1999; 
Baroudi et al., 2001). However, collectively these associations do not account for the all 
of the variability expected to be explained by genetic factors (<10% of the trait variability 
total). There have been few studies that have found associations in genes other than 
voltage-gated ion channels but the role these genes play in ECG trait variability is poorly 
understood. 
Fibrinogen Levels 
Fibrinogen is a glycoprotein made in the liver and is composed of three pairs of 
polypeptides: two Aα, two Bβ, and two γ (Hermans and McDonagh, 1982). Each 
polypeptide is encoded by genes (FGA, FGB, FGG ) that make up the fibrinogen gene 
cluster on chromosome 4. All three polypeptides are covalently linked to each other by 
disulfide bonds in an ordered process at the N-terminals.  Inflammatory markers, such as 
fibrinogen, are major risk factors for cardiovascular disease (Meade et al., 1986; Kannel 
et al., 1987; Green et al., 1994; Barasch et al., 1995; Lee et al., 1993; Heinrich et al., 
1994). Circulating fibrinogen plays a major role in the coagulation pathway. The 
coagulation pathway is a series of events that usually occurs following vascular injury 
resulting in the production of fibrin clots (Figure 1.3). Circulating fibrinogen is converted 
to fibrin, the main protein component of a fibrin clot, in the last stage of the coagulation 
pathway (Figure 1.3) (Collet et al., 1993; Voetsch and Loscalzo.J, 2003; Blomback et al., 
1978).  Fibrin clots can be formed in the veins or the arteries resulting in venous or 
arterial thrombosis, respectively (Mackman, 2008). Arterial thrombosis is responsible for 
known CVD outcomes, myocardial infarction and stroke, and has a strong association 
with fibrinogen levels (Feinbloom and Bauer, 2005; Voetsch and Loscalzo.J, 2003).  
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Fibrinogen levels can be measured from blood plasma and elevated levels is 
indicative of an acute infection, cancer, coronary heart disease, myocardial infarction, 
recent trauma, or an inflammatory disease (Abrahamsen et al., 2008; David Ginsburg, 
2005; Davi and Patrono, 2007; Fries et al., 2009). Normal plasma fibrinogen levels range 
from 1.5-4.0 g/L of blood. There are two common procedures used to measure levels of 
plasma fibrinogen: Clauss clotting assay and immunoassay(Mackie et al., 2003).  The 
Clauss clotting assay is a functional assay that determines the time it takes for fibrin clot 
formation whereas the immunoassay measures the fibrinogen antigen rather than 
functional fibrinogen. The Clauss clotting method is preferred to diagnose diseases 
related to thrombosis, such as arterial thrombosis (or atherosclerosis), compared with the 
immunoassay.  
 
Figure 1.3. Coagulation Pathway. Adapted from Mackman et al. (Mackman, 2008). 
 
Similar to ECG traits, CVD risk factors, such as sex (females), smoking, increased 
age, lack of exercise, and poor diet are associated with elevated fibrinogen levels 
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(Barasch et al., 1995; Lee et al., 1993; Heinrich et al., 1994).  However, after adjusting 
for these risk factors, a significant amount of the variance in fibrinogen remains 
unexplained. Heritability estimates for fibrinogen suggest that remaining variance could 
be explained by genetics. Twin studies report up to 50% of the trait variability for 
fibrinogen attributable to genetic factors (Voetsch and Loscalzo.J, 2003). To date most of 
the genetics studies have been focused on genes that encode hemostatic factors in the 
beginning stages of the coagulation pathway (Figure 1.3). Other studies have found 
several associations between variation in fibrinogen genes (FBA, FGB, and FGG) and 
fibrinogen levels (Siegerink et al., 2009; Boekholdt et al., 2001; Folsom et al., 2001; 
Koch et al., 2008; Hamsten et al., 1987). There has not been strong evidence for genes 
that alter fibrinogen levels besides those involved in the coagulation pathway. 
Hematological Traits 
Unlike fibrinogen and other well-studied coagulation factors, little is known about 
other factors measured in the blood and their association with cardiovascular disease risk.  
As previously mentioned, individuals with CVD are also diagnosed with arterial 
thrombosis or atherosclerosis. Unlike venous thrombosis, arterial thrombosis generally 
requires the rupture of the atherosclerotic plaque, which happens over time due to accrual 
of lipids in the arterial wall (Figure 1.4). Several factors such as platelets, which are 
recruited at the site of the ruptured plaque (platelet aggregation), are involved in the 
pathogenesis of arterial thrombosis and may ultimately increase CVD risk. 
Common hematological measurements include white blood cells (WBC), red blood 
cells (RBC), and platelets (PLT). These measurements are highly regulated in the body 
and can vary between individuals (Mackman, 2008; Soranzo et al., 2009).  Hematological 
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measurements are derived from a complete blood count (CBC) exam. A CBC exam is a 
common test ordered by clinicians to measure WBC, RBC, and PLT counts. Several 
other factors such as the concentration of hemoglobin (Hb), hematocrit (Hct) and the 
volumes of red blood cells and platelets (MCV and MPV, respectively) can also be 
derived from a CBC exam.  
There have been reports that hematological measurements have a genetic 
component. Heritability estimates for other traits such as Hb, WBC, and PLT range from 
0.37-0.89 (Pennington et al., 2001; Evans et al., 1999) .  Genetics also accounts for about 
20-30% of the variance in platelet aggregation (Lane and Grant, 2000). There have been 
several candidate gene studies that report association throughout the genome with 
hematological traits. More recently there have also been a few GWAS with 
hematological traits (Meisinger et al., 2009; Nalls et al., 2011; Soranzo et al., 2009). One 
study identified three common loci that were associated with mean platelet volume 
(Meisinger et al., 2009). Another GWAS from the Haem Gen Consortium identified 22 
loci that are associated with eight hematological traits in Europeans: Hb, RBC, WBC, 
PLT, MPV, MCV, mean corpuscular hemoglobin concentration (MCHC) and mean 
corpuscular content (MCH) (Soranzo et al., 2009). 
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Figure 1.4 Comparison of an arterial clot (a) compared to venous clot (b). Obtained 
from Mackman et al (Mackman, 2008). 
 
State of Cardiovascular Research in African Americans 
Over the past 30 years mortality rates for CVD has been higher in African 
Americans compared to Europeans (Liao and Cooper, 1995; Sempos et al., 1988; Lloyd-
Jones et al., 2009). Interestingly, the prevalence of CVD still remains higher in European 
Americans (Caucasians) compared to other ethnic groups in the United States, with the 
exception of southeastern states (Lloyd-Jones et al., 2009). Prevalence for CVD risk 
factors such as being hypertensive, diabetic, overweight, and having high levels of 
lipoprotein Lp (a) is higher in African Americans (Burt et al., 1995; Sorrentino et al., 
1992; Lloyd-Jones et al., 2009).  There has been considerable debate as to whether this 
disparity is due to differences in social risk factors such as education and income status, 
since these factors are associated with CVD risk regardless of race (Lloyd-Jones et al., 
2009; Sempos et al., 1999). Another explanation could be differences in genetic risk 
factors for CVDs and other related traits across populations (Ioannidis et al., 2004).  
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Several genetic association studies on rare CVDs and other related phenotypes 
such as diabetes have been performed in African Americans (Adeyemo et al., 2009; 
Cheng et al., 2009; Helgadottir et al., 2006; Hooper et al., 1999; Norris et al., 2005; Plant 
et al., 2006; Van Norstrand et al., 2008). Genetic association studies have not been 
extensively performed in African Americans for ECG and fibrinogen/hematological 
traits. Furthermore, the extent to which ancestry affects genetic risk factors is poorly 
understood for ECG traits and fibrinogen/hematological measurements. There are several 
genetic differences observed across populations such as differences in allele frequency,  
linkage disequilibrium (LD) patterns, and the amount of genetic variation (Rosenberg et 
al., 2010). Linkage disequilibrium is the non-random association of alleles in the genome. 
Numerous factors can influence LD patterns such as mutations and recombination. It is 
believed that since African populations were one of the first human populations to exist; 
Africans are more likely to have gone through more recombination events and have 
accumulated more mutations overtime (Rosenberg et al., 2010; Teo et al., 2010; Teo et 
al., 2009). Thus, in general African descent populations have more genetic variation and 
lower levels of LD in the genome compared to Europeans.  
Although genetic association studies have been performed in African descent 
populations, most studies have been performed in European populations. Furthermore, 
these studies use LD patterns in European populations (which have high LD) to select 
single nucleotide polymorphisms (SNPs) for genotyping. Identifying SNPs for 
genotyping using this approach is cost-effective but reduces the likelihood of identifying 
the true casual variant(s) in populations outside of Europeans. One solution is to use 
African descent populations to identify the true casual variant in the region where an 
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association has been identified in a European population. This is often achieved by 
densely genotyping or sequencing a region of interest in an African descent population, 
where more genetic variation exists. Another benefit to using diverse populations such as 
African Americans is to assess the extent to which results can be generalized to other 
populations. Generalization is defined here as a statically significant association with a 
consistent direction of effect observed across multiple populations. The generalization of 
results provides population-specific information about genetic risk variants, which can be 
useful in identifying the true casual variant for common diseases. Furthermore, 
determining whether an association generalizes is important for the clinical use of genetic 
risk variants for the diagnosis and treatment of common diseases for certain populations. 
Disparities for quantitative traits associated with CVD such as cardiac 
arrhythmias are also observed with African Americans (Go et al., 2001).  Genetic risk 
factors for CVDs such as sudden cardiac death (SCD) and long QT syndrome in African 
Americans have been suggested (Noseworthy and Newton-Cheh, 2008; Akylbekova et 
al., 2010; Plant et al., 2006; Van Norstrand et al., 2008). Multiple studies have suggested 
associations between SNPs in the sodium channel gene SCN5A with SCD. Interestingly, 
some of these studies have identified allelic associations that are population-specific and 
are not observed in other populations. For example, SCN5A S1103Y, a polymorphism 
unique to African descent populations, is associated with prolonged QT interval  and 
SCD (Splawski et al., 2002; Burke et al., 2005).  
With the increase of GWAS in recent years, there has been an increase of genetic 
associations identified with ECG traits. An association between another sodium channel 
gene, SCN10A, has been identified in several European and some Asian populations for 
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PR and QRS intervals. (Chambers et al., 2010; Holm et al., 2010; Pfeufer et al., 2010; 
Denny et al., 2010b).  There is one GWAS in African Americans for PR interval (an ECG 
trait), but this study did not identify any novel associations nor did it generalize the 
SCN10A association (Smith et al., 2011).  In addition to sodium channel genes, GWAS 
have identified several associations with other genes throughout the genome, such as 
NOS1AP (Arking et al., 2009; Newton-Cheh et al., 2009).  One study successfully 
generalized the NOS1AP association in African Americans but only examined tagSNPs 
based from a European population; thus, the casual variant has yet to be identified (Smith 
et al., 2011). Further characterization of these associations, as well as the identification of 
novel genetic associations in African Americans, may explain the inter-individual trait 
variability observed for ECG traits across populations. 
Similarly to genetic research for ECG traits, there is also a lack of genetic 
association studies for fibrinogen /hematological traits in African Americans. There have 
been both GWAS and candidate gene studies that have identified associations with white 
blood cell count (WBC) and fibrinogen levels in African Americans (Reiner et al., 2011; 
Wassel et al., 2010j; Reiner et al., 2006b; Nalls et al., 2011; Crosslin et al., 2011). For 
fibrinogen, European-identified variants in the fibrinogen gene cluster (FBA, FGB and 
FGG)  and other inflammatory gene loci (i.e. IL6R, IL1RN, and  NLRP3T) are also 
associated in African Americans (Wassel et al., 2010i). These associations have yet to be 
replicated in other African American populations. Two GWAS have recently been 
performed in African Americans with white blood cell count (Nalls et al., 2011; Reiner et 
al., 2011; Crosslin et al., 2011). Both studies confirm an association with SNPs in the 
DARC gene with white blood cell count and other WBC related phenotypes. Aside from 
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this association, collectively these studies have identified an additional twelve loci 
associated with WBC but unfortunately these associations do not overlap across studies. 
One genetic association study identified genetic variants for twelve hematological traits 
(Lo et al., 2011). In this study,  pleiotropic effects were identified between G6PD, 
originally associated with malaria resistance, and RBC, Hct, and Hb in African 
Americans (Lo et al., 2011). Additionally, a novel association in both European and 
African Americans was identified for TPM4 and platelet count. These associations have 
not been replicated in an independent African American population. 
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CHAPTER II 
 
GENETIC VARIANTS ASSOCIATED WITH ELECTROCARDIOGRAPHIC 
TRAITS 
 
A. Identification and Replication of SCN5A Variants with ECG traits in 
African Americans
1
 
 
Introduction 
Many factors are known to influence electrocardiograph (ECG) measurements, 
including underlying heart disease such as coronary heart disease or hypertension, drug 
therapy, body mass index, and age.  These factors, however, do not explain the majority 
of the trait variance observed in ECG traits, and a large portion of the variance remains 
unknown(Zheng et al., 2001; Roberts and Day, 1985). Studies in twins and populations 
have reported that >35% of the variance observed for specific ECG traits is 
heritable(Akylbekova et al., 2009; Kao et al., 2009; Friedlander et al., 1998; Jouven et al., 
1999; Dekker et al., 2006; George, Jr., 2005). Given the heritability of ECG traits, it is 
possible that common genetic variation in genes that modulate the electrical activity of 
the heart can explain a proportion of the unknown trait variance observed in the general 
population. Insights into such normal variability may in turn provide the starting point for 
predicting serious cardiovascular events such as drug-induced arrhythmias or Sudden 
Cardiac Death (SCD)(Kao et al., 2009; Friedlander et al., 1998; Jouven et al., 1999; 
Dekker et al., 2006). SCD accounts for 10-20% of all deaths in adults, and risk factors 
                                                     
1
 Adapted from: Jeff JM, Brown-Gentry K, Buxbaum SG, Sarpong DF, Taylor HA, George Jr AL., Roden 
DM, Crawford DC. SCN5A variation is associated with electrocardiogram traits in the Jackson Heart Study. 
Circulation: Cardiovascular Genetics. April 2011. 4(2):139-144. PMC3080430 
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include underlying heart disease and a family history of SCD(Friedlander et al., 1998; 
Jouven et al., 1999; Dekker et al., 2006). 
The opening of sodium channels is responsible for initiating and propagating 
action potentials in cardiac and other excitable cells(George, Jr., 2005; Abriel and Kass, 
2005; Bezzina et al., 1999; Gellens et al., 1992; George, Jr. et al., 1993; Gouas et al., 
2007; Gouas et al., 2005b; Probst et al., 2009; Schott et al., 1999; Wang et al., 1995c). 
Sodium channels are encoded by nine pore-forming alpha subunit genes(George, Jr., 
2005), and each channel consists of a single pore-forming α-subunit and a variable 
number of function-modifying β-subunits and other interacting proteins(Abriel and Kass, 
2005). The NAv1.5 sodium channel α subunit (encoded by SCN5A) is the predominant α-
subunit expressed in cardiac muscle(George, Jr. et al., 1993; Gellens et al., 1992).  
Mutations in SCN5A have been identified in cardiac conduction disease, long QT 
syndrome, Brugada syndrome, and other life threatening arrhythmias(Wang et al., 1995c; 
Bezzina et al., 1999; Schott et al., 1999; Chen et al., 1998). 
  In addition to rare variants, other studies have implicated common variants in 
SCN5A with arrhythmia susceptibility or with variable ECG traits(Gouas et al., 2007; 
Gouas et al., 2005a; Probst et al., 2009; Bezzina et al., 2006; Tan et al., 2005). One non-
synonymous SCN5A variant, rs7626962 (S1103Y, which is sometimes reported as 
S1102Y depending whether the reference sequence includes a common splice variant that 
eliminates a single residue)(Makielski et al., 2003), is common in African populations 
and rare in others. This SNP has been implicated in susceptibility to SCD, drug-induced 
arrhythmias, and SIDS in African American populations(Splawski et al., 2002; Plant et 
al., 2006; Van Norstrand et al., 2008). With this exception, however, there is very little 
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information on ion channel variation in African Americans.  These lack of data cannot be 
underscored as epidemiologic studies have demonstrated that the risk factor burden for 
CVD differs across race/ethnicities, with African Americans typically having a greater 
burden compared with European and Mexican Americans(Ford et al., 2009).  The rural 
south region of the US, which has the largest African American population, has a higher 
rate of CVD compared to other regions(Rosamond et al., 1998; Crook and Taylor, 2003).   
Disparity of CVD in African Americans is an emergent concern to clinicians and 
epidemiologists. Admixed populations such as Hispanics and African Americans have 
different genetic backgrounds due to the mixture of distinct  ancestral populations(Reich 
et al., 2001a; Lohmueller et al., 2008) and patterns of linkage disequilibrium (LD) 
compared with European-descent populations(Bush et al., 2009).  Thus, it is possible that 
genetic determinants associated with ECG traits can vary depending on the ancestral 
populations. Given these potential differences, we genotyped 72 common single 
nucleotide polymorphisms (SNPs) in the SCN5A gene in 4,558 African Americans from 
the Jackson Heart Study (JHS) to test for an association with nine ECG traits: P, PR, QT, 
QTc and QRS durations, heart rate, and the P, QRS and T axes.  We identified 14 
significant associations at p<1.0x10
-4
, 13 of which have not been described in 
populations of European-descent.  Overall, SCN5A variations reported here explain up to 
2% of the variation in ECG traits. For replication, we genotyped five of the 14 significant 
SCN5A associated SNPs in the Third National Health and Nutrition Examination Survey 
(NHANES III).  This study represents an important first step in the identification and 
characterization of genetic variants associated with ECG traits in African-descent 
populations. 
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Methods 
Population characteristics and ECG measurements 
The Jackson Heart Study (JHS) was developed to help resolve the disparity of 
cardiovascular disease among African Americans(Wilson et al., 2005). The JHS is a 
longitudinal study established in 2000 to characterize the determinants of CVD in 5,301 
African Americans ascertained in Jackson, Mississippi(Campbell-Jenkins et al., 2009). 
For the purpose of genetic analysis, consenting family members age 21 or older were 
ascertained(Wilson et al., 2005).  The participants’ ages ranged from 21-85 years old at 
the time of ascertainment (Appendix A), and 62% of the participants were female. Each 
participant received a clinical examination and interview on CVD status and other 
environmental factors during enrollment. ECG measurements were collected during the 
clinical examination using the Marquette MAC/PC digital electrocardiograph(Carpenter 
et al., 2004). All measurements were documented and sent by phone to the 
Electrocardiographic Reading Center (ECGRC) in Minnesota. The Minnesota Code 
Modular ECG Analysis System (MC-MEANS) computer program was used by the 
ECGRC to generate representative averaged measurements of ECG waves 
simultaneously over all leads. Population demographics and summary statistics of ECG 
measurements are given in Table 2.1 for JHS participant. 
All replication analyses were performed in non-Hispanic blacks from the Third 
National Health and Nutrition Examination Survey (NHANES III). Ascertainment of 
NHANES III and method of DNA collection have been previously described (Crawford 
et al., 2006; Chang et al., 2009; Steinberg et al., 1997).  The National Health and 
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Nutritional Examination Surveys are cross-sectional surveys conducted across the United 
States by the National Center for Health Statistics (NCHS) at the Centers for Disease 
Control and Prevention (CDC). NHANES III was conducted between 1988-1990 (phase 
1) and 1991-1994 (phase 2) (1996; 2004) as a complex survey design that over-sampled 
minorities, the young, and the elderly.  All NHANES have interviews that collect 
demographic, socioeconomic, dietary, and health-related data.  Also, all NHANES study 
participants undergo a detailed medical examination at a central location known as the 
Mobile Examination Center (MEC).  Beginning with phase 2 of NHANES III, DNA 
samples were collected from study participants aged 12 years and older. 
 Electrocardiograms (ECGs) were recorded on men and women in the mobile 
examination center (MEC) using a standard 12-lead resting ECG. ECGs were recorded 
using the Marquette MAC 12 (Marquette Medical Systems, Inc, Milwaukee, Wisconsin 
(U.S. DHHS, 1996). NHANES III 12-lead ECG data were recorded with eight 
independent components of the 12 standard leads simultaneously. ECG data were also 
sampled at 250 samples per second per channel; giving the availability of multiple 
simultaneous ECG leads for analysis. ECGs were only performed on individuals 40 years 
of age or greater and NHANES III was the last NHANES that collected ECG data. 
Population demographics and summary statistics of ECG measurements are given in 
Table 2.3. 
Genotyping and SNP selection 
For the Jackson Heart Study, blood samples were collected from consented 
individuals during enrollment for future genetic analysis. DNA was isolated from blood 
samples and genotyped for 72 single nucleotide polymorphisms (SNPs) using the 
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Sequenom iPlex Gold assay on the MassARRAY platform (San Diego, CA). SNPs were 
selected based on the linkage disequilibrium patterns in African Americans (Bush et al., 
2009).  The location of the 72 genotyped SNPs for JHS participants, minor allele, minor 
allele frequencies, Hardy-Weinberg p-values, and genotyping call rates are given in 
Appendix B.   
For NHANES III participants, DNA was extracted from crude cell lysates from 
lymphoblastoid cell lines established for NHANES III participants aged 12 and over as 
part of Genetic NHANES (Steinberg et al., 1997). We chose 12 SNPs that were 
significant at p 1.0x 10
-4
 in Jackson Heart Study for genotyping in NHANES III. To date 
five SNPs have been successfully genotyped for this study, the others have yet to be 
genotyped. All genotyping was performed in the Center for Human Genetics Research 
DNA Resources Core and the laboratory of Dr. Jonathan Haines using either Sequenom’s 
iPLEX Gold assay on the MassARRAY platform (San Diego, CA) or Illumina’s 
BeadXpress.  All genotype data reported here passed CDC quality control metrics and are 
available for secondary analysis through CDC.   
Statistical Methods 
The JHS in this analysis is comprised of 3,071 unrelated participants and 1,487 
related participants from 263 families selected for genotyping.  Unrelated individuals 
from 263 pedigrees with two or more successfully genotyped relatives were randomly 
selected and analyzed. Individuals selected by this random algorithm had to have all 
phenotype information and have at least 95% genotyping efficiency for targeted SNPs. In 
two families, only one participant was genotyped; as a result, these participants were 
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always selected.  We repeated the random selection several times (five times), and data 
suggest that our results are robust to the random selection process (data not shown).   
To determine if ECG traits were strongly correlated (i.e., redundant), we 
calculated pair-wise correlations for 11 ECG traits (Appendix C). Prolonged QRS 
duration (>120 m/sec) is an indication of congestive heart failure. Patients with abnormal 
QRS duration measurements (>120 m/sec) were excluded from the QRS analysis (n = 
169; Appendix D); however, these patients were included in subsequent analysis with the 
other ECG traits. The exclusion of these patients in the analysis of QRS duration or other 
ECG traits yielded similar results compared with the inclusion of these patients (data not 
shown) due to the relatively small sample size of patients with prolonged QRS duration 
compared with the overall sample size. Of all ECG traits, T and QT durations and PR 
duration in leads II and VI were highly correlated (r
2
=0.93 and 0.87 respectively, 
Appendix C).  To minimize redundancy, we chose to analyze QT duration instead of both 
QT and T durations and PR in lead II instead of both PR in leads II and VI. Although 
modest, a correlation was also observed for P wave and PR durations, QTc and QT 
duration, as well as QTc and heart rate (r
2 
>0.40, Appendix C).  All of these moderately 
correlated traits were retained for subsequent analyses. 
For the analysis, we excluded SNPs with a minor allele frequency (MAF) <0.05, 
genotyping efficiency <95% or Hardy Weinberg equilibrium (HWE) p-value <0.0001. 
Using these criteria, seven SNPs were excluded from the analysis.  We also excluded 280 
DNA samples due to poor genotyping efficiency, resulting in a total study population of 
3,054 participants.   
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Global admixture estimates were previously calculated using genome-wide data 
(Deo et al., 2009) to determine the amount European ancestry using ANCESTRYMAP 
Version 2.0(Patterson et al., 2004a) and expressed as “mean percent European ancestry” 
based on a probabilistic term representing the genome-wide mean percentage of 
European ancestry as determined from markers on the autosomes.  European ancestry 
was associated with durations (P, QTc, and QRS) and T axes (p<0.05).   
We calculated skewness and kurtosis and performed formal tests of normality for 
all ECG traits.  For QRS duration, the skewness (0.34) and kurtosis (2.4) suggested that 
this ECG trait is normally distributed.  However, QRS duration failed a formal test of 
normality while all other ECG traits followed a normal distribution. Based on these 
results, we performed tests of association for QRS duration untransformed and log 
transformed (data not shown).  Because the results did not differ between the 
untransformed and transformed analyses, we chose to present the untransformed results 
for ease of interpretation. 
Using linear regression, we performed single SNP tests of association assuming 
an additive genetic model for 65 SNPs that passed QC in the unrelated sample with nine 
ECG traits using PLINK(Purcell et al., 2007).  Analyses were performed unadjusted and 
adjusted for age, sex, and European ancestry, and results were plotted using Synthesis-
View (Pendergrass et al., 2010a).  To account for multiple testing, we employed a 
significance threshold of p<1.0 x10
-4
.  We also performed unadjusted family-based tests 
of association for all ECG traits using the QFAM procedure from PLINK(Purcell et al., 
2007). This method uses traditional linear regression but uses permutation to correct for 
family structure. We employed this method with all genotyped samples that passed 
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quality control [5 families (n=19) were removed due to Mendelian errors] and tested for 
an association with each SNP for all ECG traits. The results from this analysis are 
consistent with results from the unrelated samples (data not shown). To determine the 
amount of the variance in ECG traits explained by each SNP, R
2
 was computed using 
STATA version 10.  Linkage disequilibrium (r
2
) was calculated using Haploview (Barrett 
et al., 2005). 
All replication analyses in NHANES III were performed using the Statistical 
Analysis Software (SAS v.9.2; SAS Institute, Cary, NC) either locally or via the Analytic 
Data Research by Email (ANDRE) portal of the CDC Research Data Center (RDC) in 
Hyattsville, MD. All traits followed a normal distribution and descriptive statistics are 
reported in Table 2.3.  Participants with QRS duration >120 m/sec were excluded from 
all analysis. Using standard linear regression, assuming an additive model, we tested each 
SNP for an association with ECG traits: P duration, QRS duration, QT interval and heart 
rate. We did not test SCN5A variants with heart rate and QT interval since these SNPs 
were not associated with these traits in the original analysis in JHS. All tests were limited 
to self-identified non-Hispanic blacks and adjusted for age and sex. We did not formally 
adjust for genetic ancestry; however all analysis were stratified by race/ethnicity. We 
declared significance at p<0.05 uncorrected for multiple testing.  Power calculations were 
performed using QUANTO (Gauderman and Morrison, 2006)using effect sizes from the 
original JHS study.  Fst was calculated between JHS and NHANES III NHB using the 
Platform for the Analysis, Translation, and Organization of large-scale data (PLATO) 
(Grady et al., 2010). 
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Results 
ECG interval durations 
The P, PR, QRS, QT and QTc durations were tested for an association with 65 
SNPs in SCN5A that passed quality control measures.  Overall there were 14 significant 
associations (p<1.0 x10
-4
) amongst 65 SNPs for P, PR, QRS and QT durations.  PR 
duration had the most significant SNP associations, with eight SNPs significantly 
associated with decreased PR duration: nonsynonymous rs7626962 (S1103Y) and seven 
intronic SNPs (Table 2.2).  Three intronic SNPs were associated with increased PR 
duration but not with any other ECG trait.  Four SNPs were associated with decreased P 
wave duration, one with decreased QRS duration. A single intronic SNP was associated 
with increased QRS duration, but no other ECG trait. Unique to QT duration, rs9311195 
was associated with decreased QT duration (Table 2.2). There were no significant 
associations observed with QTc duration at p<1.0x10
-4
 (Appendix E).   
Heart Rate 
Of the SCN5A SNPs tested for an association with heart rate, none of the 
associations survived the significance threshold of p<1.0 x10
-4
. Two SNPs that were also 
associated with decreased P and PR duration trended towards significance with increased 
heart rate:  SNPs rs7629265 (β= 0.97, p= 0.04) and rs7626962 (β= 0.91, p= 0.05) 
(Appendix E).  These two SNPs are in high linkage disequilibrium (LD) with one another 
(r
2
=0.87); thus, these associations are not independent. 
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ECG axes 
In addition to ECG durations, the P, QRS and T axes were also tested for an 
association with the same 65 SNPs. There were no significant associations with our SNPs 
and ECG axes measurements using a significance threshold of p<1.0x10
-4
 (Appendix E). 
One SNP that was associated with decreased PR duration trended towards significance 
with P axis (β= 1.95, p= 0.05). 
SNPs associated with multiple ECG traits 
Intronic SNP rs3922844 was associated with increased P, PR, and QRS. SNPs 
rs7374138, rs7626962, rs76229265, rs7637849, rs7627552, and rs6763048 consistently 
trended towards decreased PR, QRS and P wave durations (Figure 2.1). Although most 
SNPs did not survive our significance threshold for QRS duration, SNPs that were 
associated with PR and P wave duration trended towards significance with QRS duration 
compared with other ECG traits. 
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Table 2.1 Study population demographics and ECG trait descriptive statistics for 
the unrelated (n= 3,054) JHS participants. 
 
 
Variable Mean or % 
Standard Deviation 
(minimum, maximum) 
Age (yrs) 56.5 ±11.73 (21, 85) 
% Female 62 - 
% Cardiovascular disease 11 - 
P duration (msec) 118.5 ±13.08 (80, 170) 
PR duration (msec) 171.6 ±33.02 (0,338) 
QRS duration (msec) 92.3 ±10.12 (64, 120) 
QT duration (msec) 414.7 ±27.64 (290, 580) 
QTc duration (msec) 426.4 ±27.64 (334, 594) 
P axis (degrees) 48 ±21.06 (-136, 151) 
QRS axis (degrees) 16.9 ±31.18 (-137, 157) 
T axis (degrees) 30.6 ±40.03 (-179, 179) 
Heart rate (beats/min) 64.6 ±10.72 (30, 118) 
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Table 2.2 Beta coefficients and p-values for SNPs significantly associated with at least one ECG trait in unrelated JHS 
participants. Linear regression adjusting for age, sex, and European ancestry was performed for 65 SNPs assuming an 
additive model for nine quantitative ECG traits (for QRS duration only patients with <120 msec were included, n= 2,878).  
Fifteen significant SNPs that met our significance threshold were associated with at least one ECG trait and are listed above. In 
bold are significant associations at p< 1.0x10
-4
.
  
SNP Location 
P duration QRS duration PR lead II QT duration 
β 
(95% CI) 
p-value 
β 
(95% CI) 
p-value 
β 
(95% CI) 
p-value 
β 
(95% CI) 
p-value 
rs11129796 Intron 
-0.81 
(-1.6, 0.7) 
1.8E-1 
-1.1 
(-1.6, -0.3) 
2.5E-3 
-3.5 
(-5.0, -0.2) 
2.4E-4 
-1.4 
(-4.1, 0.3) 
2.3E-1 
rs13084981 Intron 
1.6 
(-0.0, 2.9) 
2.7E-2 
1.4 
(0.4, 2.2) 
9.4E-4 
3.5 
(0.8, 6.5) 
1.1E-2 
-0.61 
(-3.1, 2.1) 
6.5E-1 
rs3922844 Intron 
1.5 
(0.4, 2.0) 
6.3E-4 
1.3 
(0.8, 1.8) 
7.5E-8 
4.7 
(3.1, 6.4) 
3.9E-9 
-0.68 
(-2.3, 0.8) 
3.9E-1 
rs6763048 Intron 
-1.7 
(-2.5, 0.6) 
6.6E-4 
-0.91 
(-1.3, -0.2) 
1.4E-3 
-4.3 
(-6.1, -2.3) 
3.5E-6 
-0.54 
(-2.8, 1.4) 
5.5E-1 
rs6768664 Intron 
0.60 
(-0.2, 1.5) 
1.8E-1 
0.67 
(0.2, 1.2) 
9.5E-3 
3.0 
(1.5, 4.9) 
2.3E-4 
2.4 
(0.46, 
3.7) 
4.0E-3 
rs7373102 Intron 
0.81 
(-0.2, 1.6) 
8.1E-2 
0.71 
(0.13, 1.2) 
1.1E-2 
2.8 
(1.5, 5.1) 
1.4E-4 
2.1 
(-0.1, 3.3) 
2.1E-2 
rs7374138 Intron 
-1.5 
(-2.3, -0.4) 
3.6E-3 
-1.3 
(-1.8, -0.6) 
6.2E-6 
-4.0 
(-6.0, -2.1) 
2.4E-5 
-0.73 
(-3.5, 0.1) 
4.4E-1 
rs7374605 Intron 
1.1 
(-0.4,1.6) 
3.6E-2 
0.76 
(0.2, 1.4) 
9.9E-3 
4.0 
(2.0, 6.0) 
3.3E-5 
-1.4 
(-3.0, 0.7) 
1.3E-1 
rs7626962 Ser->Tyr 
-3.3 
(-4.9,-1.8) 
2.5E-5 
-1.4 
(-2.2, -0.4) 
2.3E-3 
-6.9 
(-9.9, -4.0) 
2.5E-6 
-0.74 
(-3.1, 2.6) 
6.1E-1 
rs7627552 Intron 
-2.2 
(-2.9,-0.8) 
5.8E-5 
-1.0 
(-1.7, -0.5) 
1.5E-3 
-6.4 
(-3.7, -5.5) 
4.6E-10 
-2.1 
(3.5, 0.5) 
3.6E-2 
rs7629265 Intron -3.2 7.5E-5 -1.5 1.8E-3 -7.8 2.4E-7 -1.3 3.8E-1 
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(-4.6,-1.6) (-2.4, -0.6) (-10, -4.4) (-3.2, 2.5) 
rs7637849 Intron 
-1.7 
(-2.9, -0.9) 
1.1E-3 
-0.76 
(-1.2, 0.0) 
1.2E-2 
-4.2 
(-6.1, -2.1) 
2.3E-5 
-0.43 
(-1.9, 1.9) 
6.6E-1 
rs9311195 Intron 
0.29 
(-0.5, 1.7) 
6.2E-1 
0.21 
(-0.6, 0.7) 
5.3E-1 
-0.58 
(-2.5, 2.0) 
6.0E-1 
-3.5 
(-5.0, -
0.7) 
1.6E-4 
rs9832586 Intron 
-1.3 
(-2.6,0.59) 
1.1E-1 
-0.58 
(-1.5, 0.3) 
2.1E-1 
-5.2 
(-7.8, -1.4) 
7.3E-4 
-2.9 
(-7.4, -
1.5) 
4.8E-2 
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Figure 2.1 Significant associations across ECG traits. Each SNP was tested for an 
association with each ECG trait assuming an additive genetic model adjusted for age, sex, 
and European ancestry. P-values are –log10 transformed along the y-axis and 
corresponding location for each SNP is located on the x-axis. Each point represents a p-
value for each trait indicated by color (see legend). The direction of the arrows 
corresponds to the direction of the beta coefficient. The exact beta coefficients are 
reported on the bottom panel. The significance threshold is indicated by the red  line at 
p= 1.0x10
-4
.  
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Replication in NHANES III non-Hispanic blacks 
Using non-Hispanic blacks from NHANES III, we sought to replicate significant 
SCN5A associations. ECG trait measurements between NHANES III non-Hispanic blacks 
and JHS African Americans are described in Table 2.3.  Mean age, P duration, PR 
interval, and QRS duration differed between NHANES III NHB and JHS African 
Americans (Table 2.3).  On average, NHANES III participants were younger compared 
with JHS study individuals (53.9, 56.5).  Average PR interval was shorter and QRS 
duration was longer, consistent with the lower average age of NHANES III participants 
compared with JHS individuals (Ramirez et al., 2011).  
Although both JHS individuals and NHANES III NHB participants are self-
described African Americans, it is possible that the genetic ancestry of the two 
populations differ due to admixture, which is known to varying widely by geography 
(Rosenberg et al., 2010; Hammer et al., 2011; Tishkoff et al., 2009).  To examine this, we 
examined the coded allele frequencies of the five SNPs in NHANES III NHB with JHS 
(Table 2.4).  Two SNPs had higher coded allele frequencies in JHS compared with 
NHANES III NHB:  rs7374138 (0.23 versus 0.15) and rs11129796 (0.15 and 0.08).  One 
SNP, rs7637849, had a lower coded allele frequency in JHS compared with NHANES III 
(0.79 versus 0.86).  We then calculated Fst to quantitate possible population differences.  
The Fst values for these five SNPs ranged from <0.0001 to 0.019; therefore, there was no 
evidence for significant population differentiation at these loci (Table 2.4).  
We tested five previously identified SNPs from the JHS for associations with 
ECG traits in NHANES III non-Hispanic blacks. A total of five tests of association 
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involving three ECG traits (P duration, PR interval, and QRS duration), equivalent to 
fifteen tests total, was performed.  None of the SNP-trait associations identified in JHS 
replicated in NHANES III non-Hispanic blacks at p<0.05 (Table 2.5). Regardless of 
significance, nine out of 15 (60%) tests of association resulted have a consistent direction 
of effect with the original study in JHS.  
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Table 2.3 Population characteristics comparisons. Mean and Standard deviation was calculated ECG traits tested and age 
for all NHANES III non-Hispanic blacks compared to JHS African American. Student’s T-test was performed to assess the 
difference in means for each trait between JHS and non-Hispanic blacks. 
 
 
  
Trait 
JHS 
African Americans 
(n= 3,054) 
 
NHANES III 
Non-Hispanic Blacks 
(n=530) 
 
Mean SD Mean SD 
Age (yrs) 56.5 ±11.73 53.9 ±11.61 
P Duration (msec) 118.5 ±13.08 113.1 ±14.57 
PR Interval (msec) 171.6 ±33.02 164.6 ±25.56 
QRS duration (msec) 92.3 ±10.12 95.52 ±10.90 
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Table 2.4 Comparison of minor allele frequencies SCN5A variants between NHANES III non-Hispanic blacks and 
Jackson Heart Study African Americans.  To compare allele frequency differences between NHANES III NHB and JHS, 
we calculated Fst for all SCN5A SNPs.  For each SNP, the alleles, the minor allele frequencies (MAF) for each study, and FST 
are given. 
 
 
 
 
 
 
 
 
 
 
SNP 
Major 
Allele/Minor 
Allele 
MAF 
Jackson Heart 
Study 
(n~3,054) 
 
MAF 
Non-Hispanic 
blacks 
(n~530) 
 
 
FST 
rs7374138 C/G 0.23 0.15 <0.0001 
rs7637849 G/A 0.79 0.86 0.014 
rs11129796 C/T 0.15 0.08 0.019 
rs7629265 G/T 0.08 0.09 <0.0001 
rs6768664 A/G 0.36 0.36 <0.0001 
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Table 2.5 Replication of SCN5A variants in non-Hispanic blacks from NHANES III. Linear regression adjusted for age 
and sex was performed for  five JHS identified genetic variants and three ECG traits in non-Hispanic blacks. All genetic 
variants were coded assuming an additive genetic model, and coding was consistent between studies. 
SNP Phenotype 
NHANES III Non-Hispanic Blacks 
(n =552) 
JHS African Americans 
(n = 3,054) 
Effect size  P-value Effect size  P-value 
rs7637849 P Duration 0.94 0.41 -1.70 1.1E-3 
rs7374138 P Duration -1.37 0.24 -1.50 3.6E-3 
rs11129796 P Duration -0.64 0.66 -0.81 0.18 
rs7629265 P Duration -1.51 0.38 -3.20 7.5E-5 
rs6768664 P Duration -1.09  0.23 0.60 0.18 
rs7637849 PR Interval 0.11 0.96 -4.20 2.3E-5 
rs7374138 PR Interval -1.65 0.40 -4.0 2.4E-5 
rs11129796 PR Interval 0.12 0.96 -3.50 2.4E-4 
rs7629265 PR Interval -4.13 0.17 -7.80 2.4E-7 
rs6768664 PR Interval 0.16  0.92 3.00 2.4E-4 
rs7637849 QRS Duration -0.39 0.66 -0.76 0.012 
rs7374138 QRS Duration -0.69 0.41 -1.30 6.2E-6 
rs11129796 QRS Duration 0.09 0.94 -1.10 0.0025 
rs7629265 QRS Duration 1.07 0.82 -1.50 1.8E-3 
rs6768664 QRS Duration 1.93  0.73 0.67 9.5E-3 
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Discussion 
Using a candidate gene approach, we sought to identify genetic variations within 
SCN5A associated with ECG measurements in African Americans from the Jackson 
Heart Study. We were able to detect both previously known as well as novel genetic 
associations with four ECG measurements (Table 2.2).  Notably, to our knowledge, we 
are the first to report an association with the genetic variant S1103Y and atrial ECG 
traits, PR and P wave durations.  We were also able to detect novel associations between 
intronic rs3922844 and QRS, P wave, and PR durations. SNP rs3922844 explains 
approximately 2% of the variability in these traits. Consistent with previous studies, no 
other SNP explained greater than 2% of variance for any ECG trait(Smith et al., 2009a). 
We also attempted to replicate five SNPs originally identified as associated with ECG 
traits in JHS participants in NHANES III non-Hispanic blacks; none replicated (Table 
2.5).   
To minimize redundancy in our JHS results, we calculated linkage disequilibrium 
(LD) among SNPs in the unrelated participants (Appendix F). Of the 14 significant 
associations, 13 SNPs represent independent associations. Correlated SNPs 
rs7626962/rs7627552 are in high LD with each other (r
2
= 0.87), and each likely 
represents the same effect. SNP pairs rs6793245/rs3935472 and rs9833086/rs4130467 are 
also in LD; however, they were not significantly associated with any ECG trait. 
Several genome-wide association studies (GWAS) have been published for the 
ECG traits in populations of non-African descent.  For example, two studies report 
associations within SCN5A and the QT interval (Newton-Cheh et al., 2007b; Newton-
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Cheh et al., 2009; Newton-Cheh et al., 2007a; Newton-Cheh and Shah, 2007). A recent 
GWAS in the isolated Kosrae population from the Federated States of Micronesia 
identified an association between rs7638909, a SNP located in intron 27 of SCN5A, and 
the PR interval, P wave duration and PR segment(Smith et al., 2009c). Other GWAS 
studies on ECG traits report an association with rs7638909 (or correlated SNPs 
rs12053903, rs1805126 and rs1805124) with the QT interval, PR interval, and QRS 
duration in Icelandic and European populations(Holm et al., 2010; Newton-Cheh et al., 
2009). We tested for these associations and all ECG traits in the JHS but failed to 
replicate these findings. The lack of replication across studies is perhaps not surprising 
given the different linkage disequilibrium patterns and allele frequencies in these 
populations.   The SNPs we choose for genotyping for this study are common in African 
Americans such as rs7626962 and rs7629265 but are monomorphic or rare in other 
populations.  GWAS for ECG traits in African-descent populations has yet to be reported 
in the literature.   
Unlike previous studies, we were unable to detect an association between S1103Y 
and ventricular related traits QRS, T, and QT durations in JHS at our significance 
threshold.  Given previous studies, we had expected to detect a strong association with 
S1103Y (rs7626962) and our ECG traits. The effect of 1103Y and QTc duration is 
consistent with previous studies (β = 1.53, p = 0.20; Appendix E), but given the minor 
allele frequency of this SNP (0.08), our study was underpowered to detect this 
association (20%). In our study population, there were only 20 homozygotes for the 
1103Y allele; thus, it is not surprising that mean QTc is not associated with S1103Y 
genotype (data not shown). S1103Y was associated with P wave and PR durations 
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(p<1.0x10
-5
), but there was no other association at p<1.0x10
-4
 with other ECG traits. A 
significant effect was also observed with rs7629265, which is in LD with S1103Y (r
2
= 
0.87). Intronic rs7629265 ranked higher than S1103Y in four ECG traits: PR duration, 
QRS duration, QT duration, and heart rate (Table 2, Appendix E). Because of the strong 
LD, the association with intronic rs7629265 could be a capturing the effect of S1103Y. 
As opposed to mutations, the effects of common variation are less clear.  Our 
most significant finding in JHS, rs7627552, is in LD with rs7626962 (S1103Y), a 
nonsynonymous missense mutation that changes the amino acid serine to tyrosine.   
Studies of this variant in heterologous expression systems have reported differences 
between variant and wild-type channels especially under stress conditions such as low 
pH(Plant et al., 2006; Splawski et al., 2002).   The other significant SCN5A SNPs from 
the present study are all located in the 3’ region of the gene.  While none of them have 
obvious function, it is noteworthy that this gene region is highly conserved with mouse.  
Also, it may be that these associated SNPs are in linkage disequilibrium with the “causal” 
or functional SNPs not genotyped in this study.  However, examination of the Yoruba 
International HapMap data in this region (100kb upstream and downstream of 
rs7627552) revealed only one SNP with minor allele frequency >1% in LD at r
2
>0.20 in 
this region (rs7629265). 
We were unable to replicate SCN5A associations identified in JHS in non-
Hispanic blacks from NHANES III. The lack of replication is most likely due to power 
given we had 552 participants with ECG trait data available for analysis.  To further 
explore this possibility, we calculated the power to detect the originally reported 
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association assuming the effect size reported in JHS, average/SD for each trait, the coded 
allele frequency observed in NHANES III NHB, and the sample size observed in 
NHANES III NHB. At a liberal significance threshold of p<0.05, we had 20%, 15%, and 
20% power to detect the original JHS associations for P duration, PR interval, and QRS 
duration, respectively. Thus, we were under-powered to replicate JHS associations in 
NHANES III NHB.  Large samples in diverse populations are sorely needed to replicate, 
establish, and elucidate genetic associations relevant to normal cardiac conduction. 
Genetic variation in the normal electrical activity of the heart, assessed by the 
ECG, may provide a starting point for studies of genetic susceptibility to serious 
arrhythmias, such as SCD during myocardial infarction or drug therapy. We identified 
several novel associations between SCN5A common genetic variants and the ECG traits 
in JHS African Americans, and we report here the direction and magnitude of effect for 
all tests of association. Of the 14 significant associations, rs7627552, which is in LD with 
a common missense mutation (S1103Y) observed in African Americans previously 
associated with arrhythmia susceptibility, was the SNP most strongly associated with 
ECG traits P wave and PR durations. We were also able to identify 13 novel associations, 
one of which (rs3922844) explains as much as 2% of the variance in P wave, QRS and 
PR durations.  Collectively, these data suggest that multiple SNPs rather than one 
(S1103Y) in SCN5A have an effect on ECG traits. The results of this study may offer 
insight relevant to future genetic studies of cardiac diseases in African-descent 
populations. 
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B. Using Genome-Wide Assocition Studies (GWAS) to Identify Novel 
Variants and Generalize Previously-Identified Variants Associated with 
ECG traits in African Americans
2
 
 
Introduction 
Candidate gene studies have identified several genes that affect cardiac 
depolarization and conduction measured by ECG traits. One set of candidates is genes 
that encode voltage gated potassium and sodium channels, which also play an important 
role in the pathophysiology of long QT syndrome (George, Jr. et al., 1995; Wang et al., 
1995b; Wang et al., 1995a; Lai et al., 1994; Splawski et al., 2002; Splawski et al., 1997; 
Wang et al., 1996). These associations have been confirmed by molecular genetic studies, 
and, in the past five years, GWAS have also identified these associations with various 
ECG phenotypes in Europeans, Korsae, and Indian Asian populations (Newton-Cheh et 
al., 2009; Smith et al., 2009b; Chambers et al., 2010). These GWAS have not only 
implicated common variation in congenital long QT syndrome genes but also have 
identified associations between genes not previously implicated in cardiac 
electrophysiology and ECG traits,  such as NOS1AP with QT interval (Arking et al., 
2006; Post et al., 2007). Genome-wide association studies of variation in ECG traits have 
also revealed pleiotropy: for example, the cardiac sodium channel gene SCN5A, has been 
associated with variation across multiple ECG traits (Smith et al., 2009b; Holm et al., 
2010; Holm et al., 2010; Newton-Cheh et al., 2007b; Marroni et al., 2009; Newton-Cheh 
et al., 2007b; Pfeufer et al., 2010). Variants in SCN10A, a gene previously known to play 
                                                     
2
Jeff JM, Ritchie MD, Ramirez AH, Denny J, Kho AN, Hayes MG, Armstrong L, Basford M, 
Wolf WA, Pacheco JA, Chisholm RL, Roden DM, Crawford DC Generalization of Variants 
Identified by Genome-wide Association Studies for ECG Traits in African Americans. (In 
preparation) 
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a role in the action potentials in nociceptive nerve fibers(Akopian et al., 1999; 
Zimmermann et al., 2007; Abrahamsen et al., 2008),  have been identified by GWAS for 
an association with PR and QRS interval (Chambers et al., 2010; Pfeufer et al., 2010; 
Holm et al., 2010; Sotoodehnia et al., 2010; Denny et al., 2010b).  
As of October 2011, there were 127 unique trait-SNP associations reported in the 
National Human Genome Research Institute’s (NHGRI) GWAS catalog for 
electrocardiographic (ECG) traits (http://www.genome.gov/gwastudies/). Most of these 
studies were limited to European (118 associations) or Asian (9 associations) descent 
populations, and it is unclear if these GWAS-identified variants generalize across 
populations, particularly the extent to which these associations generalize to African 
Americans. There is considerable variability in ECG traits across populations. African 
Americans have a shorter QRS duration, QTc interval, and a longer PR interval compared 
to Europeans (Ramirez et al., 2011). From a genetic standpoint there are also significant 
differences in allele frequencies and linkage disequilibrium patterns between Africans 
and Europeans. For example, rs7626962 (S1103Y) in SCN5A is rare in European and 
Asian descent populations but is common in African Americans (Jeff et al., 2011b; 
Splawski et al., 2002) and has been associated with arrhythmia susceptibility.  
Assessing the utility of electronic medical records (EMR) systems coupled to 
DNA repositories as a tool for genome science is one of the primary objectives for the 
National Human Genome Research Institute’s electronic MEdical Records and 
GEnomics (eMERGE) Network (Roden et al., 2008). Studies from eMERGE, including 
those on PR duration, have demonstrated that EMR-based genetic studies replicate 
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existing findings and discover new ones (Denny et al., 2011; Denny et al., 2010b; 
Crosslin et al., 2011; Turner et al., 2011). Here we performed a GWAS of ECG 
measurements to identify novel genetic associations and to describe the extent to which 
previous associations generalize in African Americans within the eMERGE network. We 
also examine factors that contribute to non-generalization of associations in our African 
American study population. 
Methods 
Study population  
African American subjects were collected from the Vanderbilt or Northwestern 
University biobanks. The Vanderbilt biobank, BioVU, is a collection of DNA samples 
from discarded blood samples collected for routine clinical care linked to de-identified 
electronic medical records (EMRs) (McCarty et al., 2011).  The Northwestern biobank, 
NUgene, combines DNA samples from consented participants with enrollment 
questionnaire and longitudinal data from the EMR (McCarty et al., 2011). Both biobanks 
were approved by Institutional Review Boards at their respective sites.   
Study population demographics and characteristics are described in Table 3.6. 
Individuals with a normal ECG without evidence of cardiac disease before or within one 
month following the ECG, without concurrent use of medications that interfere with QRS 
duration, and who did not have abnormal electrolyte values at the time of the ECG were 
included. Using natural language processing combined with EMR (structured database 
queries) to query (specific to BioVU), we excluded individuals with any of the following 
before or within one month of the ECG: indication of heart failure, arrhythmia, 
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cardiomyopathy, cardiac conduction defect, or myocardial ischemia/infarct based on 
clinical notes, unstructured text, billing codes, and labs. BioVU subjects were African 
American as indicated by observer reported ancestry, which is highly concordant with 
genetic ancestry (Dumitrescu et al., 2010).   African American ancestry was self-reported 
for Northwestern subjects (McCarty et al., 2011), which is also known to be highly 
concordant with genetic ancestry. All ECGs had normal Bazett’s corrected QT intervals 
(<450ms), heart rates (between 50-100 bpm), and QRS duration (65-120 ms).  
Genotyping 
Genotyping for the eMERGE network was performed by the Center for Inherited 
Disease Research (CIDR) and the Broad Institute.  All individuals that met the inclusion 
criteria (n = 501) were genotyped for >1.1 million SNPs using the Illumina 1M BeadChip 
at the Broad Institute. Data were cleaned by the eMERGE QC pipeline (Zuvich et al., 
2011). Individuals with cryptic relatedness, ancestry inconsistent with observer- or self-
reported ancestry, anomalous X-chromosome heterozygosity or poor genotyping 
efficiency were removed from further analysis (n = 46). All markers that were intensity 
probes had technical failure, minor allele frequency ≤ 0.05 genotyping efficiency <99%, 
discordant calls with duplicates, and Mendelian errors >0 were removed. Tests of 
association were performed with and without SNPs that deviated from Hardy Weinberg 
Equilibrium (p-value <1.0 x 10 
-4
); consistent findings were observed for both tests (data 
not shown). 
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Statistical methods 
Greater than 930K SNPs from the Illumina 1M BeadChip were tested for an 
association with PR interval, QRS duration, QTc interval, and heart rate using linear 
regression assuming an additive genetic model. Tests of association were performed 
unadjusted and adjusted for age, sex, PR/QT drug usage (for PR and QT interval only), 
and principal components  (PCs; two to four PCs depending on the trait) using PLINK 
(Purcell et al., 2007). Power calculations were performed using QUANTO (Gauderman 
and Morrison, 2006) using effect size from the original, published GWAS. The fixation 
index Fst, a measure of population differentiation, was calculated using the Weir and 
Cockerham algorithm (Weir and Cockerham, 1984). We calculated Fst between 
European descent populations and our African American study population using the 
Platform for the Analysis, Translation, and Organization of large-scale data (PLATO) 
(Grady et al., 2010). Pair-wise linkage disequilibrium was calculated (r
2
) around the 
SCN5A/SCN10A and NOS1AP regions using the SeattleSNPs Genome Variation Server 
(http://gvs.gs.washington.edu/GVS/index.jsp). 
Generalization 
Using the NHGRI GWAS catalog (Hindorff et al., 2009), we identified SNPs 
associated with PR interval, QTc interval, QRS duration, and heart rate at significance 
threshold of p<10
-6
 from European, Indian or Asian-descent populations.  We then 
examined the significance level and direction of effect for the same SNP-trait pair in this 
African American dataset. 
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Results 
Discovery 
None of the SNPs tested for an association met genome-wide significance 
(p<5.0x10
-8
) with any ECG trait. Although we did not detect associations at genome-
wide significance, we were able to detect associations at p<10
-6
 (Table 3.7, Appendix G). 
Nine common variants were associated with increased heart rate, three of which were in 
complete linkage disequilibrium with each other (r
2
= 1.0) in SERPINI1 on chromosome 3 
(Appendix G). Aside from SNPs associated with heart rate, nine associations at p<10
-6
 
were observed for QT interval, QRS duration, and PR interval, separately (27 
associations total, Table 3.7). None of these associations have been reported by previous 
GWAS for ECG traits in any population. 
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Table 2.6. Descriptive statistics of the study population. Mean and standard deviation 
were calculated in the study population for all covariates and ECG traits. 
 
 
 
 
 
 
 
Study Population Descriptive Statistics, n =455 
Variable Mean /% SD 
Female 77% -- 
Age (yr) 46 15 
PR duration (msec) 159 21 
QRS duration (msec) 82 8 
QTc duration  (msec) 410 21 
Heart Rate (msec) 74 11 
On QT drug 10% -- 
On PR drug 21% -- 
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Table 2.7 Most significant GWAS results in African Americans (n = 455). We 
performed linear regression assuming an additive genetic model for over 930 SNPs in the 
genome. All tests were adjusted by age, sex, and principal components. SNP-trait.  
significant associations at p≤ 10-6 are shown. 
 
Heart Rate 
CHR SNP LOCATION MINOR ALLELE BETA P 
8 rs1015003 Intergenic G 3.94 1.21E-06 
8 rs6468401 Intergenic A 3.93 1.55E-06 
5 rs816475 Intergenic T 3.69 2.83E-06 
3 rs13090836 SERPINI1 (intron) T 3.58 6.86E-06 
3 rs9815034 SERPINI1 (intron) A 3.59 7.26E-06 
3 rs1473511 SERPINI1 (intron) T 3.59 7.26E-06 
12 rs12824981 TMEM132D (intron) T 4.56 8.90E-06 
9 rs35061590 DAB2IP (intron) T 16.03 9.45E-06 
9 rs13290547 DAB2IP (intron) T 16.03 9.45E-06 
QT Interval 
CHR SNP LOCATION MINOR ALLELE BETA P 
5 rs6894385 Intergenic C -9.92 1.03E-06 
6 rs9342616 Intergenic A -6.92 1.04E-06 
7 rs12666280 DPP6 (intron) C 8.93 1.66E-06 
20 rs237450 Intergenic A 6.86 5.36E-06 
4 rs6819013 Intergenic A 6.06 5.50E-06 
4 rs4698433 FGFBP2 (near 5’ region) T 7.23 5.53E-06 
4 rs1483012 LDB2 (intron) G 6.02 7.19E-06 
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16 rs8045405 Intergenic G -11.38 9.44E-06 
15 rs17237606 UNC13C (intron) G -8.91 9.92E-06 
QRS Duration 
CHR SNP LOCATION MINOR ALLELE BETA P 
14 rs1867082 Intergenic A 2.82 1.46E-06 
6 rs504008 NKAIN2 (intron) C 2.70 2.58E-06 
5 rs6861497 Intergenic A 2.40 4.73E-06 
11 rs308309 Intergenic C 4.39 4.95E-06 
6 rs12194062 C6orf190 (intron) T 5.16 5.10E-06 
4 rs6820368 ADH6 (intron) C 9.90 5.57E-06 
12 rs10784762 Intergenic T -2.38 6.31E-06 
16 rs17444745 Intergenic A -6.39 6.96E-06 
1 rs13375391 HMCN1 (intron) A 5.82 9.37E-06 
PR Interval 
CHR SNP LOCATION MINOR ALLELE BETA P 
11 rs1994318 MICAL2 (intron) A -6.79 1.52E-06 
6 rs10447419 Intergenic A -8.65 1.95E-06 
10 rs16926523 MYO3A (intron) A 9.55 4.23E-06 
2 rs7604827 VWC2L (intron) C 6.54 4.52E-06 
3 rs3733017 BCL6 (intron) G -10.07 5.55E-06 
15 rs746265 Intergenic C -6.27 7.92E-06 
3 rs1524976 MAGI1 (intron) A 7.99 7.96E-06 
1 rs3103778 MFSD2 (intron) G 6.30 8.67E-06 
15 rs12595668 Intergenic G -6.26 9.01E-06 
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Generalization 
In European-descent populations, 118 GWAS-identified SNPs have been reported 
for ECG traits in the NHGRI GWAS catalog as of October 2011. We examined the 
reported European-descent SNP-trait association to determine if the association 
“generalized” to African Americans.  We considered an association generalized if the 
observed association was significant at a liberal threshold (p<0.05) and had consistent 
direct of effect as the original study. Of the 118 SNPs identified in the NHGRI GWAS 
catalog, 92 were also directly genotyped in our study population:  26, 14, 19, and 33 
SNPs were previously associated with heart rate, PR interval, QRS duration, and QT 
interval, respectively.   
Overall, there were five (of 92) SNP-trait associations that generalized to African 
descent populations with respect to both level of significance (p<0.05) and direction of 
effect:  for heart rate rs4352210 (intergenic, β= -1.6, p= 0.03), for QTc interval, 
rs1112795 (SCN5A, β = - 4.77; p=0.05) and rs4725982 (KCNH2, β = 4.79; p=0.03), and 
for QRS duration, rs6795970 (SCN10A, β = 2.43; p=0.01) and rs11710077 (SCN5A, β= 
2.42; p=0.004) (Table 2.8). No SNPs generalized for PR interval. There were six 
additional SNP-trait associations from the GWAS catalog that were significant (p-value 
<0.05) but trended in the opposite direction in African Americans compared with 
European-descent populations (after accounting for the coded allele): four for PR 
interval, three for heart rate, and one for QT interval (Appendix H).   
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An additional 40 SNP-trait associations failed to achieve the liberal threshold of 
significance (p<0.05) in African Americans but did have consistent directions of effect 
compared with European-descent populations (Figure 2.2, Appendix I). Based solely on 
direction of effect, approximately 50% and 52% of the associations tested for PR and QT 
intervals, respectively, have a consistent direction of effect in African Americans 
compared with European descent populations. For QRS duration, 37% of the associations 
tested generalized in African Americans while 44% generalized for heart rate.  
Collectively, 44 out of 92 (47%) SNP-trait associations had a consistent direction effect 
regardless of significance in African Americans compared to previously-identified 
associations in European-descent populations. The remaining 48/92 (52%) SNP-trait 
associations identified in European-descent populations did not generalize to African 
American with respect to either level of significance or direction of effect. 
There were ten SNPs reported in the NHGRI catalog that are associated with ECG 
traits in Asian and Indian descent populations. Of these, six SNPs were also genotyped in 
our study population. None of these SNPs generalized in African Americans with respect 
to significance and direction of effect, although two (out of six) of these associations had 
a consistent direction of effect compared with the original study population. 
Power 
SNP-trait associations that failed to achieve significance or failed to generalize to 
African Americans may represent lack of power or true differences in allelic architecture 
and/or linkage disequilibrium patterns between the two populations.  To help distinguish 
between these two possibilities, we calculated the power to detect the European-reported 
53 
 
association in this African American sample.  Overall, 17 SNP-trait tests of association 
were adequately powered (>80%).  Among the adequately powered tests of association, 
almost all (16/17) SNP-trait tests of association failed to generalize in African Americans 
with respect to level of significance and/or direction of effect (Table 2.9). 
Allele Frequencies 
We calculated the coded allele frequencies for previously identified SNPs (from 
European descent populations) in African Americans (Appendix J). To measure 
population differences, we calculated Fst for all SNPs previously identified by GWAS in 
European descent populations that report sample sizes and minor allele frequencies (85 
SNPs). There were 20 SNPs with an Fst value >0.15 (ranging from 0.15 to 0.85), which 
is indicative of significant population differentiation at these loci. We observed the 
largest Fst value (F= 0.85) for rs789852 located in the intron region of the TMEMFF 
gene located on chromosome 3. This SNP was previously associated with QT interval in 
Europeans (β= 0.25, p=7.0 x 10-7) (Marroni et al., 2009). This association did not 
generalize in African Americans and trended in the opposite direction compared to 
Europeans (β = -0.95, p =0.60). 
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Table 2.8 GWAS-identified associations that generalize in African Americans. We compared GWAS-identified 
associations originally identified in European or Asian descent populations to tests of associations performed in 450 African 
Americans from BioVU and NUgene. We declared  generalization as having a consistent direction of effect and a  p-value ≤ 
0.05. Abbreviations: CAF= coded allele frequency. 
 
 
 
 
Trait SNP 
Coded 
Allele 
Gene 
Original Study African Americans 
Population P-value β CAF 
P-
value 
β CAF 
QT interval rs11129795 A SCN5A European 5.0E-14 -1.27 0.23 0.05 -4.77 0.16 
QT interval rs4725982 T KCNH2 
European 
and Indian 
Asian 
5.0E-16 1.58 0.22 0.03 4.79 0.23 
QRS duration rs6795970 A SCN10A 
European 
and Indian 
Asian 
4.0E-09 5.17 0.36 0.01 2.43 0.08 
QRS duration rs11710077 T SCN5A European 1.0E-06 0.44 0.21 0.004 2.42 0.11 
Heart rate rs4352210 A Intergenic European 
2.00E-
06 
-0.14 0.37 0.03 -1.6 0.44 
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Table 2.9 Adequately powered GWAS identified SNPs that do not generalize in African Americans.  Using the effect 
size, mean and standard deviations reported in the original study, we calculated our  power to detect the association given our 
sample size and minor allele frequency in African Americans. Abbreviations: CAF = coded allele frequency 
 
 
SNP Trait Gene 
Coded 
Allele 
Original Study African Americans (n=450) 
CAF P-value Beta CAF 
P-value 
 
Beta Power 
rs10494366 QT Interval NOS1AP G 0.39 5.00E-22 12.20 0.60 0.88 0.28 0.99 
rs11129795 QRS duration SCN5A G 0.77 5.00E-10 -8.24 0.84 0.73 -0.25 0.99 
rs12296050 QT Interval KCNQ1 T 0.15 1.00E-11 13.16 0.50 0.52 -1.20 0.99 
rs3807989 PR interval CAV1 A 0.40 7.00E-13 6.40 0.62 0.46 0.94 0.95 
rs3825214 QRS duration TBX5 G 0.22 3.00E-13 7.35 0.23 0.52 -0.41 0.99 
rs3825214 PR interval TBX5 G 0.22 1.00E-07 5.88 0.22 0.79 -0.40 0.81 
rs1321311 QRS duration CDKN1A T 0.21 3.00E-10 6.52 0.39 0.17 0.77 0.99 
rs174547 Heart Rate FADS1 C 0.33 2.00E-09 6.20 0.10 0.43 1.03 0.99 
rs223116 Heart Rate MYH7,NDNG A 0.24 3.00E-08 7.40 0.76 0.44 -0.64 0.99 
rs2461751 PR interval Intergenic G 0.44 8.00E-06 4.54 0.68 0.83 -0.30 0.80 
rs281868 Heart Rate SLC35F1 G 0.50 4.00E-10 6.30 0.53 0.41 0.64 0.99 
rs314370 Heart Rate SLC12A9 C 0.19 6.00E-10 7.60 0.07 0.28 1.58 0.99 
rs365990 Heart Rate MYH6 G 0.34 7.00E-06 5.25 0.61 0.61 -0.41 0.99 
rs3807375 QT Interval KCNH2 T 0.35 5.00E-11 11.95 0.69 0.32 1.95 0.99 
rs452036 Heart Rate MYH6 A 0.36 4.00E-14 7.80 0.61 0.41 -0.68 0.99 
rs7660702 PR interval ARHGAP24 T 0.74 3.00E-17 8.46 0.44 0.60 0.65 0.99 
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Figure 2.2  SNP-trait association comparison between European or Asian-descent and African American populations 
across ECG traits. Each SNP was tested for an association with each ECG trait assuming an additive genetic model adjusted 
for age and sex. P-values are –log10 transformed along the y-axis and corresponding location for each SNP is located on the x-
axis. Each point represents a p-value for each population indicated by color (see legend). The direction of the arrows 
corresponds to the direction of the effect (measured by beta coefficient). The significance threshold is indicated by the red bar 
at p= 0.05. The bottom panel displays the minor allele frequency comparisons for both populations for each SNP.
European Americans 
African Americans 
Indian Asians 
Korsae 
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Discussion 
We conducted a genome-wide association study for ECG traits in African 
Americnas ascertained from biorepositories linked to electronic medical records. 
Although no test of association achieved genome-wide significance, here we 
identify novel associations with heart rate, QT interval, QRS duration, and PR 
interval at p < 10
-6
.  We also characterized previously reported associations in our 
African American study population derived in a clinical based setting. To our 
knowledge we are the first to perform a genome-wide association study for heart 
rate in African Americans and to characterize GWAS-identified variants from 
European and Asian-descent populations to African Americans for heart rate, QT 
interval, and QRS duration.   
Discovery 
We identified 36 novel associations with the four ECG traits at the liberal 
threshold of p< 1.0 x 10 
-6
. While none of our associations met genome-wide 
significance, reporting these associations can provide insight to novel regions in the 
genome that impact ECG trait variability yet to be explored in African populations. 
Interestingly we were able to detect a novel region on chromosome 3 with three 
SNPs that are in high LD and were associated with increased heart rate in the 
SERPINI1 (Appendix G.3). The SERPINI1 gene encodes serine peptidase inhibitors 
secreted by axons in the brain and are associated with familial encephalopathy 
(Davis et al., 1999b; Davis et al., 1999a).  
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We also identified a region on chromosome 9 within the DAB2IP gene 
encompassing two SNPs that were associated with increased heart rate. This gene 
encodes a GTPase-activating protein and is an inhibitor of cell growth and survival. 
DAB2IP has been identified by a GWAS for an association with prostate cancer in 
European and African descent populations (Duggan et al., 2007). Recently, a 
GWAS of individuals from Iceland and the Netherlands identified an association 
with DAB2IP with abdominal aortic aneurysms and other vascular diseases 
including early onset myocardial infarction (Gretarsdottir et al., 2010). 
Generalization 
Four of the five generalizations we identified in African Americans are 
located in voltage-gated channels (Table 2.8). For QRS duration, two of these 
variants are within the SCN5A/SCN10A region and generalize in African 
Americans (Table 2.8).  SCN10A variant rs975970, originally associated with PR 
interval, has been previously reported to have pleiotropic effects with QRS duration 
(Holm et al., 2010; Chambers et al., 2010). This association for QRS duration 
generalized to African Americans (β = 2.43, p= 0.01).  There were a total of three 
associations that generalized in African Americans for QT interval, two of which 
are in voltage gated channels KCNH2 and SCN5A for QT interval (Table 2.8). The 
third association, rs12143842, is located in NOS1AP, which has been consistently 
associated with prolonged QT interval (Arking et al., 2006; Post et al., 2007; 
Arking et al., 2009). The effect of this variant accounts for more than 1.5% of the 
trait variability in Europeans (Arking et al., 2006) and 1.3% in African Americans.  
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For PR interval, two previously identified associations in the SCN10A gene have 
consistent directions of effect with African Americans (Figure 2.2, Appendix I). 
Non-synonymous variant rs6795970 (in the SCN10A gene) has been recently 
reported to have an association with increased PR interval in Indians and 
Europeans (Holm et al., 2010; Pfeufer et al., 2010; Chambers et al., 2010; Denny et 
al., 2010b). In African Americans the magnitude this effect (β= 3.67) is consistent 
with Europeans (β= 5.17) (Figure 2.2, Appendix I).  
There were 48 associations that did not generalize to African Americans 
with respect to direction of effect and statistical significance. GWAS associations 
identified in European descent populations may not generalize in African 
Americans for several reasons. More often than not, this is due to discordant minor 
allele frequencies and linkage disequilibrium (LD) patterns, both of which impact 
statistical power. On average for SNPs that do not generalize, the MAF in the 
original population was significantly different compared to the MAF in our study 
population (p ≤ 0.01). The MAF was lower in African Americans compared to the 
original study population for 60% of the SNPs that did not generalize (Figure 2.2).  
Low minor allele frequency is directly correlated with power in genetic association 
studies. We also noticed this correlation with in our study; 13/79 inadequately 
powered tests of association had a minor allele frequency < 0.09.  
The Effects of Linkage Disequilibrium 
Linkage disequilibrium (LD) is often used in genetic association studies to 
select tagSNPs for genotyping to represent a region in the genome. While this 
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method is cost effective, identifying an association with a tagSNP does not 
necessarily identify the true functional variant given that the un-assayed functional 
variant is most likely in LD with the assayed variant.  TagSNPs are also 
population-specific; therefore, associations identified in one population may not 
necessary generalize to another population if only the index variant is genotyped. 
Our observations in this African American population compared with European 
descent populations for ECG trait associations are consistent with known properties 
of tagSNPs.  That is, there are differences in LD between African Americans and 
Europeans for known loci associated with PR interval, QRS duration, and QT 
interval.  For the SCN10A/SCN5 and NOS1AP regions we calculated pair-wise LD, 
measured by r
2
 for each SNP pair. As expected, there is less linkage disequilibrium 
in African descent populations compared to European populations (Appendices K 
and L) (Barrett et al., 2005; Mueller et al., 2005; Reich et al., 2001b). This lack of 
LD could account for the non-generalization of associations in African Americans 
originally identified in European descent populations. 
LD is often described as a “double-edged” sword:  strong LD can be 
advantageous to identifying associations, but is it not useful when searching for the 
functional variants.  Using populations with low amounts of LD can help fine map 
the functional variant (Rosenberg et al., 2010).  Therefore, index associations that 
robustly associate with ECG traits in European descent populations but do not 
generalize to African descent populations could be prioritized for fine-mapping 
studies to identify the functional variant.  Also, further large discovery and fine-
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mapping studies should be performed in African descent populations to identify 
additional ECG-trait associated loci not found in other populations.   
Limitations and Strengths 
There were several factors that limit our ability to detect novel associations 
at the GWAS level ( p< 1.0 x 10 
-8
) with ECG traits.  Our study population 
compared to recently published GWAS for ECG traits is relatively small and 
underpowered. Specifically, we were underpowered (<80%) to detect effects that 
explain less than 10% of the trait variability at p<1.0 x 10 
-8
 even for common 
variants (MAF >0.05). Power also limited our ability to generalize European/Asian 
identified associations to African Americans.  As previously mentioned power is 
directly correlated to allele frequencies. Most GWAS fixed-content products are 
biased to common variation and based on LD patterns European populations 
(Rosenberg et al., 2010). Therefore, the SNPs previously identified may only be 
common in Europeans and rare in other populations such as African Americans, 
limiting our power to generalize these variants. It is important to note the power 
calculations we report in our generalization analysis was limited to the effect sizes 
detected in the original study. These effect sizes could be subject to the “winner’s 
curse” and over estimate the true effect size (Xiao and Boehnke, 2009; Zhong and 
Prentice, 2010). Using these potentially over estimated effect sizes in our power 
calculations could consequently over estimate our power to detect these effects.  
Here we confirm the ability to use electronic medical records (EMRs) 
linked to DNA to identify genotype-phenotype relationships. We identify several 
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novel associations across the genome for heart rate, PR interval, QT interval, and 
QRS duration. Additionally, we generalize several biologically relevant 
associations identified by GWAS in European and Asian descent populations to 
African Americans. Most importantly, we extensively characterize European and 
Asian identified associations in African Americans by reporting population specific 
information such as allele frequency and linkage disequilibrium differences. 
Reporting population specific information on GWAS-identified variants can be 
useful to clinicians as it indirectly contributes to the field of personalized medicine. 
Conclusions 
We successfully assessed the generalizability of European identified genetic 
associations for ECG traits in African Americans derived from an electronic 
medical record. Additionally, we report novel associations for ECG traits in 
African Americans. Replication of these findings in an independent African 
American population is needed to confirm these associations. Most of the 
associations identified in European and Asian descent populations failed to 
generalize due to power (as a consequence of sample size and low minor allele 
frequencies). However, there were several adequately powered associations that did 
not generalize to African Americans. These data suggest that the function variant 
has yet to be identified for these traits by GWAS and demonstrate the need for 
future fine mapping studies in a large African-descent population.  
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C. Genetic Modifiers of ECG traits in African Americans 
 
Introduction 
 There are several known risk factors of ECG traits such as age, sex, 
hyperlipidemia, hyperinsulinaemia, and hypertension (Lind et al., 1997). As 
previously mentioned, ECG traits also have a genetic component. Current 
heritability estimates report 30-60% of the variability in ECG traits is  attributable 
to genetic factors (MATHERS et al., 1961; Perez and Keith, 1978; Havlik et al., 
1980; Hanson et al., 1989; Kupper et al., 2004; Moller et al., 1982; Russell et al., 
1998).  It is important to note that original heritability estimates only account for 
additive genetic effects and could be underestimating the genetic component of 
common disease traits by not accounting for the possibility of gene-gene and gene-
environment interactions(Manolio et al., 2009). To date there are few studies that 
investigate the role of genetic modifiers and ECG traits especially in African 
Americans. 
 One of the primary goals of the Population Architecture using Genomics 
and Epidemiology (PAGE) study is to identify genetic modifiers of common 
disease (Matise et al., 2011).  As a member of the PAGE study, the Epidemiologic 
Architecture of Genes Linked to Environment (EAGLE),  uses a diverse, cross-
sectional survey, NHANES III, to identify genetic modifiers. Here we examine the 
effect of genetic modifiers (gene-gene and gene-environment) for three ECG 
traits: P duration, PR interval, and QRS interval in non-Hispanic blacks from 
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NHANES III (previously described). Using five previously identified SNPs from 
the Jackson Heart Study (See Section A of this Chapter) in SCN5A; we test for 
SNP-SNP interactions, as well as SNP-environment interactions with these SNPs 
and known environmental risk factors (age and sex). 
Methods 
Study Population and ECG measurements 
Non-Hispanic blacks with normal ECGs from NHANES III were available 
for this study. For more detail on exclusion/inclusion criteria as well as population 
characteristics please refer to the methods sub section “Study Population” and 
Table 2.3 in part A of this chapter.  Electrocardiograms (ECGs) were recorded on 
men and women in the mobile examination center (MEC) using a standard 12-lead 
resting ECG. ECGs were recorded using the Marquette MAC 12 (Marquette 
Medical Systems, Inc, Milwaukee, Wisconsin (U.S. DHHS, 1996). ECGs were 
only performed on individuals 40 years of age or greater, and NHANES III was the 
last NHANES survey that collected ECG data. More in-depth description on ECG 
measurements in NHANES III can be found in section A under “Study 
Characteristics and ECG Measurements” of this chapter (page 22).   
SNP selection and Genotyping 
DNA was extracted from crude cell lysates from lymphoblastoid cell lines 
established for NHANES III participants aged 12 and over as part of Genetic 
NHANES (Steinberg et al., 1997). We chose 12 SNPs that were significant at p 
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1.0x 10
-4
 in Jackson Heart Study for genotyping in NHANES III. To date five 
SNPs have been successfully genotyped for this study for P duration, QRS interval 
and PR interval (7 SNPs have yet to be genotyped). All genotyping was performed 
in the Center for Human Genetics Research DNA Resources Core and the 
laboratory of Dr. Jonathan Haines using either Sequenom’s iPLEX Gold assay on 
the MassARRAY platform (San Diego, CA) or Illumina’s BeadXpress.  All 
genotype data reported here passed CDC quality control metrics and are available 
for secondary analysis through CDC. 
Statistical Analysis 
Using linear regression, cross product terms (all pair-wise SNP-SNP or 
SNP-environment terms for five SCN5A variants) were added to the regression 
models for each ECG trait (PR interval, P duration, and QRS interval).  All SNPs 
were coded additively, and all models were adjusted for the main effect of the SNP 
(both the SNP-SNP and SNP-environment models) and environmental factor (only 
the SNP-environment models). In addition to adjusting for main effects, all 
analyses were adjusted for known covariates age and sex. Analyses were limited to 
self-identified non-Hispanic blacks from NHANES III.  All analyses were 
performed using the Statistical Analysis Software (SAS v.9.2; SAS Institute, Cary, 
NC) via the Analytic Data Research by Email (ANDRE) portal of the CDC 
Research Data Center (RDC) in Hyattsville, MD. We consider an interaction 
significant at p<0.05.     
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Results 
  We first sought to identify SNP-SNP interactions between the five SNPs in 
the SCN5A gene. We performed a total of 30 tests in non-Hispanic blacks with 
ECG measurements in NHANES. We did not detect any significant associations at 
p<0.05.  In addition to SNP-SNP interactions we also tested for SNP-environment 
interactions between  age and sex and each SCN5A SNP for three ECG traits. We 
performed a total of 30 tests and identified one interaction term (rs6768664* age; 
β= 0.25) that trended towards significance (p= 0.06).  
Discussion 
 Here we tested for geneti or environmental modifiers of candidate genes 
identified association for ECG traits. None of the tests of GxG or GxE were 
significant at the p<0.05 level; however one trends towards significance. Several 
limitation imoacted our ability to identify modifiers as described below. 
 A major study limitation was sample size.   We were severely under 
powered (<20%) to detect SNP-SNP and SNP-environment interactions, which 
typically have very small genetic effects and thus require larger sample sizes 
compared with studies designed to detect the main effects. Given our allele 
frequencies for SCN5A SNPs (Table 2.4),  >4,000 participants would be required to 
detect gene-gene or gene-environment effects that explain less than 2% of the trait 
variability for any ECG traits tested. 
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 In addition to sample size, another reason we failed to detect interactions in 
the present analysis maybe due to our limited SNP set. This study was limited to a 
small SNP set of five SNPs that were previously associated in JHS participants. 
Therefore all SNPs had to have a significant main effect with an ECG trait in order 
to be included in the present study.  It is possible that GxG and/or GxE interactions 
can exsists in the absence of main effects.  
Preliminary studies such as this provide the framework for future analysis. 
The results from this study give information about the sample size needed to detect 
gene-gene and gene-environment interactions in African Americans for SCN5A 
variants. One way to increase the sample size is to perform a meta-analysis, which 
combine association results across several study populations. Since NHANES 
participants  are a part of EAGLE, a study site within PAGE, we can increase our 
sample size by including additional study sites within PAGE that also have  ECG 
measurements in African Americans.  
Although the results from this study did not successfully identify genetic 
modifiers ECG traits, it gives insight to the possibility of detecting interactions in 
future studies.  
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CHAPTER III 
 
GENETIC VARIANTS ASSOCIATED WITH FIBRINOGEN AND 
HEMATOLOGICAL TRAITS 
 
A. Identification and Replication of Fibrinogen Cluster Variants with Plasma 
Fibrinogen and Hematological Traits in African Americans
3
 
Introduction 
Circulating levels of hemostatic factors, such as plasma fibrinogen, and 
cellular components of the blood such as the concentration of hemoglobin (Hb), the 
numbers of white blood cells (WBC), red blood cells (RBC) and platelets (PLT), 
and the volumes of red blood cells (mean corpuscular volume, MCV) and platelets 
(mean platelet volume, MPV) are tightly regulated (Pennington et al., 2001; Evans 
et al., 1999). Abnormal levels of Hb, MPV, PLT, plasma fibrinogen, serum 
triglycerides, and WBC are associated with myocardial infarction (MI), coronary 
artery disease (CAD), and stroke (Meade et al., 1986; Tosetto et al., 2011; Boos 
and Lip, 2006; Danesh and Lewington, 1998; Ensrud and Grimm, Jr., 1992; Kannel 
et al., 1987). Plasma fibrinogen is a key player in the pathogenesis of 
cardiovascular disease, specifically arterial thrombosis. In the coagulation pathway, 
fibrinogen is converted to fibrin, the main protein component of an arterial clot 
(Collet et al., 1993; Voetsch and Loscalzo.J, 2003). The roles of genetic factors for 
                                                     
3
  Partially adapted from: Jeff JM, Brown-Gentry K, Crawford DC. Replication and 
characterization of genetic variants in the fibrinogen gene cluster with fibrinogen 
levels and hematological traits in the Third National Health and Nutrition 
Examination Survey.Thrombosis and Haemostasis. January 2012. 107 (3) 
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plasma fibrinogen and other coagulation factors have been well studied over the 
past 30 years; however, little is known about the genetics of other common 
hematological measurements and their relationship with cardiovascular related 
diseases. 
Genetic factors are reported to account for up to 50% of the variability 
observed in plasma fibrinogen levels (Voetsch and Loscalzo.J, 2003). Heritability 
estimates for hematological measurements such as Hb, WBC, and PLT range from 
0.37-0.89 (Pennington et al., 2001; Evans et al., 1999).  Several genetic association 
studies have been conducted to assess the relationship between candidate genes of 
the coagulation pathway and fibrinogen, coagulation factors, and other common 
hemostatic measurements. Candidate gene studies have demonstrated that variation 
in fibrinogen genes (FBA, FGB and FGG) are associated with plasma fibrinogen 
levels (Siegerink et al., 2009; Boekholdt et al., 2001; Folsom et al., 2001; Koch et 
al., 2008; Hamsten et al., 1987).  
While these studies have identified genetic variation associated with these 
quantitative traits, the discovery effort has been limited to European-descent 
populations. It is well known that genetic backgrounds vary among populations, 
both in allele frequency and in linkage disequilibrium patterns  for many diseases 
including venous thrombosis (Margaglione and Grandone, 2011).  As an example 
of allele frequency differences, one study performed in diverse populations 
demonstrated that Factor V Leiden (rs6025) and the prothrombin G20210A 
(rs1799963) variants differ across populations (Rosendaal et al., 1998). The 
prevalence of these variants in African Americans and Hispanics is 1-2% and 
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<0.04%, respectively compared to 5% and 2-4% observed in Europeans (Grody et 
al., 2001; Grody, 2003; McGlennen and Key, 2002). Since these well-known 
variants are less common in African Americans and Hispanics, it is possible that 
other variants have yet to be identified in these populations that explain more of the 
variance in hemostatic and/or hematological traits. 
Using a candidate gene approach we investigated the role of several genetic 
variants in the fibrinogen gene cluster with plasma fibrinogen and several 
hematological parameters. We characterized the association of 25 single nucleotide 
polymorphisms (SNPs) and plasma fibrinogen levels in African Americans 
(referred to non-Hispanic blacks here) from the Third National Health and 
Nutrition Examination Survey (NHANES). We also tested for an association with 
these genetic variants and mean platelet volume, white blood cell count, platelet 
count, platelet distribution width, and serum triglycerides.   
Methods 
Study Population 
All procedures were approved by the CDC’s Ethics Review Board and 
written informed consent was obtained from all participants. This candidate gene 
association study was approved by the CDC’s Ethics Review Board (protocols 
#2003-08 and #2006-11) and the University of Washington’s Institutional Review 
Board (IRB #23667; HSRC D committee).  Because no identifying information 
was accessed by the investigators, this study was considered exempt from Human 
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Subjects by Vanderbilt University’s Institutional Review Board (IRB #061062; 
HS2 committee).   
Ascertainment of NHANES III and method of DNA collection have been 
previously described (Crawford et al., 2006; Chang et al., 2009; Steinberg et al., 
1997).  The National Health and Nutritional Examination Surveys are cross-
sectional surveys conducted across the United States by the National Center for 
Health Statistics (NCHS) at the Centers for Disease Control and Prevention (CDC). 
NHANES III was conducted between 1988-1990 (phase 1) and 1991-1994 (phase 
2) (1996; 2004) as a complex survey design that over-sampled minorities (non-
Hispanic blacks and Mexican Americans), the young, and the elderly.  All 
NHANES have interviews that collect demographic, socioeconomic, dietary, and 
health-related data.  Also, all NHANES study participants undergo a detailed 
medical examination at a central location known as the Mobile Examination Center 
(MEC).  The medical examination includes the collection of physiological 
measurements by CDC medical personnel and blood and urine samples for 
laboratory tests.  Beginning with phase 2 of NHANES III, DNA samples were 
collected from study participants aged 12 years and older.  
Hematological Measurements 
Blood was collected from all participants with the exception of those who 
reported having hemophilia or chemotherapy in the past four weeks (Gunter E. et 
al., 1996). Complete blood counts (CBCs) were performed on qualifying NHANES 
participants using the Beckman Coulter method, a method that sizes and counts 
particles by using measurable changes in electrical resistance produced by 
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nonconductive particles suspended in an electrolyte (Daum et al., 2000). A 
quantitative, automated, differential cell counter was used to calculate exact values 
for hematological measurements (Gunter E. et al., 1996).  Plasma fibrinogen was 
measured from blood plasma on participants 40 years and older using the Clauss 
clotting method (Daum et al., 2000). Serum triglycerides were measured using 
standard enzymatic methods.  
SNP Selection and Genotyping 
DNA was extracted from crude cell lysates from lymphoblastoid cell lines 
established for NHANES III participants aged 12 and over as part of Genetic 
NHANES (Steinberg et al., 1997). TagSNPs were selected using LDSelect (Carlson 
et al., 2004) for multiple populations at r
2 
>0.80 for common variants (minor allele 
frequency (MAF) >5%) in three candidate genes (FGA, FGB, and FGG) based on 
data available for European Americans and African Americans in SeattleSNPs 
(Crawford et al., 2005).  A total of 25 SNPs were genotyped using the Illumina 
GoldenGate assay (as part of a custom 384 oligonucleotide pool assay (OPA) by 
the Center for Inherited Disease Research (CIDR) through the National Heart Lung 
and Blood Institute’s Resequencing and Genotyping Service.  A total of 7,159 
samples were genotyped, including 2,631 non-Hispanic whites, 2,108 non-Hispanic 
blacks and 2,073 Mexican Americans. The data presented in this analysis were 
limited to non-Hispanic blacks. Quality control measurements were calculated 
locally using the Platform for the Analysis, Translation, and Organization of large-
scale data (Grady et al., 2010). The average genotyping call rate was 96%. We 
flagged SNPs that deviated from Hardy Weinberg Equilibrium expectations (p-
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value <0.001), MAF<0.05, and SNP call rates <95% for each subpopulation.  In 
addition to these quality control metrics, we genotyped blinded duplicates as 
required by CDC, and all SNPs reported here passed quality control metrics 
required by CDC.  All genotype data reported here were deposited into the 
NHANES III Genetic database and are available for secondary analysis through 
CDC. 
Statistical Methods 
All analyses were performed using the Statistical Analysis Software (SAS 
v.9.2; SAS Institute, Cary, NC) either locally or via the Analytic Data Research by 
Email (ANDRE) portal of the CDC Research Data Center (RDC) in Hyattsville, 
MD.  Analyses were limited to self-identified non-Hispanic blacks and were at least 
18 years of age.  Participants with measurements outside of the normal range for 
any trait were excluded from the analysis, as extreme measurements for these traits 
can indicate inflammation or recent trauma.  Pair-wise correlations for each trait 
were calculated using Pearson’s correlation coefficient. None of the traits were 
correlated (defined as r>0.50; Appendix M). Descriptive statistics for all traits are 
reported in Table 3.1. Coded allele frequencies for all SNPs are reported in 
Appendix N. All traits followed a normal distribution with the exception of 
triglycerides, which was uniformly transformed by using the natural logarithm. 
Pair-wise linkage disequilibrium was calculated for all 25 SNPs using 
Haploview (Appendix O) (Barrett et al., 2005). Single-locus tests of association 
were performed using linear regression for each fibrinogen SNP and each 
hematological trait:  plasma fibrinogen, mean platelet volume, white blood cell 
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count, platelet distribution width, log-transformed serum triglycerides, and platelet 
count.  For each test of association, we assumed an additive genetic model. 
Analyses were performed un-weighted and unadjusted and adjusted for age, sex, 
body mass index (BMI) and current smoking status (yes/no), and results were 
plotted using Synthesis View (Pendergrass et al., 2010b). Analyses were repeated 
to include time to last meal (in hours) as a covariate (data not shown). Current 
smoking status was determined by the question “Do you smoke cigarettes now?” 
and cotinine levels (>15 ng/ml).  
Results 
Plasma Fibrinogen and Replicated Associations 
We replicated several single SNP associations from previous studies (Figure 
3.1; Table 3.2). Replication was defined by statistical significance (p <0.05) and 
consistent direction of effect with the same SNP in the same ancestral population 
across studies.  
  We were able to replicate reported associations in non-Hispanic blacks 
(Table 3.2)(Reiner et al., 2006a; Wassel et al., 2010h). Intronic FGG rs2066874 
(MAF = 0.02; Appendix N) was associated with decreased plasma fibrinogen in 
non-Hispanic blacks (β = -0.28; p=0.0007; Table 3.2; Figure 3.1).  Although not 
significant, intronic FGA rs2070017, which is rare in non-Hispanic whites 
(MAF=0.0012; Appendix N), trended towards an association with increased plasma 
fibrinogen in non-Hispanic blacks (p=0.07; β = 0.07).  Overall, regardless of 
significance, all but one test in non-Hispanic blacks (FGA rs6050) trended in the 
same direction as the previous report after accounting for the coded allele (Figure 
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3.1; Table 3.2). Also, rs1049636, which was originally reported in European-
descent populations (Reiner et al., 2006a), trended toward significance in non-
Hispanic blacks (β = 0.06, p-value = 0.07; Figure 3.1). 
We did not detect novel associations between genetic variants and plasma 
fibrinogen in non-Hispanic blacks (Appendix P).  However, FGA rs2070022 
located in the 3′ untranslated region of the gene, trended towards significance in 
non-Hispanic blacks (p = 0.07; β = -0.07; Figure 3.1).  The two SNPs (replicated 
and novel) associated with decreased plasma fibrinogen in non-Hispanic blacks 
collectively accounted for 1.7% of the trait variability. With the inclusion of SNP 
rs2070017, which trended towards significance, these three SNPs accounted for 
2.0% of the trait variability of plasma fibrinogen in non-Hispanic blacks.  
Associations with Hematological Traits 
In addition to testing for an association with plasma fibrinogen levels, we 
tested for associations between the fibrinogen gene cluster variation and traits 
measured in the CBC: platelet count, mean platelet volume, platelet distribution 
width, and white blood cell count (Figure 3.2). We identified three novel 
associations with fibrinogen variants and other CBC traits in non-Hispanic blacks 
(Figure 3.2, Table 3.3). Intronic FGA variant rs2070017 is associated with 
decreased platelet count in non-Hispanic blacks (β= -8.12, p-value = 0.01). A rare 
missense mutation in FGG, rs6063 (Gly712Arg, MAF < 0.001), is associated with 
increased platelet distribution width (β = 0.60, p-value =0.03). For mean platelet 
volume we identified an association with rs227409 in non-Hispanic blacks (β= -
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1.11, p-value = 0.05). There were no significant associations observed the other 
traits and fibrinogen SNPs in non-Hispanic blacks (Figure 3.2; Appendix P). 
Associations with Triglycerides 
There were no significant associations between SNPs in the fibrinogen gene 
cluster and triglyceride levels in non-Hispanic blacks (Figure 3.2; Appendix P). 
Our primary analysis included participants regardless of fasting status, which can 
affect triglyceride levels in individual participants. To account for variability due to 
fasting status, we performed an additional analysis with inclusion of time to last 
meal as a covariate in the models. Inclusion of fasting status did not yield different 
association results compared to the original analysis (data not shown). 
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Table 3.1.  Study population characteristics and hematological trait descriptive statistics for NHANES III 
non-Hispanic blacks participants.  Un-weighted means (± standard deviations) or percentages are given for 
demographic, plasma fibrinogen, and hematologic traits, by subpopulation for adults in phase 2 of NHANES III.  
Abbreviations:  non-Hispanic black (NHB)  
 
Variable Mean or % 
Standard Deviation 
 
Age (yrs) 40.7 ±16 
Female (%) 58 - 
Current Smokers (%) 37 - 
Body Mass Index (kg/m
2
) 28.2 ±6.67 
Plasma Fibrinogen (g/L) (n=621) 2.95 ±0.51 
Platelet Count (n= 1,688) 271 ±64 
Platelet Distribution Width (mean %) (n= 1,689) 16.3 ± 0.57 
Mean Platelet Volume (fL) (n=1,720) 8.56 ±0.98 
Ln Triglycerides (mg/dL) (n= 1,708) 4.38 ±0.35 
White Blood Cell Count (n=1,722) 6.69 ±2.11 
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Figure 3.1. Synthesis view plot of association results for plasma fibrinogen in 
non-Hispanic blacks. The –log10 of the p-value and the direction of the effect 
(indicated by arrow direction) are on the y-axis and SNPs are located on the x-axis. 
Abbreviation: NHB = non-Hispanic black. Arrows above the red line represent a 
significant association (p<0.05). 
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Table 3.2. Replication of results from previous studies in non-Hispanic blacks for plasma fibrinogen levels. We 
compared results from our tests of association with plasma fibrinogen and all SNPs tested with the results from previous 
studies. Note that the coded allele may be different across studies. Abbreviations: Candidate gene Association Resource 
(CARe), Coronary Artery Risk Development in Young Adults (CARDIA), Rotterdam Study (RS), Framingham Heart Study 
(FHS), Cardiovascular Health Study (CHS), Atherosclerosis Rick in Communities Study (ARIC), Monitoring of Trends and 
Determinants of Cardiovascular Disease/Cooperative Health Research in the Region Augsburg (MONICA/KORA), genome-
wide association study (GWAS). 
Abbreviations: NS = not significant  
 NHANES III non-Hispanic blacks 
CARe 
Wassel et al (GWAS) 
CARDIA 
Reiner et al (candidate gene) 
SNP Alleles 
Coded 
Allele 
β P-value 
Coded 
Allele 
β P-value 
Coded 
Allele 
β P-value 
rs2070017 A/G G 0.07 0.07 T -0.16 4.82E-9 A decreased NS 
rs2066874 A/G G -0.28 7.00 E-4 C -0.33 2.86E-11 G decreased NS 
rs6050 A/G G 0.01 0.52 -- -- -- G decreased NS 
rs6058 G/T G 0.06 0.18 T -0.17 9.52E-7 -- -- -- 
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Figure 3.2. Synthesis view plot comparing significant results from tests of 
association for five hematological traits in NHANES non-Hispanic blacks. The 
–log10 of the p-value and the direction of the effect (indicated by arrow direction) 
is on the y-axis and SNPs are located on the x-axis.  Each color represents the 
hematological traits tested for each SNP. Points above the red line represent a 
significant association (p<0.05). Abbreviations:  non-Hispanic black (NHB, mean 
platelet volume (MPV), transformed triglycerides (ln_TRI), white blood cell count 
(WBC), and platelet distribution width (PDW). 
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Discussion 
Using a large, diverse study population, we were able to replicate 
associations as well as identify novel associations between SNPs located in the 
fibrinogen gene cluster and levels of plasma fibrinogen in non-Hispanic blacks. 
Additionally, we were able to detect associations with fibrinogen SNPs and other 
CBC traits, indicative of pleiotropic effects.   
While we successfully replicated genetic associations reported for  plasma 
fibrinogen in non-Hispanic blacks (Table 3.2), three variants did not replicate the 
findings of previous studies  (Table 3.2; Appendix P) (Reiner et al., 2006a; Wassel 
et al., 2010g; Dehghan et al., 2009).  We were also unable to replicate the 
association with rs6058 and plasma fibrinogen in non-Hispanic blacks, most likely 
due to power (Table 3.2; Appendix P). 
  Several genetic variants have been identified to have an association with 
plasma fibrinogen in all three genes in the fibrinogen cluster (Reiner et al., 2006a; 
Wassel et al., 2010c). Most of these genetic variants are in non-coding regions of 
FGB, the rate limiting gene for the production of the fibrinogen polypeptide 
(Kottke-Marchant K, 2011). Little is known about function of genetic variation in 
the other genes, FGA and FGG, in the fibrinogen gene cluster.  Of the SNPs 
targeted for replication for plasma fibrinogen levels, three were putatively 
functional SNPs based on gene location.  Unfortunately, none of the novel variants 
we identified are in the coding regions of the fibrinogen cluster.  
This study has several strengths; one is the breadth of laboratory 
measurements available for tests of association.  Until recently, most genetic 
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association studies have ignored pleiotropy and have limited tests of association to 
a single trait or pathway. Pleiotropy is defined here and elsewhere as a locus 
affecting multiple traits (Wagner and Zhang, 2011).  In a statistical setting, 
pleiotropy is detected as a single genetic variant associated with multiple traits, but 
this setting does not establish causality without further experiments.   
Epidemiologic studies such as NHANES make statistical tests for pleiotropy 
possible, which may ultimately identify novel genotype-phenotype relationships 
and pathways (Pendergrass et al., 2011). Our study is unique in that we also 
investigated the pleiotropic effects of the fibrinogen cluster with hematological 
traits. This is important given the complex pathophysiology of cardiovascular 
disease and the role hematological traits play in the development of disease. 
Several studies have been published on genetic variation with levels of plasma 
fibrinogen but little is known about how these same variants impact hematological 
traits. It is known that elevated levels of plasma fibrinogen are observed for several 
disease states such as inflammation, deep venous thrombosis, and arterial 
thrombosis (David Ginsburg, 2005). However, it is still unclear as to whether 
elevated levels of plasma fibrinogen are a result of fibrinogen itself or other 
intermediate phenotypes underlying the pathophysiology. For example, arterial 
thrombosis, a common characteristic and intermediate phenotype for cardiovascular 
disease, is very complex and is likely to involve the fibrinogen gene cluster. 
However, unlike venous thrombosis, which is mainly due to the accumulation 
fibrin clots, arterial thrombosis is primarily due to platelet adhesion and it is likely 
involve hematological traits tested in this study (Feinbloom and Bauer, 2005; Lane 
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and Grant, 2000; Lowe, 2008; Mackman, 2008; Lowe, 2008).  We identified 
genetic associations with fibrinogen SNPs and other hematological traits suggesting 
possible pleiotropic effects. These findings support the idea that variants in the 
fibrinogen gene cluster may also affect the regulation of hematological traits. 
A weakness of the present study is power and sample size.   While 
NHANES III contains over 33,000 study participants, our study population sample 
size was limited for several reasons.  The Centers for Disease Control and 
Prevention (CDC) only collected DNA samples from a subset of the entire dataset, 
which includes 7,159 participants from phase 2 of NHANES III (from three 
racial/ethnic groups). DNA was not collected from participants who reported 
having hemophilia or chemotherapy within four weeks of collection (Gunter E. et 
al., 1996). Of these samples, plasma fibrinogen levels in NHANES III was only 
measured for participants > 40 years of age (Gunter E. et al., 1996), which 
drastically reduces our sample size with plasma fibrinogen (n~ 620) compared to 
the hematological traits (n ~ 1,650) . Despite the small sample sizes for plasma 
fibrinogen, we were able to successfully replicate known associations at a liberal 
significance threshold of p<0.05.   
 In summary, we have replicated previous associations within the fibrinogen 
gene cluster with plasma fibrinogen levels in an African descent population (non-
Hispanic blacks).  Additionally, we show that these variants are also associated 
with other hematological traits. Identifying these associations will provide 
important information about intermediate phenotypes with the ultimate goal of 
predicting cardiovascular disease outcome. 
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B. Replication and Generalization of Genome-Wide Association Study 
(GWAS)-Identified Variants in African Americans as Part of the 
Population Architecture using Genomics and Epidemiology (PAGE) 
Study 
 
Introduction 
 Genome wide association studies (GWAS) provide a relatively hypothesis 
free approach for detecting candidate disease regions in the genome. This approach 
tests the entire genome for an association between common variants and disease 
status or inter-individual trait variability. To date there are 31 GWAS in the 
NHGRI catalog of genome wide association studies for plasma fibrinogen and/or 
hematological traits (http://www.genome.gov/gwastudies/). Despite the success of 
these studies, only 6 % (5/31 GWAS) have been performed in African descent 
populations for these same traits. Most of these studies validate an association with 
alleles in the Duffy antigen/chemokine receptor (DARC) gene and white blood cell 
count (Crosslin et al., 2011; Reiner et al., 2011; Ramsuran et al., 2011). The 
presence of these “Duffy” alleles are common in African descent populations and 
are protective against malaria (Hadley and Peiper, 1997). Aside from these GWAS, 
there have been only two GWAS performed in African Americans: one for 
fibrinogen (Wassel et al., 2010f) and one for platelet aggregation-related traits 
(Johnson et al., 2010).  No GWAS has yet been performed in African Americans 
for the other hematological traits such as mean platelet volume or platelet count. 
The remaining 94% (26/31) of GWAS for fibrinogen or hematological traits 
have been limited to European or Asian descent populations, and it is unclear the 
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extent to which these associations generalize to African Americans. There is 
considerable trait variability between African and European descent populations for 
fibrinogen, platelet count, and white blood cell count (Cook et al., 2001; Hsieh et 
al., 2007; Segal and Moliterno, 2006). African Americans on average have a lower 
white blood cell count compared to Europeans, which is explained partly by the 
DARC locus; however recent GWAS have identified additional loci that explain 
this difference. Genetic association studies in African Americans for fibrinogen 
have yet to identify genetic risk factors that account for the differences in 
fibrinogen across populations. 
 In addition to trait variability between populations, there are also 
significant differences in allele frequencies and linkage disequilibrium patterns 
between Africans and Europeans at loci reported to effect fibrinogen and other 
coagulation factors. As previously mentioned, one study performed in diverse 
populations demonstrated that Factor V Leiden (rs6025) and the prothrombin 
G20210A (rs1799963) variants differ across populations (Rosendaal et al., 1998). 
The prevalence of these variants in African Americans and Hispanics is 1-2% and 
<0.04%, respectively compared to 5% and 2-4% observed in Europeans (Grody et 
al., 2001; Grody, 2003; McGlennen and Key, 2002) .   
 Replication and generalization of previously identified associations in 
African-descent populations has become an essential step for identifying the true 
“casual variant(s)” for common/complex diseases. The Population Architecture 
using Genomics and Epidemiology (PAGE) study is a large collaborative effort that 
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aims to examine whether GWAS-identified variants generalize to ethnically diverse 
population-based studies (Matise et al., 2011).   The Epidemiologic Architecture 
for Genes Linked to the Environment (EAGLE) is a part of the PAGE study. 
Parallel with the goals of PAGE, EAGLE aims to characterize candidate gene and 
GWAS-identified variants using data from the cross-sectional survey, the National 
Health and Nutrition Examination Survey (NHANES). In the present study, we 
replicate previous GWAS associations in African Americans for fibrinogen and 
generalize GWAS-identified in Europeans to non-Hispanic blacks from NHANES. 
Additionally, we tested these variants for possible pleiotropic effects with 
triglycerides, mean platelet volume, and platelet count. 
Methods 
Study Population 
 All NHANES procedures were approved by the CDC Ethics Review 
Board and written informed consent was obtained from all participants.  The 
present study was approved by the CDC Ethics Review Board.  Because the study 
investigators did not have access to personal identifiers, this study was considered 
non-human subjects research by the Vanderbilt University Institutional Review 
Board.     
 As previously mentioned in section A of this chapter, NHANES are cross-
sectional surveys that are conducted across the United States by the National 
Center for Health Statistics (NCHS) at the Centers for Disease Control and 
Prevention (CDC). One of the main goals of NHANES is to describe the health and 
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nutritional status of children and adults in the United States.  To do so, they 
oversampled non-Hispanic blacks, Mexican-Americans, the young, and the elderly. 
NHANES III was conducted between 1988 and 1994, and DNA was extracted from 
crude cell lysates  (Chang et al., 2009).    In 1999 NHANES became a yearly 
survey and ~8000 new DNA samples were extracted from blood between 1999 and 
2002.   
 For this study, ~ 2,108 and 1,350 samples from self-described non-
Hispanics blacks from NHANES III and NHANES 1999-2002, respectively, were 
available for genotyping. We refer to this dataset as combined NHANES (n=3,458 
non-Hispanic blacks). All participants were at least 18 years of age, and 
participants with measurements outside of the normal range for any trait were 
excluded from the analysis, as extreme measurements for these traits can indicate 
inflammation or recent trauma.   
Hematological Measurements 
Complete blood counts (CBCs) were performed on qualifying NHANES III 
participants using the Beckman Coulter method, a method that sizes and counts 
particles by using measurable changes in electrical resistance produced by 
nonconductive particles suspended in an electrolyte (Daum et al., 2000). For 
NHANES 1999-2000 and 2001-2002, CBCs were performed by a certified 
phlebotomist in the MEC using venipuncture. A quantitative, automated, 
differential cell counter was used to calculate exact values for hematological 
measurements (Gunter E. et al., 1996).  Plasma fibrinogen was measured from 
blood plasma on participants 40 years and older using the Clauss clotting method in 
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all NHANES participants (Daum et al., 2000). Serum triglycerides were measured 
using standard enzymatic methods. Blood was collected from all participants with 
the exception of those who reported having hemophilia or chemotherapy in the past 
four weeks (Gunter E. et al., 1996). 
SNP Selection and Genotyping  
 Using the NHGRI GWAS catalog (http://www.genome.gov/gwastudies/), 
we selected SNPs that have been previously identified by GWAS for the following 
traits: fibrinogen, mean platelet volume, red blood cell volume, platelet 
aggregation, mean corpuscular hemoglobin content, white blood cell count, red 
blood cell count and red blood cell volume.   A total of 32 SNPs that were 
previously identified from GWA studies or well-studied in candidate gene analysis 
were selected for genotyping (Appendix Q), and four of the nominated SNPs were 
available for this study (the other SNPs have yet to be genotyped). Genotyping was 
performed in the Center for Human Genetics Research DNA Resources Core and 
the laboratory of Dr. Jonathan Haines.  All SNPs were genotyped using either 
Sequenom’s iPLEX Gold assay on the MassARRAY platform (San Diego, CA) or 
Illumina’s BeadXpress.  All genotype data reported here passed CDC quality 
control metrics and are secondary analysis through CDC.  Aggregate data will be 
available through dbGaP under EAGLE/PAGE. 
Statistical Methods 
All analyses were performed using the Statistical Analysis Software (SAS 
v.9.2; SAS Institute, Cary, NC) either locally or via the Analytic Data Research by 
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Email (ANDRE) portal of the CDC Research Data Center (RDC) in Hyattsville, 
MD.  Pair-wise correlations for each trait were calculated using Pearson’s 
correlation coefficient. None of the traits were correlated (defined as r>0.50; 
Appendix M). Descriptive statistics for all traits are reported in Table 3.3. All traits 
followed a normal distribution with the exception of triglycerides, which was 
uniformly transformed by using the natural logarithm. 
Using standard linear regression, assuming an additive model, we tested 
two GWAS-identified variants for an association with fibrinogen, one GWAS-
identified variant with platelet count and one GWAS-identified variant with mean 
cell volume. Since we did not test mean cell volume in this analysis, this SNP was 
limited our analysis of pleiotropic effects with fibrinogen and the aforementioned 
hematological traits. To identify possible pleiotropic effects, we tested GWAS-
identified variants for fibrinogen with an association with mean platelet volume, 
platelet count, and log-transformed triglycerides, and the GWAS-identified variant 
for platelet count was tested for an association with fibrinogen, triglycerides, and 
mean platelet volume. All tests were limited to non-Hispanic blacks and adjusted 
for age, sex, body mass index (BMI), and smoking status. Current smoking status 
was determined by the question “Do you smoke cigarettes now?” and cotinine 
levels (>15 ng/ml). Participants that answered “yes” and have cotinine levels 
>15ng/ml were classified as a current smoker. 
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Results 
We were able to successfully replicate previous GWAS associations with 
fibrinogen cluster variants and plasma fibrinogen in our combined NHANES non-
Hispanic blacks (Table 3.4). Replication is defined here as having a consistent 
direction of effect and statistical significance at the p<0.05 level in the same study 
population as the original study.  We were able to replicate two associations:   
rs2070017 (β = -0.08, p= 0.02) located in the FGA gene and FGG intronic SNP 
rs2066874 (β = -0.28, p= 1.5 E-4) with decreased fibrinogen. Both associations 
were originally identified in African Americans(Wassel et al., 2010e) and are rare 
or monomorphic in European (MAF <0.001) and Asian (MAF <0.001) descent 
populations from HapMap (2003). The minor allele frequency for these variants in 
the Yoruban (YRI) or other African reference populations is ~0.20 and ~0.02 for 
rs2070017 and rs2066874, respectively (2003). Consistent with the YRI ancestral 
populations, the allele frequencies are comparable in non-Hispanic blacks:  MAF = 
0.10 and 0.02 for rs2070017 and rs2066874, respectively (Appendix N).  
Currently, there are no GWAS published for hematological traits platelet 
count and mean platelet volume in African Americans. We tested a GWAS-
identified variant from European Americans, rs210135, for an association in 
combined NHANES non-Hispanic blacks for platelet count. SNP rs210135 is 
located in the BAK1 gene and is common in both European (CEU) and African 
(YRI) HapMap reference populations, 0.32 and 0.25 respectively (2003). The 
minor allele frequency in combined NHANES non-Hispanic blacks is 0.28 and is 
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consistent with reported values in HapMap reference populations (Appendix N). In 
Europeans rs210135 was associated with increased platelet count (β = 5.43, p- 
value = 3.7E-10 (Soranzo et al., 2009), an association that generalized in non-
Hispanic blacks (β = 5.69, p-value 0.003; Table 3.4). 
In addition to replication and generalization, we tested for pleiotropic 
effects with GWAS-identified variants and other related traits available in 
NHANES.  For example rs1800562, identified by a GWAS in Europeans and was 
originally associated with mean cell volume (Soranzo et al., 2009), was tested here 
for an association with mean platelet volume, fibrinogen, triglycerides, and platelet 
count. Using this approach, a total of 13 tests of pleiotropy were performed in non-
Hispanic blacks, and two were significant at a liberal threshold of p<0.05 (Table 
3.5).   More specifically, intronic variant rs1800562, located in the protein coding 
hemochromatosis gene HFE, was associated with plasma fibrinogen in combined 
NHANES non-Hispanic blacks (β = 0.25, p-value = 7.50 E-5; Table 3.5). SNP 
rs210135,  originally associated with platelet count in Europeans (Soranzo et al., 
2009) and this non-Hispanic black sample, was also associated with mean platelet 
volume in non-Hispanic blacks (β = 0.05, p-value = 0.04; Table 3.5). 
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Variable 
NHANES III NHANES 1999-2002 Combined NHANES 
N 
Mean 
(SD) 
N Mean N 
Mean 
(SD) 
Plasma Fibrinogen (g/L) 651 
2.94 
(± 0.52) 
480 
3.35 
(± 0.46) 
1,133 
3.11 
(± 0.53) 
Platelet Count 1,688 
271.44 
(± 63.39) 
1,328 
258.00 
(± 62.87) 
3,071 
272.01 
(± 70.93) 
Mean Platelet Volume (fL) 1,720  
8.56 
(± 0.99) 
1,348 
8.46 
(±0.94) 
3,068 
8.52 
(± 0.97) 
ln(Triglycerides) (mg/dL) 1,708 
4.59 
(± 0.53) 
543 
4.39 
(± 0.35) 
2,385 
4.60 
(± 0.61) 
Table 3.3. Study Population Characteristics.  All study participants were self-described non-Hispanic blacks ascertained for NHANES III 
or NHANES 1999-2002. Unweighted means (± standard deviations) or percentages are given for plasma fibrinogen, and hematologic traits 
in combined NHANES non-Hispanic blacks Abbreviations: Standard Deviation (SD),   Nutrional Health or Nutrition Examination Survey 
(NHANES) 
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SNP Gene Phenotype 
Original Study 
Combined NHANES 
Non-Hispanic blacks 
 
Population 
Studied 
n β P-value MAF n β P-value MAF 
rs2070017 FGA Fibrinogen 
African 
American 
6,657 -0.16 4.8E-9 0.11 1,055 -0.08 0.02 0.10 
rs2066874 FGG Fibrinogen 
African 
American 
6,657 -0.33 2.9E-11 0.03 1,089 -0.28 1. 5 E-4 0.02 
rs210135 BAK1 
Platelet 
count 
Europeans 13,943 5.43 3.7E-10 NR 2,963 5.98 0.003 0.28 
Table 3.4. Replication/Generalization of GWAS identified variants in non-Hispanic blacks in combined NHANES 
dataset (NHANES III and NHANES 1999-2002) for fibrinogen and blood traits. We performed a standard linear 
regression adjusted for age, sex, body mass index (BMI) and smoking status for three GWAS-identified variants with noted 
phenotypes. Abbreviations NR = not reported, MAF = minor allele frequency. 
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Table 3.5. Significant pleiotropic effects detected with GWAS identified variants in non-Hispanic blacks in the 
combined NHANES dataset. We performed linear regression with GWAS-identified variants and hematological traits: 
platelet count, mean platelet volume, and log- transformed triglycerides. Significance was declared at p<0.05. Abbreviations: 
MPV = mean platelet volume  
SNP Gene 
Original Study 
Combined NHANES Non-Hispanic blacks 
 
Original 
Phenotype 
Population  n β P-value 
Associated 
Phenotype 
n β P-value 
rs1800562 HFE 
Mean cell 
volume 
Europeans 13,943 0.37 1.4E-23 Fibrinogen 1,102 0.25 7.5 E-5 
rs210135 BAK1 
Platelet 
Count 
Europeans 13,943 5.43 3.7E-10 MPV 2,960 0.05 0.04 
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Discussion 
Replication of genetic associations is imperative, as initial studies are 
subject to the overestimated effect sizes referred to as the “winner’s curse” (Xiao 
and Boehnke, 2009; Zhong and Prentice, 2010). We sought to first replicate 
previously identified fibrinogen associations in an independent African-descent 
population (non-Hispanic blacks from NHANES).  Notably, we replicated two 
associations, rs2070017 and rs2066784 originally identified by GWAS for 
fibrinogen, in our study population (Table 3.4).  These associations have been 
reported to be exclusive to individuals of African descent, as the effect allele is rare 
or not observed in European-descent populations. Our data support the latter 
observation as we also did not detect these associations in non-Hispanic whites 
from NHANES (p-value >0.2; see Chapter IV part B). 
Variants targeted for replication here were originally identified using a 
specialized fixed-content 50K BeadChip known as the ITMAT-Broad-CARe (IBC) 
(Wassel et al., 2010b). Unlike traditional GWAS chips, the IBC BeadChip is 
hypothesis-driven and only includes markers in genes biologically relevant to 
cardiovascular disease or related phenotypes (Keating et al., 2008). A major 
objective of this custom-content chip was to target population-specific tagSNPs in 
these biologically-relevant genes so that all known common proxies could be 
captured in the experiment either directly or via linkage disequilibrium (Keating et 
al., 2008). The data we report in NHANES mirror the design of this BeadChip as 
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both variants have low frequencies in non-Hispanic whites and are population 
specific to African-descent samples. 
The majority  of the literature on the synthesis of fibrinogen has been 
limited to  FGB, the rate limiting gene for the production of the fibrinogen poly 
peptide (Kottke-Marchant K, 2011).  Little is known about the impact of genetic 
variants in the other genes, FGA and FGG, and the effect they may or may not have 
on fibrinogen production.   The SNPs targeted for replication for plasma fibrinogen 
levels are located in the FGA or FGB genes. Although both SNPs are intronic, 
replication of these results can still be useful as intronic variants have been reported 
to effect protein synthesis(Law et al., 2007; Tokuhiro et al., 2003). Another 
possibility is that these intronic SNPs are correlated with the true functional SNP 
and tag this region in the genome. However, functional studies are needed to 
confirm role if, at all, these variants have on fibrinogen production.  
GWAS fixed-content products are based on a subset of common SNPs in 
the genome that serve as proxies for SNPs not directly assayed (also known as 
tagSNPs) (Carlson et al., 2004).  The use of tagSNPs is a cost effective alternative 
to genotyping all known common variants based on linkage disequilibrium patterns 
throughout the genome. Until recently tagSNPs targeted by GWAS products have 
been primarily based LD patterns and common variation in European populations, 
limiting the generalization of GWAS results to other populations.  
Despite these challenges, we were able to generalize GWAS-identified 
variant rs210135 in non-Hispanic blacks for platelet count (Table 3.4). Rs210135 
was previously genotyped on GWAS-fixed content platform in Europeans (Soranzo 
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et al., 2009). We were able to detect this association due to our increase in sample 
size (n= 2,963) and lack of minor allele frequency population differences between 
Europeans and non-Hispanic blacks (Fst < 0.01). Notably, this signal contains the 
gene BAK1 which encodes a protein that has proapoptotic effects that control the 
lifespan of platelets (Mason et al., 2007) . 
Recent searches for pleiotropy using methods such as the Phenome-wide 
associations studies (PheWAS) design (Pendergrass et al., 2011) has proven 
successful (Denny et al., 2010a; Denny et al., 2011). Using a similar approach, we 
identified two pleiotropic associations with GWAS-identified variants (Table 3.5). 
Our most significant finding rs1800562, originally reported to have an association 
with mean cell volume, is associated with increased levels of fibrinogen. This 
variant is located in the High Iron Fe (HFE) gene, which encodes the human 
hemochromatosis protein. This protein regulates iron absorption, and mutations in 
this gene lead to high levels iron in the blood resulting in hemochromatosis 
(Distante, 2006; Distante et al., 2000). The pleiotropic effect we detected with 
rs1800562 and increased fibrinogen levels is biologically relevant, as increased iron 
levels are also associated elevated fibrinogen levels in westernized 
populations(Miura et al., 2006). 
An important aspect of replication and generalization of genetic variants is 
power. In the new era of GWAS most studies have thousands to hundred 
thousands of samples thereby increasing power to detect small genetic effects 
throughout the genome. Our study is small compared to the original studies we 
sought to replicate/generalize (Soranzo et al., 2009; Wassel et al., 2010l). In fact 
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our sample size is only about 16% of the size used in the Wassel et al GWAS 
(6,657 African Americans) and 21% of the samples from the Soranzo GWAS 
(13,943 Europeans). Given our sample size we had >99% power to detect 
genetic effects comparable with the Wassel et al GWAS with a minor allele 
frequency of ≥ 0.10 (in our sample) at α= 0.05. We similarliy had 80% power to 
detect the effect originally reported by Soranzo et al in our non-Hispanic blacks 
given our sample size, minor allele frequency, and α =  0.05.  
 In addition to power, it is important to note that we did not correct for 
multiple testing. We declared significance at a liberal p-value of > 0.05. Another 
limitation to this study is that we did not adjust for population stratification. 
While our study was limited to non-Hispanic blacks we did not perform formally 
adjust for possible population stratification that could have confounded our 
results. Ancestry informative markers (AIMs) are currently not available for 
NHANES; therefore we are limted to stratifying samples by race/ethnicity to 
avoid population stratification. 
To our knowledge we are the first to report the replication of GWAS-
identified variants in an African-descent population for fibrinogen levels. Not 
surprisingly, we were able to generalize GWAS-identified variants with 
comparable allele frequencies across populations. We are also the first to report 
pleiotropic effects with GWAS-identified variants for these traits in African 
Americans.  Increased fibrinogen and other hematological traits have been 
consistently associated with cardiovascular disease, which disproportionately 
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affects African Americans at a higher rate compared with European descent 
populations (Segal and Moliterno, 2006; Mensah et al., 2005). Results from this 
study add to the limited genetic associations studies performed in African-
descent populations for fibrinogen and hematological traits with the ultimate 
goal of finding genetic risk factors of cardiovascular disease. 
  
102 
 
C. Genetic Modifiers of Fibrinogen Levels in African Americans 
 
Introduction 
Fibrinogen levels are highly heritable with reports of up to 50% of the trait 
variability attributable to genetic factors (Voetsch and Loscalzo.J, 2003). These 
estimates include genes within the fibrinogen gene cluster (FGA, FGB, and 
FGG) as well as other genes that regulate the production of fibrinogen (de Maat, 
2005). However, collectively these loci do not account for the expected genetic 
component for fibrinogen levels.   For complex traits such as fibrinogen that are 
highly variable, the search for novel disease loci that are highly penetrant or 
accurately predict fibrinogen levels has not been as successful compared to 
simple Mendelian disorders. Like many traits associated with cardiovascular 
disease, the role of the environment, several loci in the genome, or the 
interaction  amongst genes and/or with environment can account for some of the 
heritability yet to be described for fibrinogen levels. 
Fibrinogen has three pairs of polypeptides Aα, Bβ, γ that are encoded by 
three genes: FGA, FGB, and FGG, respectively(Mosesson, 1998). These 
polypeptides form disulfide bonds at the near their N-terminus and once 
connected make up fibrinogen (Zhang and Redman, 1996; Zhang and Redman, 
1994).  Fibrinogen synthesis is highly dependent on the interactions between 
fibrinogen polypeptide pairs. Therefore it is highly plausible that interactions 
between genes within the fibrinogen gene cluster may affect fibrinogen levels. In 
addition to possible gene-gene interactions, the interplay between genes and 
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environmental risk factors can explain the inter-individual variability of 
fibrinogen levels. Risk factors such as smoking, age, lack of exercise, sex, use of 
contraceptives, and body mass index (BMI) significantly contribute to the 
variability of fibrinogen levels amongst individuals (de Maat, 2001).  However, 
after accounting for these risk factors, a significant amount of the variance in 
fibrinogen levels remains unknown.   
One of the primary goals of the Population Architecture using Genomics 
and Epidemiology (PAGE) consortium is to identify genetic modifiers of 
common disease (Matise et al., 2011). Likewise, the Epidemiologic Architecture 
of Genes Linked to Environment (EAGLE), which is a part of the PAGE 
consortium, uses a diverse, cross-sectional survey that is rich in environmental 
information to identify genetic modifiers. Here we examine the effect of genetic 
modifiers (gene-gene and gene-environment) with plasma fibrinogen levels in 
non-Hispanic blacks from NHANES III (previously described). Using 25 SNPs 
in the fibrinogen cluster, we test for and identify gene-gene interactions within 
this cluster, as well as gene-environment interactions with these SNPs and 
known environmental risk factors. 
Methods 
Study Population 
 Non-Hispanic blacks with normal fibrinogen levels from NHANES III were 
available for this study. For more detail on exclusion/inclusion criteria as well as 
population characteristics please refer to the methods sub section “Study 
Population” and Table 3.1 in part A of this chapter. 
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 SNP selection and Genotyping 
 A total of 25 tagSNPs in FGA, FGB, or FGG were genotyped using the 
Illumina GoldenGate assay.  TagSNPs were selected using LDSelect (Carlson et 
al., 2004) for multiple populations at r
2 
>0.80 for common variants (minor allele 
frequency (MAF) >5%) in three candidate genes (FGA, FGB, and FGG) based 
on data available for European Americans and African Americans in 
SeattleSNPs (Crawford et al., 2005).  For more information on genotyping and 
SNP selection please refer to the methods sub section “SNP selection and 
genotyping” in part A of this chapter (page 75). 
Fibrinogen measurements 
  Plasma fibrinogen was measured from blood plasma on participants 40 
years and older using the Clauss clotting method (Daum et al., 2000). 
Descriptive statistics for fibrinogen levels are described in the results sub-section 
“Population Characteristics” and Table 3.1 in part A of this chapter (page 81). 
Participants with fibrinogen levels greater than >4.0 g/L were excluded from the 
analysis since extreme measurements can indicate inflammation or recent 
trauma. 
Statistical Methods 
  Using linear regression, cross product terms (all pair-wise gene-gene or 
gene-environment terms for 25 fibrinogen variants) were added to the regression 
models for plasma fibrinogen.  All SNPs were coded additively and all models 
were adjusted for the main effect of the SNP (both the GxG and GxE models) 
and environmental factor (only the GxE models). In addition to adjusting for 
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main effects, all analyses were adjusted for known covariates age, BMI, sex, and 
smoking status. Analyses were limited to self-identified non-Hispanic blacks 
from NHANES III.  All analyses were performed using the Statistical Analysis 
Software (SAS v.9.2; SAS Institute, Cary, NC) via the Analytic Data Research 
by Email (ANDRE) portal of the CDC Research Data Center (RDC) in 
Hyattsville, MD. We consider an interaction term significant at p<0.05.    
Results  
Gene-Gene Interactions  
We identified several gene-gene (GxG) interactions within the fibrinogen 
gene cluster that effect fibrinogen levels in non-Hispanic blacks (Table 3.6). We 
define a significant GxG interaction here as having significant interaction term 
(p<0.05) from two different genes in the fibrinogen gene cluster. A total of six 
unique GxG interactions were significant at the p< 0.05 level out of 276 total 
tests performed, which is less than expected by chance alone. Three GxG 
interactions were associated with decreased fibrinogen levels and three were 
associated with increased fibrinogen levels (Table 3.6).   
Missense variant rs6050 (Thr312Ala) in the FGA gene is a variant known to 
be associated with fibrinogen levels in Europeans. We were unable to detect this 
association with non-Hispanic blacks in our original single SNP analysis (see 
results section of part A of this chapter). However, the interaction term rs6050 x 
rs2227395 (FGG) was significantly associated with decreased fibrinogen levels 
in non-Hispanic blacks (β = 0.15, p-value = 0.017). Significant interactions 
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terms with FGB variant rs2227395 were consistently observed with SNPs in the 
FGA gene (3/4 tests of interaction; Table 3.6). None of the SNPs with significant 
GxG interaction terms were significantly associated with fibrinogen levels in the 
single SNP tests of association (Table 3.6; Appendix P). 
Gene-Environment Interactions  
We tested for gene-environment (GxE) interactions with fibrinogen cluster 
variants and sex, age, smoking status, and BMI separately for an association 
with plasma fibrinogen. All three environmental factors we tested have 
previously described as significant risk factors for elevated fibrinogen (de Maat, 
2001). We were able to detect 11 significant SNP environment interactions at p 
<0.05 level out of 99 total test performed. Interestingly interaction terms with 
two SNPs, rs2227434 (FGB, Pro337Ser) and rs6063 (FGG, Gly712Arg) were 
consistently associated fibrinogen levels and represent more than half (6/11) of 
the significant interactions (Table 3.7). These SNPs were not significant in the 
single SNP test of association and are rare in all NHANES III populations 
MAF<0.001, which could a result of small sample size (Table 3.7; Appendices 
N and P).  
Two SNP x BMI interactions were associated with fibrinogen levels at 
p<0.05 (Table 3.7). The interaction term rs6050 x BMI was significantly 
associated with increased fibrinogen levels (Table 3.7). Non-synonymous SNP 
rs6050 (Thr331Ala) is located in the FGA and was associated with decreased 
levels of serum fibrinogen in non-Hispanic whites but not non-Hispanic blacks 
in a single SNP test of association (Appendix P). Another interaction term with 
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BMI, rs2070006 x BMI, was significantly associated with decreased fibrinogen 
levels (Table 3.7). Rs2070006 is also located in the FGA gene; however this 
SNP was not significant in any NHANES III population in a single SNP model 
(Appendix P). Excluding rs2227434 and rs6063, there was only one SNP x sex 
interaction that was significantly associated with increased fibrinogen levels in 
non-Hispanic blacks, rs6058 x sex (Table 3.7).   This SNP was not associated 
with fibrinogen levels in non-Hispanic blacks in the single SNP test of 
association (Table 3.6; Appendix P).  
There were two SNP x smoking interaction terms that were significantly 
associated with decreased serum fibrinogen, rs2070033 x smoking and 
rs2070008 x smoking in non-Hispanic blacks (Table 3.7).  Both SNPs are 
located in the FGA gene and were not associated with fibrinogen levels in the 
single SNP test of association (Appendix P). 
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Gene-Gene 
Interactions 
SNP-SNP Interactions 
SNP 1 Main Effect SNP 2 Main Effect Interaction Term 
Beta 
(SE) 
p-value 
Beta 
(SE) 
p-value 
Beta 
(SE) 
p-value 
FGB x  FGG rs1800791 x rs1800792 
-0.08 
(0.04) 
0.07 
-0.01 
(0.04) 
0.71 
0.20 
(0.08) 
0.02 
FGA x  FGB rs2070006 x rs2227395 
0.01 
(0.03) 
0.85 
<0.001 
(0.03) 
0.94 
0.14 
(0.07) 
0.04 
FGA x  FGB rs2070009 x rs2227395 
<0.001 
(0.03) 
0.94 
<0.001 
(0.03) 
0.94 
-0.16 
(0.07) 
0.02 
FGA x  FGG rs2070022 x rs1049636 
-0.08 
(0.04) 
0.06 
0.06 
(0.03) 
0.07 
-0.18 
(0.08) 
0.03 
FGB x  FGG rs2227395 x rs2066861 
-0.02 
(0.05) 
0.61 
0.05 
(0.03) 
0.12 
0.17 
(0.07) 
0.01 
FGA x  FGB rs6050 x rs2227395 
0.02 
(0.03) 
0.52 
<0.001 
(0.03) 
0.94 
-0.15 
(0.06) 
0.02 
Table 3.6. Significant fibrinogen cluster gene-gene interactions in NHANES III non-Hispanic blacks for plasma fibrinogen 
(n = 621).  Using multivariate linear regression, we added cross product terms (all pair-wise SNP-SNP) to the regression models 
for serum fibrinogen.  Abbreviations: SE = standard error. 
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Interaction Gene 
SNP Main Effect 
Environment Main 
Effect 
SNP-Environment 
Interaction Effect 
Beta 
(SE) 
p-value 
Beta 
(SE) 
p-value 
Beta 
(SE) 
p-value 
rs6063 *age FGG Suppressed 
0.008 
(0.002) 
3.69E-07 
0.004 
(<0.01) 
3.69E-07 
rs2227434*age FGB 
0.26 
(0.49) 
0.59 
0.008 
(0.002)  
3.76E-07 
0.004 
(<0.01) 
3.76E-07 
rs6063*BMI FGG Suppressed 
0.02 
(0.003) 
4.21E-06 
0.01 
(<0.01) 
4.21E-06 
rs2227434*BMI FGB 
0.26 
(0.49) 
0.59 
0.02 
(0.003) 
4.32E-06 
0.01 
(<0.01) 
4.32E-06 
rs6050*BMI FGA 
0.01 
(0.03) 
0.52 
0.01 
(0.003) 
5.87E-06 
0.01 
(0.05) 
8.10E-03 
rs6063*sex FGG Suppressed 
0.10 
(0.04) 
0.02 
0.05 
(0.02) 
0.02 
rs2227434*sex FGB 
0.26 
(0.49) 
0.59 
0.09 
(0.04) 
0.02 
0.05 
(0.02) 
0.02 
rs6058*sex FGB 
0.06 
(0.05) 
0.18 
0.10 
(0.04) 
0.01 
0.22 
(0.10) 
0.03 
rs2070033*smoking FGA 
0.07 
(0.05) 
0.16 
-0.06 
(0.04) 
0.14 
-0.22 
(0.10) 
0.03 
rs2070006*BMI FGA 
0.005 
(0.03) 
0.85 
0.02 
(0.003) 
6.94E-06 
-0.01 
(<0.01) 
0.03 
rs2070008*smoking FGA 
-0.01 
(0.04) 
0.75 
-0.05 
(0.04) 
-0.16 
-0.19 
(0.01) 
0.04 
Table 3.7. Gene-environment interactions with fibrinogen variants and age, sex, BMI, and smoking status in non-Hispanic blacks 
(n=621) from NHANES III. Using linear regression we added the multiplicative terms (SNP x environmental factor) to the regression model 
while simultaneously adjusting for covariates: age, sex, BMI, and smoking status when necessary. Below are the results for the single SNP or 
environmental factor tests of association as well as the results for the interaction term. Note: there were several values that were suppressed for 
rs6063 by the the CDC’s Research Data Center (RDC) due to low counts (<5).  
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Discussion 
In the present study we performed an exhaustive analysis within the fibrinogen 
gene cluster to detect gene-gene and gene-environment interactions that may affect 
fibrinogen levels in non-Hispanic blacks from NHANES III.  Identifying genetic 
modifiers of fibrinogen levels is important since the genetic contribution of variable 
fibrinogen levels at the population level is poorly understood. Additionally, current 
heritability estimates (h
2
, or narrow sense heritability) do not include possible gene-
environment interactions. Here using a multiplicative approach, we tested for 
statistical epistasis or the deviation from linearity in the presence and absence of main 
effects. We tested for interactions amongst 25 tagSNPs in the fibrinogen gene cluster 
(gene-gene) as well as tested each SNP with environmental risk factors: age, sex, BMI 
and smoking status (gene-environment). We observed six gene-gene interactions and 
eleven gene-environment interactions with an empirical p-value < 0.05.  
One criticism of exhaustively testing for interactions is the biological 
interpretation of the results.  The fibrinogen gene cluster is an ideal candidate for 
identifying gene-gene interactions since each gene is dependent on the other to 
produce active fibrin in the blood (Zhang and Redman, 1996; Zhang and Redman, 
1994). In our gene-gene analysis we detected several interactions between different 
genes in the cluster (Table 3.6). More importantly we identify several interactions with 
rs2227395, which is in the FGB gene is the known as the rate-limiting gene in 
fibrinogen production. It is important to note that this SNP did not have a significant 
main effect in the single SNP test of association in non-Hispanic blacks (Appendix P). 
Interestingly, all gene-gene interactions we identified were observed in the absence of 
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main effects (Table 3.6). It is possible that SNPs such as rs2227395 (where we did not 
observe a significant main effect) are interacting with other SNPs and ultimately 
affecting fibrinogen levels, an effect that would not be detected at the single SNP 
level. 
Environmental variables are well-known risk factors of elevated fibrinogen levels 
(de Maat, 2001). It is accepted by many in the field that genes interact with the 
environment (Manolio et al., 2009). We identified several gene-environment 
interactions that were associated with fibrinogen levels in non-Hispanic blacks (Table 
3.7). Interestingly, we observed similar results for interaction terms containing 
rs2227434 or rs6063 and environmental factors: age, sex, and BMI (Table 3.7). More 
often than not identical association results for different SNPs is indicative of high 
correlation or linkage disequilibrium between SNPs. We attempted to calculate linkage 
disequilibrium between these SNPs in our study population but failed obtain accurate 
results due to low genotype accounts for both SNPs (Appendix O). We then attempted 
to use reference HapMap population YRI to determine LD between these SNPs but 
like our study population genotype frequencies are too low for an accurate 
measurement (2003). As previously mentioned, both SNPs are rare in non-Hispanic 
blacks with minor allele frequencies (MAF) less 0.001 and we only have 5% power to 
detect these effects given the low MAF in our study population. After evaluating the 
main effect of the environmental factors we noticed that the association results for 
these genetic variants and the interaction term with rs2227434 or rs6063 were identical 
as well (Table 3.7). The association results we observe for these interaction terms may 
be false positives and actually represent the environmental factors alone, given how 
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rare these SNPs are. For these reasons we caution the interpretation of these results. 
On the contrary, we were able to successfully identify two SNP x BMI interactions 
both of which have significant environmental main effects as well as two SNP x 
smoking interactions and one SNP x sex interaction.  
Two major weaknesses to this study are power and multiple testing. While 
NHANES III contains over 33,000 study participants, our study population sample 
size was limited for several reasons.  The Centers for Disease Control and Prevention 
(CDC) only collected DNA samples from a subset of the entire dataset, which includes 
7,159 participants from phase 2 of NHANES III. DNA was not collected from 
participants who reported having hemophilia or chemotherapy within four weeks of 
collection (Gunter E. et al., 1996). Our outcome variable for this study was limited to 
plasma fibrinogen which was only collected on a subset of NHANES participants. 
Plasma fibrinogen levels in NHANES III was only measured for participants > 40 
years of age (Gunter E. et al., 1996), which drastically reduces our sample size to 621 
non-Hispanic blacks. Due to sample size, on average we were only 70% powered to 
detect effects that explain less < 0.5% of the trait variability at α = 0.05 and MAF of at 
least 0.05.  
One caveat of exhaustively testing all pair-wise interactions is the increase in type 
I error or false positives. It is important to note for this study that we did not correct 
for multiple testing, which increases the likelihood of reporting false positives, thereby 
reducing our confidence of our reported findings. 
Despite the small sample sizes, we were able to successfully identify several 
gene-gene and gene-environment associations at a liberal significance threshold of 
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p<0.05.  To date this is the first study that examines the role genetic modifiers have on 
plasma fibrinogen levels in an African American population. Therefore, all results 
reported are novel and yet to be reported in the literature. Despite the statistical 
evidence of epistasis, we cannot confirm the effect these interactions have on 
fibrinogen levels. Future analyses are needed with larger sample sizes for replication 
and to distinguish between a true interaction and a spurious false positive result. 
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CHAPTER IV 
 
GWAS- AND CANDIDATE GENE-IDENTIFIED VARIANTS FOR 
ELECTROCARDIOGRAPHIC TRAITS AND FIBRINOGEN LEVELS: 
REPLICATION IN EUROPEAN AMERICANS AND CHARACTERIZATION IN 
MEXICAN AMERICANS 
A. Electrocardiographic traits:  Replication in European Americans and 
Characterization in Mexican Americans 
 
Introduction 
 
Cardiovascular disease (CVD) by definition is the pathogenesis related to the 
heart and its associated vasculature (Arking and Chakravarti, 2009). An 
electrocardiogram (ECG) measures the electrical activity of the heart and is a useful tool 
in assessing cardiac arrhythmias, myocardial infarction, pericarditis, and other cardiac 
abnormalities (Micheal A Chizner, 2004). The ECG records electrical depolarization and 
repolarization of the heart and provides information about the electrical activity of the 
cardiac cycle. Candidate gene studies have identified several genes throughout the 
genome that effect heart depolarization and conduction measured by ECG traits. Genes 
that encode voltage gated potassium and sodium channels play an important role in the 
pathophysiology of long QT syndrome (George, Jr. et al., 1995; Wang et al., 1995b; 
Wang et al., 1995a; Lai et al., 1994; Splawski et al., 2002; Splawski et al., 1997; Wang et 
al., 1996). In Chapter II, we identified 13 independent associations in the NAv1.5 sodium 
channel α subunit gene (SCN5A) with ECG traits in African Americans from the Jackson 
Heart Study (Table 2.2;(Jeff et al., 2011b). Many of the associations identified in this 
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African American population were novel, and it is unclear if these associations generalize 
to other populations such as Mexican Americans. 
There are over 120 unique trait-SNP associations reported in the National Human 
Genome in Research Institute’s (NHGRI) GWAS catalog for ECG traits in European or 
Asian descent populations (http://www.genome.gov/gwastudies/). The successes of these 
GWAS have identified several variants throughout the genome such as NOS1AP and 
SCN10A that replicate across several studies (Newton-Cheh et al., 2009; Smith et al., 
2009b; Chambers et al., 2010; Arking et al., 2006; Post et al., 2007); (Holm et al., 2010); 
(Newton-Cheh et al., 2007b) (Marroni et al., 2009) (Pfeufer et al., 2010). Most of these 
studies, discovery and replication, have been limited to European and Asian descent 
populations. To date, there have been no studies confirming whether these associations 
generalize in Mexican Americans.  
One of the primary goals of Epidemiologic Architecture for Genes Linked to the 
Environment (EAGLE) as part of the Population Architecture using Genomics and 
Epidemiology (PAGE) study is to characterize GWAS-identified variants in a diverse 
cross-sectional survey, the National Health and Nutrition Examination Surveys 
(NHANES) (Matise et al., 2010). Using the Third NHANES (Elaine W et al., 1996), we 
first generalize SCN5A candidate gene associations identified in African Americans to 
non-Hispanic whites (a European descent population) and Mexican Americans. 
Additionally, we determine the extent to which GWAS-identified variants replicate in 
non-Hispanic whites and generalize to Mexican Americans. 
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Methods 
Study Population 
 All analyses were performed in non-Hispanic whites and Mexican Americans 
from NHANES III. Ascertainment of NHANES III and method of DNA collection have 
been previously described (Crawford et al., 2006; Chang et al., 2009; Steinberg et al., 
1997).  The National Health and Nutritional Examination Surveys are cross-sectional 
surveys conducted across the United States by the National Center for Health Statistics 
(NCHS) at the Centers for Disease Control and Prevention (CDC). NHANES III was 
conducted between 1988-1990 (phase 1) and 1991-1994 (phase 2) (1996; 2004) as a 
complex survey design that over-sampled minorities, the young, and the elderly.  All 
NHANES have interviews that collect demographic, socioeconomic, dietary, and health-
related data.  Also, all NHANES study participants undergo a detailed medical 
examination at a central location known as the Mobile Examination Center (MEC).  
Beginning with phase 2 of NHANES III, DNA samples were collected from study 
participants aged 12 years and older.  
ECG traits 
 Electrocardiograms (ECGs) were recorded on men and women in the mobile 
examination center (MEC) using a standard 12-lead resting ECG. ECGs were recorded 
using the Marquette MAC 12 (Marquette Medical Systems, Inc, Milwaukee, Wisconsin 
(U.S. DHHS, 1996). NHANES III 12-lead ECG data were recorded with eight 
independent components of the 12 standard leads simultaneously. ECG data were also 
sampled at 250 samples per second per channel, giving the availability of multiple 
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simultaneous ECG leads for analysis. ECGs were only performed on individuals 40 years 
of age and older.  NHANES III is the only contemporary NHANES that collected ECG 
data. 
SNP Selection and Genotyping  
DNA was extracted from crude cell lysates from lymphoblastoid cell lines 
established for NHANES III participants aged 12 and over as part of Genetic NHANES 
(Steinberg et al., 1997). SCN5A SNPs were previously identified in African Americans 
from the Jackson Heart Study (Jeff et al., 2011b). In this analysis, SNPs were selected 
based on the linkage disequilibrium patterns in African Americans (Bush et al., 2009). 
Twelve SNPs were associated with ECG traits at p<1.0x 10
-4
 in Jackson Heart Study, and 
to date, five of these SNPs have been successfully genotyped in NHANES III. 
 We also selected SNPs that have been previously identified by GWAS for all 
ECG traits using the NHGRI genome catalog (http://www.genome.gov/gwastudies/).    A 
total of 46 SNPs that were previously identified from GWA studies or well-studied in 
candidate gene analysis were selected for genotyping, and 15 of the nominated SNPs 
were available for this study. We did not consider SNPsfrom publicatons that did not 
report effect sizes and coded alleles from the original analysis (7 SNPs total; (Newton-
Cheh et al., 2007b; Vasan et al., 2007; Smith et al., 2009b)).  
All genotyping was performed in the Center for Human Genetics Research DNA 
Resources Core and the laboratory of Dr. Jonathan Haines.  All SNPs were genotyped 
using either Sequenom’s iPLEX Gold assay on the MassARRAY platform (San Diego, 
CA) or Illumina’s BeadXpress.  All genotype data reported here passed CDC quality 
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control metrics and are available for secondary analysis through CDC.  Aggregate data 
will be available through dbGaP under EAGLE/PAGE. 
Statistical Methods 
All analyses were performed using the Statistical Analysis Software (SAS v.9.2; 
SAS Institute, Cary, NC) either locally or via the Analytic Data Research by Email 
(ANDRE) portal of the CDC Research Data Center (RDC) in Hyattsville, MD. All traits 
followed a normal distribution and descriptive statistics are reported in Table 4.1.  
Participants with QRS duration >120 m/sec were excluded from all analysis. Using 
standard linear regression and assuming an additive genetic model, we tested each SNP 
for an association with ECG traits: P duration, QRS duration, QT interval and heart rate. 
We did not test SCN5A variants for an association with heart rate and QT interval since 
these SNPs were not associated with these traits in the original analysis. All tests were 
limited to non-Hispanic whites and Mexican Americans and adjusted for age and sex. All 
analysis were stratified by self-reported race/ethnicity. Significance was declared at a 
liberal threshold of p<0.05 unadjusted for multiple testing. 
Results 
Population Characteristics  
Our study population characteristics in NHANES III non-Hispanic whites and 
Mexican Americans were comparable to JHS African Americans (Table 4.1). Non-
Hispanic whites on average were younger (average age = 61.5 yrs) compared to JHS 
African Americans and Mexican Americans (Table 4.1). However, age was not 
statistically different between Mexican Americans and JHS African Americans (Table 
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4.1). There were differences between NHANES III populations and Jackson Heart Study 
(JHS) African Americans (Table 4.1). In addition to age, P duration, PR interval, and 
QRS duration all varied between non-Hispanic whites and JHS African Americans (Table 
4.1).  
Generalization of Candidate Gene-identified Variants 
  We genotyped five candidate SNPs in the SCN5A gene in non-Hispanic whites 
and Mexican Americans from NHANES III that were previously associated in JHS 
African Americans (see Chapter II(Jeff et al., 2011b). Using the same approach as the 
original study, we performed tests of association to generalize JHS associations in non-
Hispanic whites and Mexican Americans for ECG traits. We considered a SNP 
generalized if it had consistent direction of effect and was statistically significant at 
p<0.05. We performed a total of 15 tests of association for three ECG traits: P duration, 
PR interval, and QRS duration (five SNP tests of association per trait).   
We were able to generalize two ECG trait-SNP associations in non-Hispanic 
whites and Mexican Americans (Table 4.2). In JHS African Americans, rs7374138 was 
associated with decreased P duration (  = -1.5, p=3.6R-03), PR interval (  = -4.0, 
p=2.4E-05) and QRS duration (  = -1.3, p=6.2E-06) (Chapter II, Table 2.2). For P 
duration, the association generalized in non-Hispanic whites (  = -2.50, p=0.006).  For 
PR interval, the association generalized to Mexican Americans (  = -5.57, p< 0.005; 
Table 4.2).  Interestingly, the magnitude of the effect is larger compared to JHS results 
for both NHANES III populations. Though not statistically significant, rs7374138 had a 
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consistent direction of effect in non-Hispanic whites and Mexican Americans for the 
other ECG traits (Table 4.2).  
Generalization of GWAS-identified variants 
A total of 15 GWAS identified SNPs were genotyped and tested for an 
association with ECG traits in Mexican Americans. We declared a generalization as 
being statistically significant and having the same direction of effect with the previous 
study. Notably, rs12143842 located in NOS1AP, which has been replicated several times 
in Europeans, generalizes to Mexican Americans (β= 4.03, p= 0.02; Table 4.3). 
Regardless of significance, half of the SNPs tested also have a consistent direction of 
effect compared to the original study (Table 4.3).  
Replication 
We genotyped 15 GWAS identified variants in non-Hispanic whites for 
replication and generalization. As previously mentioned, we did not consider SNPs from 
publications that did not report effect sizes and coded alleles from the original analysis 
(seven SNPs), resulting in total of eight SNPs considered here. Replication was defined 
by statistical significance (p <0.05) and consistent direction of effect with the same SNP 
in the same ancestral population. Seven SNPs were tested for replication with QT 
interval, and one SNP was test for replication with PR interval in NHANES III non-
Hispanic whites. Previously identified variants rs12143842 and rs12029454, located in 
NOS1AP, replicated with QT interval in NHANES III non-Hispanic whites (p< 0.001; 
Table 4.3). These two associations are not in linkage disequilibrium in CEU reference 
population (r
2
=0.03) and likely represent independent effects. Another SNP, rs11970286, 
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located in PLN, replicated in non-Hispanic whites and was associated with increased QT 
interval (β=2.97, p= 0.01; Table 4.3). Consistent with other findings in NHANES III, the 
effect size was larger compared to the original study. Regardless of significance, several 
associations (63%) had a consistent direction of effect and only three (3/8) trended in the 
opposite direction compared to the original study (Table 4.3).   
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Table 4.1 Study population characteristics. Means and standard deviations were calculated for ECG traits and age, by NHANES III 
population.   Abbreviations:  non-Hispanic white (NHW), Mexican Americans (MA), standard deviation (SD).  
 
Trait 
JHS 
African Americans 
 
NHANES III 
non-Hispanic whites 
 
NHANES III Mexican 
Americans 
 
Mean SD Mean SD Mean SD 
Age (yrs) 56.5 ±11.73 61.5 ±13.51 55.66 ±12.10 
P Duration (msec) 118.5 ±13.08 109.8 ±18.24 109.8 ±12.47 
PR Interval (msec) 171.6 ±33.02 162.6 ±26.83 157.2 ±23.01 
QRS duration (msec) 92.3 ±10.12 95.04 ±10.25 95.85 ±10.90 
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Table 4.2. Generalization of SCN5A variants in non-Hispanic whites and Mexican Americans from NHANES III.  
Linear regression adjusted for age and sex was performed on three previously identified associations in non-Hispanic whites 
and Mexican Americans.  
 
 
 
SNP Phenotype 
JHS African Americans 
(n = 3,054) 
NHANES III non-
Hispanic whites 
(n =  1,051) 
NHANESIII Mexican 
Americans 
(n = 580 ) 
β P-value β P-value β P-value 
rs7637849 P Duration -1.70 1.1E-3 2.93 0.03 -1.35 0.40 
rs7374138 P Duration -1.50 3.6E-3 -2.50 0.006 -1.10 0.20 
rs11129796 P Duration -0.81 0.18 8.41 0.14 0.07 0.96 
rs7629265 P Duration -3.20 7.5E-5 10.89 0.34 -2.53 0.65 
rs6768664 P Duration 0.60 0.18 -1.06 0.19 -0.57 0.40 
rs7637849 PR Interval -4.20 2.3E-5 1.45 0.46 -2.92 0.31 
rs7374138 PR Interval -4.00 2.4E-5 -2.24 0.09 -5.57 3.4E-4 
rs11129796 PR Interval -3.50 2.4E-4 -3.01 0.71 -0.93 0.71 
rs7629265 PR Interval -7.80 2.4E-7 2.93 0.84 17.67 0.08 
rs6768664 PR Interval 3.00 2.4E-4 -1.3 0.20 0.21 0.86 
rs7637849 QRS Duration -0.76 1.2 E-2 3.06 0.32 0.76 0.30 
rs7374138 QRS Duration -1.30 6.2E-6 -1.20 0.09 -1.90 0.16 
rs11129796 QRS Duration -1.10 2.5E-3 -0.41 0.402 0.95 0.42 
rs7629265 QRS Duration -1.50 1.8E-3 -1.00 0.85 5.99 0.20 
rs6768664 QRS Duration 0.67 9.5E-3 -0.30 0.45 -0.35 0.55 
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Table 4.3 Replication and Generalization of European GWAS-identified variants in NHANES III Non-Hispanic whites 
and Mexican Americans, respectively.  We performed a standard linear regression adjusted for age and sex for eight GWAS-
identified variants with QT or PR Intervals. Abbreviations: NR= original study did not report (NR) data. 
SNP Gene(s) Phenotype 
Original Study 
NHANES III Non-
Hispanic whites 
(n=1050) 
NHANES III 
Mexican Americans 
(n =580) 
Original 
Population 
β P-value β P-value β P-value 
rs37062 CNOT1 QT Interval European 1.75 3.0E-25 -1.02 0.44 1.95 0.17 
rs12143842 NOS1AP QT Interval European 3.15 2.0E-78 4.26 1.0E-3 4.03 0.02 
rs7188697 NDRG4 QT Interval European 1.66 7.0E-25 0.98 0.45 2.13 0.13 
rs2461751 Intergenic PR Interval 
Pacific 
Islanders 
4.54 8.0E-6 -0.15 0.92 -0.78 0.59 
rs11970286 PLN QT Interval European 1.64 2.0E-24 2.97 0.01 2.00 0.23 
rs12029454 NOS1AP QT Interval European 2.98 3.0E-45 5.25 9.0E-4 -0.80 0.64 
rs2074238 KCNQ1 QT Interval European 7.88 3.0E-17 -2.88 0.18 -0.66 0.87 
rs4725982 KCNH2 QT Interval European 1.58 5.0E-16 2.04 0.14 -0.19 0.89 
rs882300 Intergenic PR Interval European NR 3.2 E-7 0.78 0.50 0.52 0.74 
rs10498091 Intergenic 
Echo. Vent. 
Traits 
European NR 6.00 E-6 -0.87 0.57 -2.77 0.19 
rs10504543 KCNB2 
Echo. Vent. 
Traits 
European NR 5.00E-06 0.12 0.92 -0.04 0.97 
rs10507380 RPL21 QT Interval European NR 8.00E-06 -1.01 0.54 4.28 0.13 
rs1379659 SLIT2 
Echo. Vent. 
Traits 
European NR 1.00E-7 Not tested due to small sample size 
rs2008242 MSX1 PR Interval Pacific Islander NR 3.00 E-6 -0.01 0.99 -0.15 0.96 
rs7512898 NR PR Interval Pacific Islander NR 5.00E-6 -0.002 0.99 -0.24 0.86 
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Discussion 
 To identify genetic risk factors that contribute to ECG trait variability, we 
performed a candidate gene study of SNC5A variation in the Jackson Heart Study to 
determine the extent to which African American genetic risk factors generalize in other 
populations (Chapter II). We then generalized two SCN5A associations in NHANES III 
with P duration and PR interval in European Americans and Mexican Americans, 
respectively. Additionally, we replicated and generalized NOS1AP variants originally 
identified by GWAS in non-Hispanic whites and Mexican Americans, respectively.  The 
characterization of genetic variation in multiple populations adds to the understanding of 
the role of genetics in cardiovascular disease on a population level.  
Generalization of SCN5A associations 
The NAv1.5 sodium channel α subunit is encoded by SCN5A which is the 
predominant α-subunit expressed in the heart (George, Jr. et al., 1993; Gellens et al., 
1992).  Mutations in SCN5A have been previously described for cardiac conduction 
disease, long QT syndrome, Brugada syndrome, and other life threatening arrhythmias 
(Wang et al., 1995c; Bezzina et al., 1999; Schott et al., 1999; Chen et al., 1998). In 
Chapter II, we describe SCN5A variation in greater than 3,000 African Americans from 
the Jackson Heart Study. We identified 13 associations with ECG traits in the SCN5A 
region. In the present study, we examined the generalizability of these SNPs in other 
populations and generalized two associations. One association, rs7374138 was associated 
with decreased P duration in non-Hispanic whites and decreased PR interval in Mexican 
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Americans. This SNP is located intron region of SCN5A and  to date has not been 
described in non-Hispanic whites or Mexican Americans.  
Over 90% of the SNPs tested (28 out of 30 associations) did not generalize in our 
study. Of these, six and seven associations in non-Hispanic whites and Mexican 
Americans, respectively, had consistent directions of effect regardless of significance 
compared to African Americans from the JHS. The lack of generalizability could be due 
to power and/or low minor allele frequencies. Indeed, the minor allele frequencies (MAF) 
for four SCN5A variants were rare (MAF <0.05) in non-Hispanic whites and Mexican 
Americans, effectively reducing the power  for these tests of association (Appendix S). 
Overall, we were inadequately powered (<50%) to detect JHS effects in non-Hispanic 
whites and Mexican Americans for SCN5A variants with the exception of rs7374138 
(MAF >0.10in either population, Appendix R).   
The lack of generalizability could also be due to differing patterns of linkage 
disequilibrium, which can also affect the power to detect an association.  In both GWAS 
and in candidate gene studies such as the one performed in JHS for SCN5A, the majority 
of associated SNPs are tagSNPs.  That is, the associated SNPs are not the functional or 
true “risk” SNP but are in linkage disequilibrium with the un-genotyped functional 
variant.  It is known that genome-wide linkage disequilibrium patterns vary across 
populations (Bush et al., 2009). Thus, the associated or tagSNPs identified in SCN5A in 
African Americans may not tag or be in linkage disequilibrium with the true functional or 
risk variants in non-Hispanic whites and Mexican Americans.  
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Replication and generalization of ECG trait GWAS 
There have been several GWAS performed for ECG traits in recent years, many 
of which replicate known ion-channel polymorphisms and as of recently variants in the 
NOS1AP region. Here we tested eight of these previously identified variants with two 
ECG traits (PR and QT interval), in non-Hispanic whites and Mexican Americans (a total 
of 32 tests). We were able to replicate three associations in non-Hispanic whites and 
generalize one association in Mexican Americans. 
Replication was defined in this analysis as having a consistent direction of effect 
and statistical significance in the same population as the original study. Using this 
definition we were able to replicate three GWAS identified in non-Hispanic whites.  We 
replicate two independent associations in NOS1AP and one association in PLN for QT 
interval. Additionally, we were able to generalize one NOS1AP variant rs12143842 in 
Mexican Americans.  
 We were significantly underpowered to replicate/generalize GWAS identified 
variants in NHANES III non-Hispanic whites and Mexican Americans. We performed 
power calculations using the effect size from the original study to determine our power to 
detect the same effects given our sample size and minor allele frequency. For the SNPs 
that did not generalize we had <60% power to detect these effects in non-Hispanic whites 
and <45% power to detect these effects in Mexican American for any ECG trait. Despite 
this limitation, we were able to successfully generalize associations with large effects that 
we were adequately powered (>80%) to detect in non-Hispanic whites. 
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Strengths and Limitations 
 One limitation to the present study is sample size. The sample sizes in the 
NHANES III populations are less than a third the size compared to original studies. As 
previously mentioned, our small sample size limited our power to replicate and 
generalize previous associations, specifically those with small effect sizes. The 
overestimation of effect sizes is often observed in the discovery analyses and referred to 
as the “winner’s curse” (Xiao and Boehnke, 2009; Zhong and Prentice, 2010). In our 
analysis we observed the opposite of the winner’s curse, with effect sizes larger 
compared to the original study despite small sample size. This could be evidence of 
spurious associations and further analysis in a study population with larger sample sizes 
is needed to confirm these results.  
 The need for future studies with larger sample sizes is evident from this work. To 
date, NHANES III is the only NHANES dataset that collected ECG traits. The potential 
findings or lack thereof from this work emphasizes the importance of collecting these 
measurements. Since NHANES collection is continual, measuring ECG traits would be 
very useful for future analysis and possible meta-analysis.  In addition to the NHANES 
datasets, there are other study sites within the PAGE consortium with ECG 
measurements in diverse populations such as African Americans (ex. Coronary Artery 
Risk Development in Young Adults (CARDIA) and Atherosclerosis Risk in 
Communities (ARIC)). 
A major limitation related to these efforts to generalize across populations and 
across studies is the lack of standard publication or reporting guidelines.  That is, seven 
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associations reported in the literature did not contain data related to the direction of the 
effect.  Our definition of generalization requires statistical significance and consistent 
direction of effect compared with the original report.  For these seven variants, we are 
limited to reporting the NHANES III results of tests of association, but we cannot make 
definitive statements concerning generalization across populations. 
Using a diverse cohort, NHANES III, we successfully replicated and generalized 
previous associations for ECG traits. More importantly we replicated and generalized 
rs12143842, which is located in the NOS1AP gene in non-Hispanic whites and Mexican 
Americans. To date the NOS1AP SNPs have no known function; however these 
associations have successfully replicated in several European descent populations. This is 
the first time these associations have been described in Mexican Americans. Despite the 
identification of the NOS1AP variant by multiple studies, the extent to which this gene 
affects QT interval is still poor understood.  
Conclusions 
Although we were underpowered to detect most associations, we were 
successfully able to generalize SCN5A variant rs7374138 in our study populations. We 
were also able to confirm NOS1AP variants in NHANES III. The two variants we 
identify have no obvious function; therefore further fine-mapping of this region is 
warranted to determine the role of these variants with QT interval.  This study also 
suggests that genetic variants that replicate/generalize can be prioritized for clinical use 
given the generalizability of these associations in multiple populations.  Overall, these 
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data server as a starting point for future genetic association studies of ECG traits in 
Mexican Americans and other diverse populations. 
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B. Plasma Fibrinogen and Hematological Traits: Replication in European 
Americans and Generalization in Mexican Americans
4
 
 
Introduction 
 African Americans and Hispanics have more risk factors for cardiovascular 
disease (CVD) putting them at higher risk compared to European Americans (Mensah et 
al., 2005; Winkleby et al., 1998). Coagulation factors such as fibrinogen and other 
hematological traits are quantitatively measured from the blood and are associated with 
CVD risk (Thompson et al., 1995; Meade et al., 1986).   Heritability estimates report 
between 0.37-0.89 of the trait variability for fibrinogen and other hematological factors 
attributable to genetic factors (Voetsch and Loscalzo.J, 2003; Pennington et al., 2001); 
(Evans et al., 1999). The accuracy of current heritability estimates studies is unclear, 
since most of the heritability studies were limited to familial data (mostly twin studies) in 
European descent populations and do not include possible gene-environment interactions 
that effect trait variability. The disparity of CVD risk disproportion could be due to 
genetic differences between populations for intermediate traits such as fibrinogen. It is 
well-known that there are significant differences in allele frequencies and linkage 
disequilibrium patterns across populations.  Despite this disparity most genetic 
association studies, including heritability studies for fibrinogen and hematological 
phenotypes have been limited to Europeans descent populations. 
                                                     
4
 Partially adapted from: Jeff JM, Brown-Gentry K, Crawford DC. Replication and 
characterization of genetic variants in the fibrinogen gene cluster with fibrinogen levels 
and hematological traits in the Third National Health and Nutrition Examination Survey 
In Press: Thrombosis and Haemostasis 
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Genome wide association studies (GWAS) and candidate gene studies have 
successfully identified several variants with fibrinogen. To date there are 31 GWAS in 
the NHGRI catalog of genome wide association studies for plasma fibrinogen and/or 
hematological traits (http://www.genome.gov/gwastudies/). Despite the success of these 
studies, the majority of these GWAS were performed in European descent populations 
and none have been reported for Mexican Americans. As previously mentioned in 
Chapter III,  the frequency of variants in the coagulation pathway vary across populations 
(Rosendaal et al., 1998; Grody et al., 2001; Grody, 2003; McGlennen and Key, 2002). 
The extent to which these variants generalize to other populations is important. In 
addition to generalization, replication of genetic associations is imperative, as initial 
studies are subject to the overestimated effect sizes referred to as the “winner’s curse” 
(Xiao and Boehnke, 2009; Zhong and Prentice, 2010). With the exception of genes that 
encode coagulation factors such as Factor V Lieden, replication of associations with 
fibrinogen and hematological phenotypes has been inconsistent. This is mainly due to 
different study designs, genetic and/or trait heterogeneity, and differences in 
environmental exposures across studies. 
 The Population Architecture using Genomics and Epidemiology (PAGE) study is 
a large collaborative effort that aims to examine whether GWAS-identified variants 
generalize to ethnically diverse population-based studies (Matise et al., 2011).   The 
Epidemiologic Architecture for Genes Linked to the Environment (EAGLE) is a member 
of the PAGE consortium and uses data from a cross-sectional survey, the National Health 
and Nutrition Examination Survey (NHANES), to identify and describe the genetic 
architecture of GWAS identified variants. In the present study, we first use NHANES III 
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to identify and replicate genetic associations with 25 fibrinogen cluster variants with 
fibrinogen and other hematological traits measured in non-Hispanic whites and Mexican 
Americans.  Then we tested for and identify gene-gene interactions within this cluster, as 
well as gene-environment interactions with these SNPs and known environmental risk 
factors. Then we sought to replicate/generalize two fibrinogen cluster variants that were 
not a part our original study in NHANES IIII in non-Hispanic whites and Mexican 
Americans from NHANES 99-02.  Lastly, using a combined NHANES dataset we 
replicate and/or generalize previous GWAS associations in non-Hispanic whites and 
Mexican Americans for fibrinogen and test for possible pleiotropic effects with 
triglycerides, mean platelet volume, and platelet count. 
Methods 
Study Population 
 The National Health and Nutritional Examination Surveys are cross-sectional 
surveys conducted across the United States by the National Center for Health Statistics 
(NCHS) at the Centers for Disease Control and Prevention (CDC). Ascertainment of 
NHANES III and method of DNA collection have been previously described (Crawford 
et al., 2006; Chang et al., 2009; Steinberg et al., 1997).   NHANES III was conducted 
between 1988-1990 (phase 1) and 1991-1994 (phase 2) (1996; 2004) as a complex survey 
design that over-sampled minorities, the young, and the elderly. To do so, they 
oversampled non-Hispanic blacks, Mexican-Americans, the young, and the elderly. In 
1999 NHANES became a yearly survey and ~8000 new DNA samples were extracted 
from blood between 1999 and 2002 (NHANES 99-02). All NHANES have interviews 
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that collect demographic, socioeconomic, dietary, and health-related data.  Also, all 
NHANES study participants undergo a detailed medical examination at a central location 
known as the Mobile Examination Center (MEC).  The medical examination includes the 
collection of physiological measurements by CDC medical personnel and blood and urine 
samples for laboratory tests.   
All procedures were approved by the CDC’s Ethics Review Board and written 
informed consent was obtained from all participants. This candidate gene association 
study was approved by the CDC’s Ethics Review Board (protocols #2003-08 and #2006-
11) and the University of Washington’s Institutional Review Board (IRB #23667; HSRC 
D committee).  Because no identifying information was accessed by the investigators, 
this study was considered exempt from Human Subjects by Vanderbilt University’s 
Institutional Review Board (IRB #061062; HS2 committee).   
For this analysis, 4,167 and 5,880 samples from self-described non-Hispanic 
whites and Mexican Americans from NHANES III and NHANES 1999-2002, 
respectively, were available for genotyping. We refer to this dataset as combined 
NHANES, which collectively contain 10,047 samples (n=6,414 non-Hispanic whites and 
3,633 Mexican Americans). All participants were at least 18 years of age, and 
participants with measurements outside of the normal range for any trait were excluded 
from the analysis, as extreme measurements for these traits can indicate inflammation or 
recent trauma.   
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Fibrinogen Measurements 
 Plasma fibrinogen was measured from blood plasma on participants 40 years and 
older using the Clauss clotting method (Daum et al., 2000). Descriptive statistics for 
fibrinogen levels are described in Table 4.4. Participants with fibrinogen levels greater 
than >4.0 g/L were excluded from the analysis since extreme measurements can indicate 
inflammation or recent trauma. 
Hematological Measurements 
Blood was collected from all participants with the exception of those who 
reported having hemophilia or chemotherapy in the past four weeks (Gunter E. et al., 
1996). Complete blood counts (CBCs) were performed on qualifying NHANES 
participants using the Beckman Coulter method, a method that sizes and counts particles 
by using measurable changes in electrical resistance produced by nonconductive particles 
suspended in an electrolyte (Daum et al., 2000). A quantitative, automated, differential 
cell counter was used to calculate exact values for hematological measurements (Gunter 
E. et al., 1996).  Serum triglycerides were measured using standard enzymatic methods. 
Descriptive statistics for hematological traits and serum triglycerides are described in 
Table 4.4. 
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SNP Selection and Genotyping 
DNA was extracted from crude cell lysates from lymphoblastoid cell lines 
established for NHANES III participants aged 12 and over as part of Genetic NHANES 
(Steinberg et al., 1997). TagSNPs were selected using LDSelect (Carlson et al., 2004) for 
multiple populations at r
2 
>0.80 for common variants (minor allele frequency (MAF) 
>5%) in three candidate genes (FGA, FGB, and FGG) based on data available for 
European Americans and African Americans in SeattleSNPs (Crawford et al., 2005).  A 
total of 25 fibrinogen cluster SNPs were genotyped using the Illumina GoldenGate assay 
(as part of a custom 384 oligonucleotide pool assay (OPA) by the Center for Inherited 
Disease Research (CIDR) through the National Heart Lung and Blood Institute’s 
Resequencing and Genotyping Service. The data presented in this analysis were limited 
to non-Hispanic whites and Mexican Americans from NHANES III. All genotype data 
reported here were deposited into the NHANES III Genetic database and are available for 
secondary analysis through CDC. 
 Using the NHGRI genome catalog (http://www.genome.gov/gwastudies/), we 
selected SNPs that have been previously identified by GWAS for the following traits: 
fibrinogen, mean platelet volume, red blood cell volume, platelet aggregation, mean 
corpuscular hemoglobin content, white blood cell count, red blood cell count and red 
blood cell volume.   A total of 32 SNPs that were previously identified from GWAS or 
well-established in candidate gene studies were selected for genotyping (Appendix Q), 
and four of the nominated SNPs were available for this study. Genotyping was performed 
in the Center for Human Genetics Research DNA Resources Core and the laboratory of 
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Dr. Jonathan Haines.  All SNPs were genotyped using either Sequenom’s iPLEX Gold 
assay on the MassARRAY platform (San Diego, CA) or Illumina’s BeadXpress.  All 
genotype data reported here passed CDC quality control metrics and are available for 
secondary analysis through CDC.  Aggregate data will be available through dbGaP under 
EAGLE/PAGE. 
Statistical Methods 
All analyses were performed using the Statistical Analysis Software (SAS v.9.2; 
SAS Institute, Cary, NC) either locally or via the Analytic Data Research by Email 
(ANDRE) portal of the CDC Research Data Center (RDC) in Hyattsville, MD.  Analyses 
were limited to self-identified non-Hispanic whites and Mexican Americans who were at 
least 18 years of age.  Participants with measurements outside of the normal range for any 
trait were excluded from the analysis, as extreme measurements for these traits can 
indicate inflammation or recent trauma.  Pair-wise correlations for each trait were 
calculated using Pearson’s correlation coefficient. None of the traits were correlated 
(defined as r>0.50; Appendix M). Descriptive statistics for all traits are reported in Table 
4.4. Coded allele frequencies for fibrinogen cluster SNPs are reported in Appendix N. All 
traits followed a normal distribution with the exception of triglycerides, which was 
uniformly transformed by using the natural logarithm. 
Pair-wise linkage disequilibrium was calculated for all 25 fibrinogen cluster SNPs 
using Haploview (Appendix O) (Barrett et al., 2005). Single-locus tests of association 
were performed using linear regression for each fibrinogen SNP and each hematological 
trait in NHANES III:  plasma fibrinogen, mean platelet volume, white blood cell count, 
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platelet distribution width, log-transformed serum triglycerides, and platelet count.  For 
each test of association, we assumed an additive genetic model. Analyses were performed 
un-weighted and unadjusted and adjusted for age, sex, body mass index (BMI) and 
current smoking status (yes/no), and results were plotted using Synthesis View 
(Pendergrass et al., 2010b). Analyses were repeated to include time to last meal (in hours) 
as a covariate (data not shown). Current smoking status was determined by the question 
“Do you smoke cigarettes now?” and cotinine levels (>15 ng/ml).  We also tested two 
additional SNPs identified by candidate gene studies in NHANES 99-02. Using the same 
approach described for NHANES III, we tested these two SNPs for an association with 
fibrinogen levels in non-Hispanic whites and Mexican Americans from NHANES 99-02. 
Using standard linear regression, assuming an additive model, we tested two 
GWAS-identified variants for an association with fibrinogen, one GWAS-identified 
variant with platelet count, and one GWAS-identified variant with mean cell volume in 
the combined NHANES dataset (NHANES III and NHANES 99-02). Since we did not 
test mean cell volume in this analysis, this SNP was limited our analysis of pleiotropic 
effects with fibrinogen and the aforementioned hematological traits. To identify possible 
pleiotropic effects we tested GWAS-identified variants for fibrinogen with an association 
with mean platelet volume, platelet count, and log-transformed triglycerides, and a 
GWAS-identified variant for platelet count was tested for an association with fibrinogen, 
triglycerides, and mean platelet volume. All tests were limited to non-Hispanic whites or 
Mexican Americans and adjusted for age, sex, body mass index (BMI), and smoking 
status. Current smoking status was determined using the same criteria as NHANES III. 
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We used a standard linear regression to perform all gene-gene (GxG) and gene-
environment (GxE) interaction analyses. Cross product terms (all pair-wise gene-gene or 
gene-environment terms for 25 fibrinogen variants) were added to the regression models 
for plasma fibrinogen in non-Hispanic whites and Mexican Americans from NHANES 
III.  All SNPs were coded additively and all models were adjusted for the main effect of 
the SNP and environmental factor. In addition to adjusting for main effects, all analyses 
were adjusted for known covariates age, BMI, sex, and smoking status. Analyses were 
limited to self-identified non-Hispanic blacks from NHANES III.  All analyses were 
performed using the Statistical Analysis Software (SAS v.9.2; SAS Institute, Cary, NC) 
via the Analytic Data Research by Email (ANDRE) portal of the CDC Research Data 
Center (RDC) in Hyattsville, MD. We consider an interaction term significant at p<0.05.    
Results 
Novel Associations 
We identified two novel associations between genetic variants and plasma 
fibrinogen in non-Hispanic whites and Mexican Americans from NHANES III (Figure 
4.1, Table 4.5).  In non-Hispanic whites, intronic FGB rs2227395 (β = -0.08, p=0.0007; 
Table 4.5) was associated with decreased plasma fibrinogen levels. FGB rs2227395 is in 
strong linkage disequilibrium (LD) (r
2
= 0.86; Appendix O) with rs4220 (previously 
identified), and thus likely represents the same effect. FGA rs2070022, located in the 3′ 
untranslated region of the gene, was associated with decreased plasma fibrinogen levels 
in Mexican Americans (β = -0.07; Table 4.5). This association accounted for 1.0% of the 
trait variability in Mexican Americans. 
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In addition to testing for an association with plasma fibrinogen levels, we tested 
for associations between the fibrinogen gene cluster variation and traits measured in the 
CBC: platelet count, mean platelet volume, platelet distribution width, and white blood 
cell count in non-Hispanic whites and Mexican Americans from NHANES III (Figure 
4.2). We identified six significant associations with fibrinogen SNPs and other 
hematological traits (Figure 4.2; Table 4.5). FGA rs6050 (Thr312Ala) and FGG 
rs2066879 were associated with decreased (β = -0.03; p = 0.04) and increased (β = 0.77; 
p = 0.02) platelet distribution width in non-Hispanic whites, respectively. Increased 
platelet distribution width was associated with rs2227425 in Mexican Americans (Table 
4.5). Non-synonymous FGG rs4220 (Arg478Lys) and FGB intronic rs2227395 were both 
associated with decreased white blood cell count in Mexican Americans (β = -0.28, p = 
0.006 and β = -0.23, p = 0.02, respectively). We identified a significant association with 
rs1800792, located in the 5′ flanking region of FGG, and decreased platelet count in 
Mexican Americans (Figure 4.2; Table 4.5). There were no significant associations 
observed between mean platelet volume and fibrinogen SNPs in any subpopulation 
(Figure 4.2).  
There were two significant associations with serum triglycerides in Mexican 
Americans. Intronic FGG rs2066860 was associated with increased serum triglycerides 
and 5′ flanking FGG rs1800792 was associated with decreased triglyceride levels (Figure 
4.2; Table 4.5).  Our primary analysis included participants regardless of fasting status, 
which can affect triglyceride levels in individual participants. To account for variability 
due to fasting status, we performed an additional analysis with inclusion of time to last 
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meal as a covariate in the models. Inclusion of fasting status did not yield different 
association results compared to the original analysis (data not shown). 
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Table 4.4 Study population characteristics and hematological trait descriptive statistics for non-Hispanic whites and 
Mexican Americans in NHANES.  Unweighted means (± standard deviations) or percentages are given for demographic, 
plasma fibrinogen, and hematologic traits, by subpopulation for adults in phase 2 of NHANES III.  Abbreviations:  non-
Hispanic white (NHW), and Mexican American (MA).   
 
Variable 
non-Hispanic Whites Mexican Americans 
NHANES III NHANES 99-02 
Combined 
NHANES 
NHANES III NHANES 99-02 
Combined 
NHANES 
n 
Mean 
(SD) 
n 
Mean 
(SD) 
n 
Mean 
(SD) 
n 
Mean 
(SD) 
n 
Mean 
(SD) 
n 
Mean 
(SD) 
Plasma 
Fibrinogen 
(g/L) 
1,452 
2.93 
(±0.50) 
1,809 
3.31 
(±0.45) 
3,262 
3.14 
(±0.51) 
696 
2.97 
(±0.50) 
763 
3.29 
(±0.47) 
1,459 
3.14 
(±0.51) 
Platelet 
Count 
2,384 
252 
(±58) 
3,945 
258 
(±62) 
6,410 
260 
(±67) 
1,732 
266 
(±62) 
1,848 
267 
(±61) 
3,628 
270 
(±68) 
Platelet 
Distribution 
Width (mean 
%) 
2,378 
16.5 
(±0.47) 
N/A N/A N/A N/A 1,729 
16.4 
(±0.54) 
N/A N/A N/A N/A 
Mean Platelet 
Volume (fL) 
2,407 
8.43 
(±0.92) 
4,000 
8.22 
(±0.87) 
6,407 
8.31 
(±0.89) 
1,748 
8.57 
(±0.98) 
1,873 
8.38 
(±0.86) 
3,621 
8.48 
(±0.87) 
ln 
Triglycerides 
(mg/dL) 
2,400 
4.51 
(±0.32) 
1,215 
4.53 
(±0.33) 
4,386 
4.87 
(±0.59) 
1,050 
4.52 
(±0.31) 
538 
4.54 
(±0.33) 
2,701 
4.93 
(±0.61) 
White Blood 
Cell Count 
2,409 
7.38 
(±2.46) 
4,001 
7.42 
(±2.19) 
N/A N/A 1,754 
7.73 
(±2.08) 
1,875 
7.44 
(±2.01) 
N/A N/A 
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Table 4.5 Novel significant associations between the fibrinogen cluster and hematological traits in NHANES III. Linear 
regressions adjusting for age, sex, BMI and smoking status were performed for 25 SNPs, assuming an additive genetic model 
for five hematological traits. Significant associations (p < 0.05) between the fibrinogen cluster variants and any one 
hematologic traits in any NHANES III population are shown. 
 
 
SNP Phenotype Location/Gene Race/Ethnicity N BETA SE p-value 
rs2227395 Plasma fibrinogen Intron/ FGB Non-Hispanic White 1,391 -0.08 0.02 7.00E-04 
rs2070022 Plasma fibrinogen 3′ UTR/ FGA Mexican American 659 -0.07 0.03 1.06E-02 
rs2066860 LN Triglycerides Intron/ FGG Mexican American 1,005 0.13 0.06 2.27E-02 
rs1800792 LN Triglycerides 5′ flanking/ FGG Mexican American 1,005 -0.03 0.01 2.84E-02 
rs6050 Platelet Distribution Width Thr312Ala/FGA Non-Hispanic White 2,270 -0.03 0.02 4.06E-02 
rs1800792 Platelet Count Promoter/ FGG Mexican American 1,663 -5.32 2.30 2.07E-02 
rs4220 White blood cell count Arg478Lys/FGB Mexican American 1,682 -0.28 0.10 6.20E-03 
rs2227395 White blood cell count Intron/ FBG Mexican American 1,682 -0.23 0.10 2.00E-02 
rs2227425 Platelet Distribution Width 3’UTR/ FGB Mexican Americans 1,661 1.14 0.54 3.00E-02 
rs2066879 Platelet Distribution Width 3’ near FGG Non-Hispanic White 2,268 0.77 0.32 2.00E-02 
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 Figure 4.1 Synthesis view plot comparing results from tests of association across 
NHANES subpopulations for plasma fibrinogen. The –log10 of the p-value and the 
direction of the effect (indicated by arrow direction) are on the y-axis and SNPs are 
located on the x-axis. Each color represents a different NHANES III population:  blue 
(non-Hispanic white; NHW), red (Mexican American; MA). Arrows above the red line 
represent a significant association (p<0.05). 
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Figure 4.2 Synthesis view plot comparing significant results from tests of association 
for five hematological traits across NHANES subpopulations. The –log10 of the p-
value and the direction of the effect (indicated by arrow direction) are on the y-axis and 
SNPs are located on the x-axis.  Each panel represents a different population from the 
NHANES III dataset and each color represents the hematological traits tested for each 
SNP. Points above the red line represent a significant association (p<0.05). 
Abbreviations:  non-Hispanic white (NHW), Mexican American (MA), mean platelet 
volume (MPV), transformed triglycerides (ln_TRI), white blood cell count (WBC), and 
platelet distribution width (PDW).  
 
 
 
 
 
 
 
NHW 
 
 
 
 
 
 
 
 
 
 
MA 
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Replication 
We replicated several single SNP associations from previous studies in non-
Hispanic whites from NHANES III (Table 4.6). Replication was defined by statistical 
significance (p <0.05) and consistent direction of effect with the same SNP in the same 
ancestral population across studies. Four of the six tests of association replicated at 
p<0.05 and, after accounting for the coded allele, all tests trended in the same direction as 
previous reports regardless of significance (Table 4.6) . In non-Hispanic whites, we 
replicated two associations previously reported in a candidate gene study (Reiner et al., 
2006a):  rs6050 (Thr312Ala; p = 0.03) and intronic rs1049636 (p =0.04) were associated 
with decreased and increased plasma fibrinogen, respectively. We also replicated two 
associations reported from recent GWA studies (Wassel et al., 2010k; Dehghan et al., 
2009):  FGG intronic rs2066861 (β = 0.05; p=0.01) and FGB nonsynonymous rs4220 (β 
= -0.08; p=0.002; Table 4.6). 
There were several SNPs in the fibrinogen gene cluster we did not genotype in 
our original analysis in NHANES III.  Our initial analysis was limited to tagSNPs chosen 
in either CEU or YRI HapMap reference populations (2003). Consequently, there were 
several SNPs that have been previously described by other candidate gene studies we did 
not analyze in NHANES III. We sought to replicate and/or generalize these variants in 
NHANES 99-02. To do so we genotyped two additional fibrinogen cluster variants that 
were originally identified by candidate gene studies in NHANES 99-02 participants. We 
did not replicate rs1800790, the only SNP previously identified in Europeans in our non-
Hispanic whites from NHANES 99-02 (Table 4.7).  This was an unexpected finding since 
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allele frequencies for rs1800790 are similar between the original population and our 
study population (MAF= 0.20, original study and MAF=0.16 in non-Hispanic whites). 
Additionally, we were adequately powered >80% to detect this effect given our sample 
sizes which is also comparable to the original study. 
To replicate variants identified by GWAS, we genotyped three SNPs that were 
originally associated with fibrinogen and/or other hematological traits in our combined 
NHANES dataset. Only one of the three SNPs (rs210135) genotyped was previously 
described in Europeans (the others were originally identified in African Americans). 
BAK1 variant, rs210135 was originally associated with decreased platelet count in 
Europeans (Table 4.8). We replicate this association in non-Hispanic whites from the 
combined NHANES dataset (Table 4.8).  
Generalization 
As previously mentioned, we genotyped two additional fibrinogen cluster variants 
in NHANES 99-02 for generalization studies. We considered a SNP generalized if it had 
consistent direction of effect and is statistically significant at p<0.05 in a different 
population that the original analysis. One SNP rs2070017 was previously identified by 
Reiner et al with decreased fibrinogen levels in African Americans.  We failed to 
generalize this association in non-Hispanic whites (Table 4.7); however this association 
generalized in Mexican Americans from NHANES 99-02 (Table 4.9). The other SNP 
genotyped in NHANES 99-02, rs1800790, was previously associated with increased 
fibrinogen levels in Europeans (Reiner et al., 2006a). This SNP did not replicate in non-
Hispanic whites (see previous section “Replication”; Table 4.7) nor did it generalize in 
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Mexican Americans (Table 4.9). While rs1800790 was statistically significant in 
Mexican Americans, the direction of effect was not consistent between studies (β=-0.07, 
p-value = 0.01; Table 4.9). 
We used the combined NHANES dataset to determine the extent to which 
GWAS-identified variants associated with fibrinogen and/or other hematological traits 
generalize/replicate in non-Hispanic whites and/or Mexican Americans. We tested total 
of three SNPs: rs2070017, rs206674, and rs210135 for an association with either 
fibrinogen or platelet count in non-Hispanic whites and Mexican Americans. Two SNPs 
rs2070017 and rs206674 were previously identified  by GWAS in African Americans and 
were associated with decreased fibrinogen levels (Wassel et al., 2010d).  These variants 
did not generalize to non-Hispanic whites and rs2070017 had a different direction of 
effect compared to African Americans (Table 4.8). One SNP, rs2070017, was associated 
with decreased fibrinogen levels (β = 0.18, p-value = 0.04) and had a consistent 
magnitude of effect compared to African Americans. As previously mentioned, we 
genotyped one SNP in the combined dataset that was originally identified in Europeans 
and is associated with deceased platelet count. We replicated this finding in non-Hispanic 
whites (previously mentioned) and we generalized this variant in Mexican Americans (β 
= -5.91, p- value 5.8E-4; Table 4.10). 
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Table 4.6 Replication of results from previous studies in non-Hispanic whites for plasma fibrinogen levels. We compared 
results from our tests of association with plasma fibrinogen and all SNPs tested with the results from previous studies. Note 
that the coded allele may be different across studies. Abbreviations: Candidate gene Association Resource (CARe), Coronary 
Artery Risk Development in Young Adults (CARDIA), Rotterdam Study (RS), Framingham Heart Study (FHS), 
Cardiovascular Health Study (CHS), Atherosclerosis Risk in Communities Study (ARIC), Monitoring of Trends and 
Determinants of Cardiovascular Disease/Cooperative Health Research in the Region Augsburg (MONICA/KORA). 
Abbreviations: CA= coded allele, NHW = non-Hispanic white 
 
 
 
 
NHANES III 
non-Hispanic white 
CARe 
Wassel et al 
CARDIA 
Reiner et al 
RS/FHS/CHS/ARIC/ 
MONICA 
Wassel et al 
SNP Alleles CA β P-value CA β P-value CA β 
P-
value 
CA β P-value 
rs4220 A/G G 0.08 2.10E-3 A 0.14 1.04E-34 -- -- -- G -0.08 2.14E-27 
rs2070011 A/G G 0.02 0.14 -- -- -- A -3.82 0.005 -- -- -- 
rs6050 A/G G 0.04 0.03 -- -- -- G -7.04 0.001 -- -- -- 
rs1800788 C/T C 0.04 0.10 -- -- -- T -6.41 0.008 -- -- -- 
rs1049636 C/T C 0.04 0.04 -- -- -- C 6.16 0.003 -- -- -- 
rs2066861 A/G G 0.05 0.01 T -0.06 4.18E-10 -- -- -- -- -- -- 
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Table 4.7 Generalization/Replication of SNPs identified by a candidate gene study of the fibrinogen gene cluster for 
plasma fibrinogen in non-Hispanic whites from NHANES 99-02. We performed standard linear regression with previously 
identified variants within the fibrinogen cluster in non-Hispanic whites from NHANES 99-02. All tests were adjusted for age, 
sex, smoking status, and BMI. The same coded allele was assigned across studies. 
 
Table 4.8 Replication of GWAS- identified variant rs210135 and generalization of African American GWAS-identified 
variants in non-Hispanic whites from the combined NHANES. We performed a standard linear regression adjusted for age, 
sex, BMI, and smoking status. The same coded allele was assigned across studies. 
 
 
SNP Gene 
Original Study NHANES 99-02 Non-Hispanic whites 
Population Studied n β P-value n β (SE) P-value 
rs1800790 FGB European 1,765 10.47 <0.001 1,733 -0.01 (0.02) 0.37 
rs2070017 FGA African American 1,461 -14.01 3.0E-3 1,647 0.14 (0.11) 0.18 
SNP Gene Phenotype 
Original Study 
Combined NHANES Non-Hispanic 
whites 
Original 
Population 
n β P-value n β (SE) P-value 
rs2070017 FGA Fibrinogen African American 6,657 -0.16 4.82E-9 3,044 0.14 (0.11) 0.20 
rs2066874 FGG Fibrinogen African American 6,657 -0.33 2.86E-11 3,102 -0.12 (0.20) 0.53 
rs210135 BAK1 Platelet Count Europeans 13,943 5.43 3.7E-10 6,094 3.10 (1.28) 0.02 
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Table 4.9 Generalization of SNPs identified by a candidate gene study of the fibrinogen gene cluster for plasma 
fibrinogen in Mexican Americans from NHANES 99-02. We performed standard linear regression with previously 
identified variants within the fibrinogen cluster in non-Hispanic whites from NHANES 99-02. All tests were adjusted for age, 
sex, smoking status, and BMI. The same coded allele was assigned across studies. 
 
Table 4.10 Generalization of GWAS identified variants in Mexican Americans from the combined NHANES dataset. 
We performed a standard linear regression adjusted for age, sex, BMI, and smoking status. The same coded allele was assigned 
across studies. 
 
SNP Gene 
Original Study 
NHANES 99-02 Mexican 
Americans 
Population Studied n β P-value n β (SE) P-value 
rs1800790 FGB European 1,765 10.47 <0.001 749 -0.07 (0.03) 0.01 
rs2070017 FGA African American 1,461 -14.01 3.00E-3 720 -0.24 (0.11) 0.02 
SNP Gene Phenotype 
Original Study 
Combined NHANES 
Mexican Americans 
Population Studied n β P-value n β (SE) P-value 
rs2070017 FGA Fibrinogen African American 6,657 -0.16 4.82E-9 1,386 -0.18 (0.09) 0.04 
rs2066874 FGG Fibrinogen African American 6,657 -0.33 2.86E-11 1,376 0.33 (0.22) 0.13 
rs210135 BAK1 Platelet Count Europeans 13,943 5.43 3.7E-10 3,545 -5.91 (1.71) 5.8E-4 
152 
 
 
Pleiotropy 
Epidemiologic studies such as NHANES make statistical tests for pleiotropy 
possible, which may ultimately identify novel genotype-phenotype relationships and 
pathways (Pendergrass et al., 2011). We tested for pleiotropic effects with GWAS-
identified variants and other related traits available in non-Hispanic whites and Mexican 
Americans from the combined NHANES dataset.  For example rs1800562, identified by 
a GWAS in Europeans and was originally associated with mean cell volume (Soranzo et 
al., 2009), was tested here for an association with mean platelet volume, fibrinogen, 
triglycerides, and platelet count. Collectively, a total of 26 tests of pleiotropy were 
performed in non-Hispanic whites and Mexican Americans and two were significant at a 
liberal threshold of p<0.05 (Table 4.11).   In Chapter III section B, we identified an 
association with intronic variant rs1800562, located in the protein coding 
hemochromatosis gene HFE, with plasma fibrinogen in combined NHANES non-
Hispanic blacks (β = 0.25, p-value = 7.50 E-5; Table 3.5). Likewise, this SNP is also 
associated with fibrinogen in both non-Hispanic whites and Mexican Americans (table 
4.11). 
Genetic Modifiers 
  In Chapter III we identified several gene-gene (GxG) and gene-environment 
(GxE) interactions with fibrinogen cluster variants in non-Hispanic blacks from 
NHANES III (Table 3.6 and 3.7). Using the same approach we tested for gene-gene and 
gene-environment interactions for plasma fibrinogen in non-Hispanic white and Mexican 
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Americans from NHANES III. Notably, we identified a total of 19 gene-gene interactions 
and five gene-environment interactions across populations. 
We identified a total of 19 GxG interactions that were significant at the liberal 
significance threshold of p< 0.05 out of 552 total tests performed (Tables 4.12 and 4.13). 
We define a significant GxG interaction here as having significant interaction term 
(p<0.05) from two different genes in the fibrinogen gene cluster.  
Greater than 60% (12/19) of the significant GxG interactions were identified in 
non-Hispanic whites, all of which include a FGB SNP in the interaction term (Table 
4.12). In fact, all of the significant interaction terms included either FGB rs2227395 or 
FGB rs4220, and the resulting associations are nearly identical in non-Hispanic whites 
(Table 4.12). As previously mentioned in the single-SNP test of association, these SNPs 
are highly correlated (r
2
 = 0.86) and likely represent the same genetic effect. After 
accounting for this correlation, there are only six unique gene-gene interactions that reach 
statistical significance at p<0.05 in non-Hispanic whites. Both rs2227395 and rs4220 had 
significant main effects in the single-SNP test of association (Figure 4.1).   
In Mexican Americans we identified seven significant interaction terms at the 
p<0.05 level. Four of these associations include rs2227395 and rs4220, and may be 
correlated in our Mexican American population; however there was no evidence proving 
this.  After accounting for the correlation between SNPs, we identified five independent 
associations at the p<0.05 level (Table 4.13). 
In addition to gene-gene interactions, we tested for gene-environment (GxE) 
interactions between fibrinogen cluster genetic variants and sex, age, smoking status, and 
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BMI separately for an association with plasma fibrinogen in non-Hispanic whites and 
Mexican Americans (from NHANES III). All three environmental factors we tested have 
been previously described as significant risk factors for elevated fibrinogen (de Maat, 
2001). We only identified five SNP x environment interactions at p <0.05 level out of 
200 total tests performed (Table 4.14). Four of the five associations we identified were 
SNP x sex interactions with nearly similar association results for the interaction term in 
non-Hispanic whites. One interaction term was significant in Mexican Americans, 
rs2006879 x BMI, which was associated with fibrinogen levels (Table 4.14).  
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Table 4.11 Significant pleiotropic effects detected with GWAS-identified variants in non-Hispanic whites and Mexican 
Americans in the combined NHANES dataset. We performed linear regression with GWAS-identified variants and 
hematological traits: platelet count, mean platelet volume, and log- transformed triglycerides. Significance was declared at 
p<0.05. 
Abbreviations: MPV = mean platelet volume  
 
 
 
 
 
 
 
 
SNP Gene 
Original Study Combined NHANES 
Original 
Phenotype 
Population n β 
P-
value 
Combined 
NHANES 
population 
Associated 
Phenotype 
n 
β 
(SE) 
P-
value 
rs1800562 HFE 
Mean cell 
volume 
Europeans 13,943 0.37 
1.4E-
23 
non-Hispanic 
whites 
Fibrinogen 3,165 
0.06 
(0.03) 
0.03 
rs1800562 HFE 
Mean cell 
volume 
Europeans 13,943 0.37 
1.4E-
23 
Mexican 
Americans 
Fibrinogen 1,434 
-0.12 
(0.06) 
0.03 
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Table 4.12 Significant fibrinogen cluster gene-gene interactions in NHANES III non-Hispanic whites (n = 1,385). Using 
linear regression, we added cross product terms (all pair-wise SNP-SNP) to the regression models for serum fibrinogen and 
adjusted for age, sex, BMI, and smoking status.  Abbreviations: SE = standard error. 
Gene-Gene Interaction 
SNP-SNP 
Interaction 
SNP 1 Main Effect SNP 2 Main Effect Interaction Term 
Beta 
(SE) 
p-value 
Beta 
(SE) 
p-value 
Beta 
(SE) 
p-value 
FGB x FGB rs1800791 x  rs2227395 
<0.001 
(0.03) 
0.89 
-0.08 
(0.02) 
6.7E-4 
0.15 
(0.06) 
0.02 
FGA x FGB rs2070006 x  rs2227395 
0.02 
(0.02) 
0.20 
-0.08 
(0.02) 
6.7E-4 
-0.09 
(0.03) 
0.005 
FGA x FGB rs2070006 x  rs4220 
0.02 
(0.02) 
0.20 
-0.09 
(0.02) 
2.1E-3 
-0.09 
(0.04) 
0.01 
FGA x FGB rs2070009 x  rs2227395 
-0.03 
(0.02) 
0.16 
-0.08 
(0.02) 
6.7E-4 
0.09 
(0.04) 
0.005 
FGA x FGB rs2070009 x  rs4220 
-0.03 
(0.02) 
0.16 
-0.09 
(0.02) 
2.1E-3 
0.09 
(0.04) 
0.01 
FGA x FGB rs2070011 x  rs2227395 
0.03 
(0.02) 
0.14 
-0.08 
(0.02) 
6.7E-4 
-0.08 
(0.04) 
0.03 
FGA x FGB rs2070011 x  rs4220 
0.03 
(0.02) 
0.14 
-0.09 
(0.02) 
2.1E-3 
-0.09 
(0.04) 
0.01 
FGA x FGB rs2070022 x  rs2227395 
-0.03 
(0.02) 
0.23 
-0.08 
(0.02) 
6.7E-4 
0.18 
(0.06) 
0.002 
FGA x FGB rs2070022 x  rs4220 
-0.03 
(0.02) 
0.23 
-0.09 
(0.02) 
2.1E-3 
0.14 
(0.06) 
0.02 
FGB  x FGG rs2227395 x  rs2066861 
-0.08 
(0.02) 
6.7E-4 
0.05 
(0.02) 
0.01 
-0.13 
(0.04) 
0.002 
FGB x FGG rs4220 x  rs2066861 
-0.09 
(0.02) 
2.1E-3 
-0.03 
(0.02) 
0.23 
-0.08 
(0.04) 
0.05 
FGA x FGB rs6050 x  rs2227395 
-0.04 
(0.02) 
0.04 
-0.08 
(0.02) 
6.7E-4 
0.13 
(0.04) 
0.001 
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Table 4.13 Significant fibrinogen cluster gene-gene interactions in NHANES III Mexican Americans (n = 664). Using 
linear regression, we added cross product terms (all pair-wise SNP-SNP) to the regression models for serum fibrinogen.  
Abbreviations: SE = standard error. 
 
 
FGA x FGB rs6050 x  rs4220 
-0.04 
(0.02) 
0.04 
-0.09 
(0.02) 
2.1E-3 
0.09 
(0.04) 
0.02 
Gene-Gene Interaction 
SNP-SNP 
Interaction 
SNP 1 Main Effect SNP 2 Main Effect Interaction Term 
Beta 
(SE) 
p-value 
Beta 
(SE) 
p-value 
Beta 
(SE) 
p-value 
FGA x FGB rs2070008 x  rs1800791 
-0.02 
(0.04) 
0.57 
-0.03 
(0.03) 
0.26 
0.18 
(0.08) 
0.022 
FGA x FGG rs2070033 x rs1049636 
-0.16 
(0.15) 
0.26 
0.04 
(0.03) 
0.08 
0.59 
(0.30) 
0.051 
FGA x FGB rs2070033 x rs1800791 
-0.16 
(0.15) 
0.26 
-0.03 
(0.03) 
0.26 
-0.66 
(0.33) 
0.048 
FGB x FGG rs2227395 x  rs1049636 
-0.02 
(0.04) 
0.58 
0.04 
(0.03) 
0.08 
0.17 
(0.06) 
0.006 
FGB x FGG rs2227395 x  rs1800792 
-0.02 
(0.04) 
0.58 
-0.03 
(0.03) 
0.36 
-0.13 
(0.06) 
0.025 
FGB x FGG rs4220 x  rs1049636 
-0.04 
(0.04) 
0.36 
0.04 
(0.03) 
0.08 
0.14 
(0.07) 
0.035 
FGB x FGG rs4220 x  rs1800792 
-0.04 
(0.04) 
0.36 
-0.03 
(0.03) 
0.36 
-0.12 
(0.06) 
0.032 
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Table 4.14 Gene-environment interactions with fibrinogen variants and age, sex, BMI, and smoking status in non-
Hispanic whites (n = 1,385) and Mexican Americans (n = 664) from NHANES III. Using linear regression we added the 
multiplicative terms (SNP x environmental factor) to the regression model while simultaneously adjusting for covariates: age, 
sex, BMI, and smoking status when necessary. Below are the association results for the single SNP or environmental factor 
tests of association as well as the association results for the interaction term.  
 
NHANES III 
Population 
Interaction Gene 
SNP Main Effect 
Environment 
Main Effect 
SNP-Environment 
Interaction Effect 
Beta 
(SE) 
p-value 
Beta 
(SE) 
p-value 
Beta 
(SE) 
p-value 
non-Hispanic whites rs2070017 x sex FGA 
0.24 
(0.22) 
0.28 
0.07 
(0.03) 
0.01 0.03 0.01 
Mexican Americans rs2066879 x BMI FGG 
-0.37 
(0.24) 
0.12 
0.02 
(0.004) 
3.1E-5 -0.28 0.03 
non-Hispanic whites rs2066861 x sex FGG 
0.05 
(0.02) 
0.01 
0.06 
(0.03) 
0.02 -0.08 0.05 
non-Hispanic whites rs2070009 x sex FGA 
-0.03 
(0.02) 
0.16 
0.06 
(0.03) 
0.02 0.07 0.05 
non-Hispanic whites rs6050 x sex FGA 
-0.04 
(0.02) 
0.04 
0.06 
(0.03) 
0.04 0.08 0.05 
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Discussion 
Using a large, diverse study population, we were able to replicate as well as 
identify two novel associations between SNPs located in the fibrinogen gene cluster 
and levels of plasma fibrinogen. We were also able to replicate and generalize 
GWAS-identified variants for fibrinogen and hematological traits in non-Hispanic 
whites and Mexican Americans from NHANES III.  This is the first genetic 
association performed in Mexican Americans with variants within the fibrinogen 
gene cluster. As well as the first study to identify both gene-gene and gene-
environment interactions with fibrinogen cluster variants in a population setting. 
Several genetic variants are associated with increased plasma fibrinogen in 
all three genes in the fibrinogen cluster. Any one SNP (replicated and novel) 
significantly associated with plasma fibrinogen in non-Hispanic whites explained 
0.3-0.7% of the trait variability. Collectively, the five associations we identified 
account for 1.6% of the trait variability in plasma fibrinogen in non-Hispanic 
whites. While we successfully replicated genetic associations reported for  plasma 
fibrinogen in non-Hispanic whites, two variants did not replicate the findings of 
previous studies (Table 4.6) (Reiner et al., 2006a; Wassel et al., 2010a; Dehghan et 
al., 2009).  We were unable to replicate the association with rs2070011 and 
rs1800788 in non-Hispanic whites. In comparison to Reiner et al, we were under-
powered to detect the same effects with our sample size in non-Hispanic whites.  
However, we identified two novel associations with plasma fibrinogen in FGB and 
FGA. The novel association we identified between plasma fibrinogen and FGA is 
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significant in Mexican Americans and trended towards significant in non-Hispanic 
blacks (Table 4.5).  
This is the first study that characterizes GWAS findings for fibrinogen and 
hematological traits in Mexican Americans. We were able to successfully 
generalize two associations originally identified in European or African descent 
populations to Mexican Americans. One association rs210135 generalized to 
Mexican Americans and replicated in non-Hispanic whites. In Chapter III this 
association also generalized in African American. Confirming associations such as 
rs210135 and other GWAS-identified variants in other populations provides the 
starting point for understanding the clinical impact these variants may have on 
disease. 
We identified 19 gene-gene associations in non-Hispanic whites and 
Mexican Americans. One criticism of exhaustively testing for interactions is the 
biological interpretation of the results.  The fibrinogen gene cluster is an ideal 
candidate for identifying gene-gene interactions since each gene is dependent on 
the other to produce active fibrin in the blood (Zhang and Redman, 1996; Zhang 
and Redman, 1994).  Notably, all but one of the gene-gene associations we detected 
includes SNPs in the rate-limiting gene FGB. The FGB gene plays an important 
role in fibrinogen production. Little is known about function of genetic variation in 
the other genes, FGA and FGG, in the fibrinogen gene cluster. Our gene-gene 
interaction data imply that there are several interactions involving these genes with 
the rate limiting gene, FGB.  
161 
 
We also identified several SNP x sex interactions in non-Hispanic whites. 
There have been several reports of an association with sex or gender specific 
hormone levels and fibrinogen (Jeff et al., 2011a); (Middeldorp, 2005; Voetsch and 
Loscalzo.J, 2003; Evans et al., 1999). We did not detect significant interactions 
with age, BMI, or smoking status. It is important to note that several genes we 
identified are in high linkage disequilibrium with each other resulting in redundant 
results for both populations. 
This study, which accesses the diverse NHANES datasets, has many 
strengths.  One strength is the breadth of laboratory measurements available for 
tests of association.  Until recently, most genetic association studies have ignored 
pleiotropy and have limited tests of association to a single trait or pathway. 
Pleiotropy is defined here and elsewhere as a locus affecting multiple traits 
(Wagner and Zhang, 2011).  In a statistical setting, pleiotropy is detected as a single 
genetic variant associated with multiple traits, but this setting does not establish 
causality without further experiments.   Epidemiologic studies such as NHANES 
make statistical tests for pleiotropy possible, which may ultimately identify novel 
genotype-phenotype relationships and pathways (Pendergrass et al., 2011). Our 
study is unique in that we also investigated the pleiotropic effects of the fibrinogen 
cluster and GWAS-identified variants with fibrinogen and other hematological 
traits. This is important given the complex pathophysiology of cardiovascular 
disease and the role hematological traits play in the development of disease. 
Several studies have been published on genetic variation with levels of plasma 
fibrinogen but little is known about how these same variants impact hematological 
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traits. It is known that elevated levels of plasma fibrinogen are observed for several 
disease states such as inflammation, deep venous thrombosis, and arterial 
thrombosis (David Ginsburg, 2005). However, it is still unclear as to whether 
elevated levels of plasma fibrinogen are a result of fibrinogen itself or other 
intermediate phenotypes underlying the pathophysiology. For example, arterial 
thrombosis, a common characteristic and intermediate phenotype for cardiovascular 
disease, is very complex and is likely to involve the fibrinogen gene cluster. 
However, unlike venous thrombosis, which is mainly due to the accumulation 
fibrin clots, arterial thrombosis is primarily due to platelet adhesion and it is likely 
to involve hematological traits tested in this study (Feinbloom and Bauer, 2005; 
Lane and Grant, 2000; Lowe, 2008; Mackman, 2008; Lowe, 2008).  We identified 
genetic associations with fibrinogen SNPs and white blood cell count, platelet 
distribution width, and platelet count suggesting possible pleiotropic effects. These 
findings support the idea that variants in the fibrinogen gene cluster may also affect 
the regulation of hematological traits. 
Another major strength of our study is its diversity.  Although there have 
been studies performed in European and African descent populations, none have 
included Mexican Americans. The characterization of variants in non-European 
descent populations has considerable scientific benefits. For example in Mexican 
Americans, we identified a novel association between plasma fibrinogen levels and 
rs2070022 that also trended towards significance in non-Hispanic blacks (Chapter 
III, section A). We also were able to report a consistent direction of effect for 
rs1049636 across all the three NHANES populations despite sample size. In 
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addition to plasma fibrinogen levels, we identified significant associations with 
serum triglycerides in Mexican Americans.   
A weakness of the present study is power and sample size.   While 
NHANES III contains over 33,000 study participants, our study population sample 
size was limited for several reasons.  The Centers for Disease Control and 
Prevention (CDC) only collected DNA samples from a subset of the entire dataset. 
DNA was not collected from participants who reported having hemophilia or 
chemotherapy within four weeks of collection (Gunter E. et al., 1996). Of these 
samples, plasma fibrinogen levels in NHANES III was only measured for 
participants > 40 years of age (Gunter E. et al., 1996), which drastically reduces our 
sample size with plasma fibrinogen compared to the hematological traits. Despite 
the small sample sizes for plasma fibrinogen, we were able to successfully replicate 
several known (GWAS identified and fibrinogen cluster candidate gene variants) 
associations at a liberal significance threshold of p<0.05.  We also identified 
potentially novel gene-gene and gene-environment interactions at the same 
significance threshold, but because of multiple testing and the increased risk of 
false positive findings, these novel associations will require replication in other 
studies.  In addition to limited power due to sample size, we were limited to only 
successfully genotyped SNPs, whih represent a small portion of the SNPs identified 
by GWAS for replication and generalization studies. 
 In summary, we have identified both previous and novel associations within 
the fibrinogen gene cluster with plasma fibrinogen levels, as well as confirmed 
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previous GWAS associations for platelet count in NHANES populations. Notably, 
we generalized GWAS variants originally identified in African Americans in non-
Hispanic whites and Mexican Americans. We also identified several genetic 
modifiers of plasma fibrinogen in NHANES III.  Identifying these associations will 
provide important information about intermediate phenotypes with the ultimate 
goal of predicting cardiovascular disease outcome.  
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CHAPTER V 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
Conclusions 
The experiments described here were designed to identify common genetic 
variants that explain or contribute to the variability of common quantitative traits 
associated with cardiovascular disease (CVD). The genetics of cardiovascular 
disease has been well-studied; however a large portion of the genetic variance is 
still unexplained. The use of quantitative traits in genotype-phenotype studies can 
be more powerful compared with disease outcomes given these traits are more 
robust to phenotypic heterogeneity or measurement error. Furthermore, the use of 
these easily and uniformly measured quantitative traits in genetic studies improves 
the reproducibility of results across studies, which is important for clinical 
validation.  
Risk of CVD is not uniformly distributed across populations, as African 
Americans have more risk factors for CVD compared with European Americans 
(Lloyd-Jones et al., 2009). Unfortunately the genetics of quantitative traits 
associated with CVD, such as electrocardiographic and fibrinogen/hematological, 
traits have been mostly limited to populations of European descent.  Using several 
approaches and diverse study populations such as African Americans; we identified 
and generalized genetic associations in candidate genes as well as other loci in the 
genome that are associated with ECG and/or fibrinogen and hematological traits. 
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Candidate gene association studies are based on previous biological 
knowledge of a gene and have been useful in identifying genetic risk factors for 
several common diseases and/or traits. In Chapter II section A, we focused on one 
candidate gene, SCN5A, and its association with ECG traits in >3,000 African 
Americans from the Jackson Heart Study. We tested 65 variants in the predominant 
sodium channel gene expressed in heart, SCN5A, for an association with nine ECG 
traits. We were able to identify 13 independent associations in this gene with PR 
interval, QRS duration, and P duration at p <1.0 x 10
-4
.  These variants individually 
explain up to 2% of the variation in ECG traits in African Americans. To confirm 
these associations, we tested for replication for five of the significant SCN5A 
associations from the JHS in non-Hispanic blacks in NHANES III. We were not 
able to replicate any of these associations most likely due to the limited sample size 
of non-Hispanic blacks in NHANES III, which is only 16% of the sample size 
compared to JHS. Thus, on average we were only powered to detect 20% of the 
effect estimates identified in JHS in non-Hispanic blacks from NHANES III for 
any ECG trait. In section A of Chapter IV, we characterized SCN5A associations in 
non-Hispanic whites and Mexican Americans from NHANES III. Two of these 
associations successfully generalized in either population. Results from these 
studies suggest SCN5A associations may be population specific but future studies 
with large sample sizes need to be performed to confirm associations in African 
Americans and generalizability of these associations in other populations. 
Genes that encode the fibrinogen polypeptide have been extensively studied 
in European descent populations and are associated with fibrinogen levels in the 
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blood. There are few studies that test for this association in African Americans. In 
section A of Chapter III, we tested 25 fibrinogen cluster variants for an association 
with fibrinogen levels with non-Hispanic blacks from NHANES III. We were able 
to replicate two associations in the fibrinogen cluster previously identified either by 
candidate gene or GWA studies in Europeans with fibrinogen levels at p<0.05. We 
also identified a novel association with rs2070022 and decreased fibrinogen levels 
(p=0.007). These SNPs (replicated and novel) explain 1.7% of the trait variability 
for fibrinogen levels.  In section B of Chapter IV, we replicated four previous 
associations, as well as identified one novel association with serum fibrinogen in 
non-Hispanic whites. In Mexican Americans, rs2070022, which is also associated 
with non-Hispanic blacks, was associated with decreased fibrinogen levels. In 
summary, we have identified both previous and novel associations within the 
fibrinogen gene cluster with plasma fibrinogen levels across three NHANES III 
populations.    
Genes that are associated with complex phenotypes such as CVD are often 
involved in multiple pathways and potentially have an effect on multiple 
phenotypes. In Chapters III and IV, we tested for pleiotropic effects with SNPs in 
the fibrinogen gene cluster and hematological traits. We also tested fibrinogen 
variants for an association with serum triglycerides, which has been consistently 
associated with CVD risk factors such as atherosclerosis. In section A of Chapter 
III, we identified three pleiotropicassociations between fibrinogen variants and 
platelet count, platelet distribution width, and mean platelet volume in non-
Hispanic blacks.  We performed the same tests in section B of Chapter IV focused 
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on non-Hispanic whites and Mexican Americans. We were able to identify one 
pleiotropic effect in non-Hispanic whites and three in Mexican Americans. None of 
these associations were observed across all three populations; nevertheless, these 
pleiotropic findings are novel and suggest that these genes may affect several 
phenotypes involved in common disease pathways.  The biological explanations for 
these pleiotropic associations remain to be elucidated and warrant further study.  
The need for genetic association studies in more informative populations 
such as African Americans is vital for the identification of casual variants for 
complex diseases. To address this concern, we generalized several GWAS 
associations, originally identified in European and/or Asian descent populations, in 
two independent African American populations for ECG and 
fibrinogen/hematological traits (section B in Chapters II and III). There were many 
associations that did not generalize most likely due low power resulting from the 
small sample sizes and differences in allele frequency in African Americans. 
Despite this limitation we were able to generalize variants that have been replicated 
in multiple studies in our African Americans.  For example, SNPs located in the 
NOS1AP gene has been replicated several GWAS of QT interval in European 
and/or Asian populations. Associations in this gene are also associated with QT 
interval in African American populations. Likewise, these associations also 
generalized in Mexican Americans and replicated in non-Hispanic whites. In 
section B of Chapter III, using African Americans from NHANES III, we 
confirmed the performance of a custom-context chip, the IBC BeadChip, which is 
designed to capture SNPs with low allele frequencies (particularly those in African 
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descent populations). We were able to replicate two of these associations:   
rs2070017 (β = -0.08, p= 0.02) and rs2066874 (β = -0.28, p= 1.5 E-4) with 
decreased fibrinogen. In addition to tests of association, we extensively 
characterized GWAS-identified loci for these traits by describing allele frequency 
and linkage disequilibrium patterns in African Americans. Understanding the 
genetic architecture of GWAS-identified variants in African descent populations 
may eventually lead to the identification of casual variants.   
In addition to the single SNP tests of association described above, another 
approach to account for the unexplained heritability is to test for genetic modifiers. 
In section C of Chapters II and III, we test for gene-gene and gene-environment 
interactions for ECG and fibrinogen/hematological traits. Using this approach we 
identified several gene-gene interactions with rate-limiting gene FGB with variants 
in FGA and FGB in non-Hispanic blacks. Many of these associations generalized in 
non-Hispanic whites (section B, Chapter IV). We also identified several gene-
environment interactions with all NHANES sub-population with age, sex, body 
mass index, and smoking with at least one fibrinogen variant. 
In conclusion, the data described from this work have identified several 
genetic risk factors in clinically relevant CVD phenotypes in African Americans.  
We identified several variants with SCN5A that are associated with ECG traits in 
African Americas, some of which generalize in other populations. Similarly, novel 
associations with the fibrinogen gene cluster were identified with fibrinogen levels, 
a number of which also have pleiotropic effects with hematological phenotypes. 
This work also confirms several GWAS variants originally identified in European 
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and/or Asian descent populations in African Americans. Finally, this work 
identifies associations that do generalize in African Americans, suggesting the need 
for future analysis such as molecular studies, more genetic association studies, or 
clinical studies to determine the effect of these putative disease loci. Collectively, 
the data presented in these chapters provide the framework for genetic association 
studies of CVD in African Americans and add to the limited genetics research in 
diverse populations. 
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Future Directions 
The future goals expanding upon the work described here could include the 
exploration of different approaches to identify novel genotype-phenotype 
associations in African Americans for ECG and fibrinogen/hematological traits.  
Our analysis was limited to three approaches: candidate gene study, genome-wide 
association study, and testing for genetic modifiers. While we were successful in 
identifying novel and previously-reported associations, there are several approaches 
we did not consider. Additionally, this work can be continued by using more study 
diverse populations with large sample sizes, which would increase our power to 
detect associations that we were underpowered to detect. 
One such approach that we did not consider in this present body of work is 
admixture mapping.  Admixed populations are derived from a combination of one 
or multiple ancestral populations (Patterson et al., 2004b; Smith et al., 2004; 
Winkler et al., 2010b). Gene flow in admixed populations, such as African 
Americans, is fairly recent and chromosomes are mosaics of European and African 
descent (Winkler et al., 2010a). An admixture scan searches for regions in the 
genome that have a higher representation from one ancestral population compared 
with the other ancestral population. To identify putative disease causing loci, the 
overrepresentation of one ancestral population is usually the population with higher 
incidence for the disease. This approach can be used to identify disease loci in our 
African American study populations missed by traditional candidate gene and 
GWA study designs. Currently we are using this approach as part of the electronic 
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Medical Records and Genomics (eMERGE) network in African Americans from 
the Vanderbilt Genome-Electronic Records (VGER) Project and Northwestern 
University NUgene Project. We performed an admixture scan on >930 SNPs to 
identify disease loci for ECG traits. The admixture scan revealed a novel region on 
chromosome 5 DPYSL3 that is possibly associated with PR interval.  Follow-up 
studies of this region need to be performed to confirm the association with PR 
interval in African Americans. 
Fine-mapping is also an alternative approach which is primarily used to 
identify true ‘causal’ variants. Unlike our candidate gene approach, fine mapping 
requires dense genotyping or sequencing of a region of interest.  In this study 
design, SNP selection is not necessarily based on linkage disequilibrium alone. 
Fine-mapping studies are usually hypothesis-driven, and investigators select a gene 
within the associated region that is suspected to be biologically relevant to the 
phenotype being studied. For example, this approach would be useful to follow-up 
the NOS1AP region, where the SNP rs10494366 is consistently replicated across 
studies (Section B, Chapter II and section A, Chapter IV), but has no obvious 
biological relevance to QT interval. Performing fine-mapping studies in this gene 
in a large sample of African Americans can help identify the putative casual variant 
in NOS1AP and other genes identified by GWAS with unknown biological 
function. Additionally fine-mapping studies will provide a better understanding of 
the GWAS-identified variants (from section B, Chapter II) that fail to generalize in 
African Americans. 
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 Perhaps one of the major limitations of this work was power. For several 
analyses, especially those for ECG traits, we were underpowered to generalize 
previously-identified association and to detect novel associations. We were 
underpowered particularly for gene-gene and gene-environment interactions, which 
typically have very small genetic effects and thus require larger sample sizes 
compared with studies designed to detect the marginal effects only. One remedy for 
this problem is to increase the sample size of the study population at the individual-
level data, if possible. Another alternative would be to perform a meta-analysis, 
which combine association results across several study populations. Both solutions 
are possible extension of the work presented here.  
The African American study population mentioned in section B of Chapter 
II was collected from two biobanks, VGER and NUgene. Samples from VGER are 
a part of the Vanderbilt biobanks BioVU, which accrues new samples every week. 
In fact there are an additional 600 African American samples in BioVU for PR 
interval since this present study was conducted. Several analyses include samples 
from NHANES participants and are a part of EAGLE, a study site within PAGE. 
Unfortunately, NHANES is a cross-sectional study and samples are collected at one 
time point for each survey, therefore additional samples cannot be added to a 
survey at one time point. But since NHANES is collected every year we can 
potentially increase our sample size for future analysis of traits such as fibrinogen 
which are measured each year.  Another alternative to improve power in our current 
analysis would be to perform a meta-analysis with African Americans at other 
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study sites within PAGE that have data for ECG and fibrinogen/hematological 
traits.  
 Complex traits such as ECG traits and fibrinogen levels can be influenced 
by current medications or dietary intake. Environmental variables tested in the 
present study were limited to age and sex for gene-environment interactions for 
ECG traits and age, sex, body mass index, and smoking status for fibrinogen levels. 
NHANES is rich in nutritional data and several dietary measurements can be tested 
for gene-environment interactions that alter fibrinogen levels. Here we did not test 
for drug interactions with candidate genes that may alter ECG traits or fibrinogen 
levels. Information on current medications is available for individuals in BioVU 
and can be tested in future analysis for possible gene-drug interactions. 
 Collectively, the findings presented in this work identify several novel 
genetic associations for ECG and fibrinogen/hematological traits in African 
Americans. This work also shows the need for more studies in diverse populations 
for these traits. Lastly, this work illustrates the full spectrum of genotype-
phenotype associations, as well as their modifiers, are needed to elucidate the 
biological pathways that may be relevant to the prevention, intervention, and/or 
treatment of cardiovascular disease in a population and/or personalized setting.   
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Appendix A. Age distribution of JHS participants in the study population (n= 
3,054). Age in the study population follows a normal distribution. The mean age is 56 
years and ranges from 21 to 85 with a standard deviation of 11.73 years. 
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Appendix B. Location, Hardy Weinberg Equilibrium, minor allele, minor 
allele frequency and marker genotyping efficiency for 72 SNPs in the SCN5A 
gene. Using thresholds of HWE p >0.0001, MAF >0.05, GE >95%, five SNPs 
(bold) did not meet these criteria were removed from further analyses.  
SNP Location HWE p-value 
Minor 
Allele 
MAF 
Genotype 
Efficiency % 
rs11129796 Intron 0.94 T 0.15 99.8 
rs11710077 Intron 0.93 T 0.11 99.8 
rs12053903 Intron 0.004 T 0.19 99.8 
rs12491987 Intron 0.08 T 0.16 99.8 
rs12498069 Intron 0.11 A 0.18 99.8 
rs13073578 Intron 0.52 G 0.18 99.8 
rs13084981 Intron 0.36 T 0.09 99.8 
rs13314361 Intron 0.31 A 0.15 99.8 
rs13315133 Intron 0.79 C 0.20 99.8 
rs1805124 His->Arg 0.23 G 0.29 99.8 
rs1805126 Asp->Asp 0.08 T 0.35 99.8 
rs3918389 Gly-> Arg 1.00 G 0.00 99.8 
rs3922843 Intron 0.50 T 0.24 99.8 
rs3922844 Intron 0.01 G 0.41 99.8 
rs3934936 Intron 0.85 T 0.35 99.8 
rs3935472 Intron 0.75 A 0.33 99.8 
rs4130467 Intron 0.31 G 0.22 99.8 
rs41313691 Ser->Tyr 0.80 T 0.04 99.8 
rs4131778 Intron 0.06 A 0.44 99.8 
rs6599214 Intron 0.30 G 0.12 99.8 
rs6599219 Intron 0.82 A 0.37 99.8 
rs6599221 Intron 0.05 T 0.09 99.7 
rs6599222 Intron 0.47 C 0.21 99.8 
rs6599223 Intron 0.95 T 0.18 99.8 
rs6599228 Intron 0.83 C 0.46 99.8 
rs6599229 Intron 0.34 A 0.46 99.8 
rs6599230 Ala->Ala 0.26 T 0.11 99.8 
rs6763048 Intron 0.03 G 0.24 99.8 
rs6768664 Intron 0.30 C 0.36 99.8 
rs6770569 Intron 0.75 C 0.50 99.8 
rs6786119 Intron 2.83E-14 C 0.33 99.5 
rs6791924 Arg -> Ser 0.46 A 0.09 99.8 
rs6793245 Intron 0.29 G 0.41 99.8 
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rs6795580 Intron 0.86 C 0.46 99.8 
rs6797133 Intron 0.09 A 0.31 99.8 
rs6799868 Intron 0.42 T 0.40 99.8 
rs7372712 Intron 0.74 T 0.09 99.8 
rs7372739 Intron 0.16 A 0.05 99.8 
rs7373102 Intron 0.01 T 0.27 99.7 
rs7373819 Intron 0.57 G 0.14 99.8 
rs7374138 Intron 0.07 G 0.23 99.8 
rs7374540 Intron 0.003 A 0.25 99.8 
rs7374605 Intron 1.00 C 0.22 99.8 
rs7427106 Intron 0.15 G 0.06 99.8 
rs7427447 Intron 0.22 C 0.36 99.8 
rs7428779 Intron 0.59 T 0.18 99.8 
rs7428882 Intron 0.32 C 0.46 99.8 
rs7429322 Intron 0.65 A 0.06 99.8 
rs7433206 Intron 0.89 A 0.16 99.8 
rs7620661 Intron 0.54 T 0.22 99.8 
rs7624535 Intron 0.70 G 0.24 99.8 
rs7626962 Ser->Tyr 0.73 T 0.08 99.8 
rs7627552 Intron 0.91 A 0.19 99.8 
rs7629265 Intron 1.00 T 0.08 99.8 
rs7633974 Intron 0.53 C 0.34 99.8 
rs7637849 Intron 0.67 A 0.21 99.8 
rs7638909 Intron 1.52E-15 G 0.50 99.5 
rs7645173 Intron 0.62 A 0.10 99.8 
rs7645358 Intron 0.86 A 0.43 99.8 
rs9311190 Intron 1.00 G 0.06 99.8 
rs9311191 Intron 2.39E-05 C 0.15 99.8 
rs9311195 Intron 0.18 G 0.16 99.8 
rs9812912 Intron 0.71 T 0.14 99.8 
rs9822819 Intron 0.48 A 0.31 99.8 
rs9831389 Intron 0.28 C 0.36 99.8 
rs9832586 Intron 0.31 T 0.08 99.8 
rs9832895 Intron 0.97 C 0.32 99.8 
rs9833086 Intron 0.69 G 0.45 99.8 
rs9853984 Intron 0.58 A 0.20 99.8 
rs9856587 Intron 0.11 T 0.41 99.8 
rs9876660 Intron 0.69 C 0.28 99.8 
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Appendix C. Correlation matrix for ECG traits. Pair wise correlations of 11 ECG traits were performed to determine if 
multiple traits are correlated. T & QT durations and PR duration II & VI are significantly correlated (r
2
=0.93 and 0.87 
respectively (bold).  
 
P       Dur 
 
PR  lead II 
 
PR  lead VI 
 
QRS 
Dur 
 
QT 
Dur 
 
Qtc 
Dur 
 
T   
Dur 
 
P 
Axis 
 
QRS 
Axis 
 
T 
Axis 
 
Heart 
Rate 
 
P     Dur 1.00           
PR  lead II 0.48 1.00          
PR  lead VI 0.47 0.93 1.00         
QRS Dur 0.24 0.12 0.13 1.00        
QT Dur 0.16 0.12 0.12 0.29 1.00       
QTc Dur 0.02 -0.003 -0.003 0.27 0.37 1.00      
T   Dur 0.05 0.06 0.06 -0.16 0.87 0.24 1.00     
P Axis -0.007 0.03 0.01 0.007 -0.05 0.07 -0.06 1.00    
QRS Axis -0.07 -0.05 -0.06 -0.16 -0.06 -0.09 0.01 0.17 1.00   
T Axis 0.008 0.02 0.01 -0.003 0.02 0.04 0.02 0.10 0.03 1.00  
Heart Rate -0.14 -0.12 -0.13 -0.06 -0.65 0.44 -0.63 0.11 -0.02 0.01 1.00 
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A.   
B.  
Appendix D. Distribution of QRS duration values in unrelated JHS study 
participants. A. QRS duration distribution including all JHS participants with a QRS 
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measurement. The histogram is skewed to the right of the normal distribution 
(skewness=2.19).  There were a total of 169 outliers with a QRS duration >120m/sec that 
were excluded from the analysis with QRS duration. B. Gaussian distribution of QRS 
duration in unrelated JHS study participants after the removal of outliers. 
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Appendix E.  Beta coefficients and p-values for single SNP tests of association with 
ECG axes and heart rate in unrelated JHS participants. Results from linear 
regressions adjusting for age, sex, and European ancestry was performed for 65 SNPs 
(n=3,054) assuming an additive genetic model are shown for five quantitative ECG traits. 
There were no significant associations at p<1.0x10
-4
 between the genotyped SCN5A 
SNPs and ECG axes and heart rate measurements. 
 
SNP 
QTC 
DURATION 
P AXIS QRS AXIS T AXIS 
HEART 
RATE 
β 
p-
value 
β 
p-
value 
β 
p-
value 
β 
p-
value 
β 
p-
value 
rs11129796 0.07 0.94 1.04 0.17 1.32 0.22 0.88 0.54 0.32 0.40 
rs11710077 0.99 0.34 -1.37 0.11 0.61 0.62 -2.43 0.14 -0.61 0.15 
rs12053903 -0.86 0.28 -0.48 0.45 1.20 0.19 -0.03 0.98 -0.65 0.04 
rs12491987 0.54 0.54 -0.90 0.21 0.24 0.81 -3.75 0.01 -0.53 0.14 
rs12498069 0.46 0.58 -0.61 0.36 -2.19 0.02 -1.82 0.16 -0.08 0.82 
rs13073578 -0.06 0.95 -0.40 0.55 0.61 0.53 -1.67 0.20 0.28 0.41 
rs13084981 -0.15 0.90 -0.64 0.48 -1.88 0.14 -3.23 0.06 -0.04 0.94 
rs13314361 -1.04 0.24 -0.63 0.38 -0.76 0.46 -1.16 0.40 -0.23 0.52 
rs13315133 0.30 0.70 -0.06 0.93 -0.30 0.74 -3.29 0.01 -0.21 0.52 
rs1805124 0.14 0.84 1.03 0.08 1.08 0.19 -1.72 0.13 -0.15 0.61 
rs1805126 -0.22 0.75 -0.40 0.46 1.67 0.03 -0.68 0.52 -0.04 0.87 
rs3922843 0.54 0.47 0.81 0.19 1.48 0.09 -2.58 0.03 -0.08 0.79 
rs3922844 -1.34 0.04 0.09 0.87 -0.63 0.40 1.69 0.09 -0.21 0.42 
rs3934936 0.77 0.26 -0.05 0.93 -1.82 0.02 -0.70 0.51 0.05 0.87 
rs3935472 -0.22 0.75 0.90 0.11 -0.13 0.88 1.10 0.31 0.33 0.24 
rs4130467 -1.36 0.08 0.95 0.13 -0.01 1.00 1.87 0.12 -0.30 0.34 
rs4131778 -0.47 0.47 0.13 0.81 0.52 0.49 0.59 0.56 -0.37 0.16 
rs6599214 -1.29 0.20 1.80 0.03 0.85 0.46 0.66 0.67 0.01 0.99 
rs6599219 -0.32 0.63 0.28 0.61 1.02 0.19 -0.89 0.39 -0.01 0.98 
rs6599221 -0.54 0.63 2.94 0.001 1.90 0.15 4.14 0.02 -0.39 0.40 
rs6599222 -0.99 0.21 1.32 0.04 0.16 0.86 3.33 0.01 -0.26 0.41 
rs6599223 -0.70 0.40 0.85 0.21 0.88 0.37 2.77 0.03 -0.16 0.64 
rs6599228 -0.72 0.27 0.20 0.71 0.94 0.21 0.15 0.88 0.03 0.90 
rs6599229 -0.93 0.15 -1.00 0.06 0.26 0.74 0.50 0.63 -0.36 0.18 
rs6599230 1.86 0.08 -0.70 0.42 -1.34 0.28 2.21 0.19 0.14 0.75 
rs6763048 0.48 0.52 -0.52 0.39 0.44 0.61 -1.63 0.16 0.37 0.22 
rs6768664 0.13 0.84 0.26 0.64 0.14 0.86 0.84 0.42 -0.72 0.01 
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rs6770569 
-
0.003 
0.99 0.67 0.21 0.40 0.60 -0.41 0.69 -0.26 0.33 
rs6791924 -0.21 0.85 -1.82 0.04 -0.17 0.89 -1.39 0.42 0.45 0.32 
rs6793245 -0.47 0.47 -0.35 0.51 1.59 0.04 -1.74 0.09 -0.44 0.10 
rs6795580 0.98 0.13 -0.28 0.60 -0.65 0.39 -0.06 0.95 -0.10 0.70 
rs6797133 -0.12 0.86 0.88 0.11 1.71 0.03 0.83 0.44 -0.17 0.55 
rs6799868 -0.18 0.78 -0.31 0.56 1.22 0.11 -1.77 0.08 -0.48 0.07 
rs7372712 -0.64 0.57 0.87 0.35 1.07 0.42 -0.21 0.91 0.94 0.05 
rs7373102 0.58 0.42 -0.50 0.41 0.23 0.79 1.02 0.37 -0.50 0.09 
rs7373819 -1.36 0.14 -0.92 0.22 -0.67 0.53 1.77 0.22 -0.13 0.72 
rs7374138 0.31 0.69 -0.14 0.82 1.51 0.09 -0.22 0.85 0.40 0.20 
rs7374540 -0.09 0.91 -1.05 0.08 0.95 0.27 -0.92 0.43 0.11 0.71 
rs7374605 -0.38 0.62 -0.31 0.63 -1.29 0.15 0.40 0.74 0.37 0.24 
rs7427106 -0.38 0.78 0.82 0.46 -0.52 0.75 0.96 0.65 -0.27 0.63 
rs7427447 0.35 0.60 0.21 0.70 -0.69 0.39 0.10 0.93 0.59 0.04 
rs7428779 0.59 0.48 -0.33 0.63 0.84 0.40 -2.70 0.04 -0.15 0.67 
rs7428882 0.71 0.27 0.55 0.30 -0.11 0.89 -1.15 0.26 0.03 0.91 
rs7429322 0.03 0.98 -0.16 0.88 -1.03 0.51 -4.11 0.05 -1.10 0.04 
rs7433206 -0.05 0.96 -1.13 0.11 -1.02 0.32 1.63 0.24 0.71 0.05 
rs7620661 1.51 0.05 -1.52 0.02 -0.21 0.81 -0.51 0.68 0.01 0.97 
rs7624535 -0.30 0.69 -0.02 0.98 1.61 0.07 0.68 0.56 -0.29 0.35 
rs7626962 1.53 0.20 -0.74 0.45 0.68 0.62 -0.75 0.69 0.91 0.06 
rs7627552 0.93 0.26 -0.72 0.28 0.38 0.69 -0.35 0.79 1.01 0.003 
rs7629265 1.19 0.32 -0.62 0.53 0.08 0.95 -1.53 0.42 0.98 0.05 
rs7633974 -0.62 0.36 -0.57 0.31 0.24 0.76 0.99 0.36 -0.04 0.89 
rs7637849 0.15 0.85 -1.06 0.10 -0.03 0.98 -0.08 0.95 0.27 0.40 
rs7645173 -0.05 0.96 2.18 0.01 1.69 0.18 -0.94 0.58 -0.17 0.70 
rs7645358 -0.54 0.41 0.16 0.76 0.78 0.31 0.01 0.99 0.14 0.61 
rs9311190 -0.34 0.80 1.81 0.10 2.04 0.19 -0.77 0.71 -0.09 0.87 
rs9311195 -1.74 0.05 0.49 0.49 0.24 0.82 0.82 0.56 0.46 0.20 
rs9812912 1.23 0.19 0.25 0.74 0.22 0.84 -2.21 0.13 -0.64 0.10 
rs9822819 0.02 0.97 -0.73 0.20 -0.89 0.27 0.34 0.76 -0.50 0.08 
rs9831389 0.25 0.71 -0.40 0.47 -0.64 0.41 -0.22 0.84 0.61 0.03 
rs9832586 0.05 0.97 1.95 0.06 1.67 0.24 -0.34 0.86 0.93 0.07 
rs9832895 -0.63 0.36 0.73 0.19 0.09 0.91 0.62 0.57 0.16 0.58 
rs9833086 -0.06 0.92 -0.34 0.53 -0.28 0.71 1.10 0.28 -0.30 0.27 
rs9853984 -0.17 0.84 -1.05 0.11 -0.93 0.33 2.15 0.09 0.28 0.40 
rs9856587 -0.28 0.67 0.12 0.82 -0.65 0.39 -0.56 0.58 -0.15 0.57 
rs9876660 -0.15 0.83 -0.08 0.90 -0.38 0.65 0.12 0.92 -0.12 0.69 
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Appendix F.  Linkage disequilibrium plots of SNPs in unrelated JHS participants. 
Linkage disequilibrium is presented as r
2
 using Haploview (Barrett et al., 2005).  SNPs 
rs6793245/rs3935472, rs7626962/rs7627552, rs9833086/rs4130467 are in LD (r
2
>0.77). 
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Appendix G.  Genome-wide association results for heart rate in African Americans 
(n= 455). (1) Manhattan plot of GWAS results for heart rate. Association results are 
plotted for each maker on the x-axis across the genome, the –log of the p-value is plotted 
on the y axis. (2)Locus Zoom Plot for the most significant association. We plotted the 
local association results around 100kb of the most significant SNP rs1015003 from our 
GWAS of heart rate. The –log of the p-value is plotted on the y-axis and each SNP is 
plotted by location on the x-axis. Pair-wise linkage disequilibrium with the index SNP, 
measured by r2, is indicated by color. (3) Locus Zoom Plot for the SERPINI1 region. 
We plotted the local association results around 100kb of the most significant SNP 
(rs13090836) region in the SERPINI1 region. 
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Appendix H. SNP-trait associations significant in African Americans (p<0.05) but trend in the opposite direction 
compared with previously identified association. We compared association results in African Americans to the association 
results from the original study accounting for the coded allele. This table only represents associations that are statistically 
significant in African Americans (p<0.05) but have discordant effect sizes (expressed as a beta coefficient) compared to the 
original study. Abbreviations: CAF= coded allele frequency 
 
Trait SNP 
Coded 
Allele 
Location 
Original Study 
African Americans 
(n=455) 
Population 
Sample 
size 
P-value β CAF P-value β CAF 
PR 
interval 
rs1937332 G FAS,CH25H European 2,334 1.00E-10 2.6 0.47 0.007 -3.48 0.49 
PR 
interval 
rs7602460 A Intergenic European 2,334 6.00E-06 2.42 0.40 0.012 -3.38 0.43 
PR 
interval 
rs12053903 T SCN5A European 13,685 1.00E-07 -6.59 0.72 0.01 3.76 0.23 
PR 
interval 
rs4944092 G WNT11 European 28,517 3.00E-08 -1.19 0.32 0.02 2.96 0.45 
QT 
interval 
rs12576239 T KCNQ1 European 13,685 1.00E-15 1.75 0.13 4.4E-04 -8.53 0.15 
Heart rate rs1024020 A Intergenic European 2,325 7.00E-14 0.18 0.21 0.02 -1.63 0.38 
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Appendix I. Effect size and p-values for GWAS-identified associations with a consistent direction of effect in African 
Americans compared to European descent populations. We compared the association results from GWAS-identified 
variants to African American association results for SNPs that have a consistent direction of effect but did not meet our 
significance threshold (p<0.05) for all ECG traits. 
Trait SNP 
Coded 
Allele 
Gene/Location 
Original Study 
African Americans 
(n=455) 
Population 
Sample 
Size 
P-value Effect CAF P-value Effect CAF 
QT 
Interval 
rs10494366 G NOS1AP European 12,670 5.00E-22 12.2 0.39 0.88 -0.28 0.60 
QRS 
duration 
rs11129795 G SCN5A European 12,670 5.00E-10 -8.24 0.77 0.73 0.25 0.84 
QT 
Interval 
rs12053903 C SCN5A European 13,685 1.00E-06 -1.23 0.34 0.27 2.45 0.77 
PR interval rs3807989 A CAV1 European 12,670 7.00E-13 6.40 0.4 0.46 -0.94 0.62 
QT 
Interval 
rs10919071 A ATP1B1 European 15,842 1.00E-15 2.05 0.87 0.93 -0.46 0.97 
PR interval rs1371867 C 
RNF19A, 
ANKRD46 
European 2,334 3.00E-10 2.32 0.42 0.28 -1.64 0.74 
PR interval rs251253 C 
NKX2-5, 
C5orf41 
European 28,517 9.00E-13 -1.49 0.4 0.53 0.85 0.64 
Heart rate rs2670321 C Intergenic European 2,325 2.00E-06 -0.16 0.27 0.7 0.31 0.63 
Heart rate rs281868 G SLC35F1 European 38,991 4.00E-10 6.30 0.5 0.41 -0.64 0.53 
QT 
Interval 
rs3807375 T KCNH2 European 12,670 5.00E-11 11.95 0.35 0.32 -1.95 0.69 
QT 
interval 
rs652889 A PTPRG European 2,325 8.00E-07 -0.15 0.36 0.44 1.43 0.60 
Ventricular 
conduction 
rs7562790 G CRIM1 European 40,407 8.00E-09 0.39 0.4 0.75 -0.18 0.59 
QT rs11129795 A SCN5A European 15,842 5.00E-14 -1.27 0.23 0.05 -4.77 0.16 
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Interval 
QT 
interval 
rs12143842 T NOS1AP European 13,685 1.00E-10 3.15 0.26 0.59 1.50 0.12 
QT 
Interval 
rs3825214 G TBX5 European 12,670 1.00E-07 5.88 0.22 0.57 1.20 0.23 
QT 
Interval 
rs4725982 T KCNH2 
European 
(and Indian 
Asian) 
13,685 5.00E-16 1.58 0.22 0.03 4.79 0.23 
QRS 
duration 
rs6795970 A SCN10A European 12,670 4.00E-09 5.17 0.36 0.01 2.43 0.08 
PR interval rs6795970 A SCN10A 
European 
(and Indian 
Asian) 
12,670 4.00E-09 5.17 0.36 0.13 3.67 0.08 
PR interval rs6800541 C SCN10A European 28,517 1.00E-13 3.77 0.4 0.2 3.07 0.09 
QT 
Interval 
rs8049607 T LITAF European 13,685 5.00E-15 1.23 0.49 0.26 2.00 0.45 
QT 
interval 
rs10488031 A ELMO1 European 2,325 2.00E-06 -0.26 0.07 0.93 0.20 0.17 
Heart rate rs10496166 A Intergenic European 2,325 3.00E-14 0.18 0.13 0.43 0.60 0.43 
Heart rate rs10514995 G Intergenic European 2,325 5.00E-10 0.15 0.36 0.2 1.00 0.48 
Heart rate rs11154022 A GJA1 European 2,325 7.00E-08 0.59 0.33 0.56 0.56 0.17 
Ventricular 
conduction 
rs11710077 T SCN5A European 40,407 1.00E-06 0.44 0.21 0.004 2.42 0.11 
Ventricular 
conduction 
rs11848785 G SIPA1L1 European 40,407 1.00E-10 0.50 0.27 0.2 1.27 0.089 
PR interval rs11897119 C MEIS1 European 28,517 5.00E-11 1.36 0.39 0.76 0.39 0.37 
Heart rate rs12554086 A Intergenic European 2,325 1.00E-10 -0.16 0.39 0.93 -0.09 0.15 
QRS 
duration 
rs1321311 T CDKN1A European 12,670 3.00E-10 6.52 0.21 0.17 0.77 0.39 
QT 
interval 
rs1348582 G PDE3A European 2,325 1.00E-06 0.20 0.18 0.59 1.00 0.34 
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Heart rate rs1541010 A FRMD4A European 2,325 1.00E-06 0.15 0.28 0.5 0.55 0.31 
Heart rate rs174547 C FADS1 European 38,991 2.00E-09 6.20 0.33 0.43 1.03 0.1 
QT 
interval 
rs2478333 A Intergenic European 2,325 4.00E-08 0.17 0.33 0.21 4.30 0.08 
QT 
interval 
rs2650951 A Intergenic European 2,325 1.00E-06 -0.29 0.05 0.84 -0.40 0.28 
Heart rate rs3117035 A Intergenic European 2,325 1.00E-06 -0.14 0.48 0.11 -1.54 0.22 
Heart rate rs314370 C SLC12A9 European 38,991 6.00E-10 7.60 0.19 0.28 1.58 0.07 
QT 
interval 
rs4318720 A Intergenic European 2,325 8.00E-07 0.28 0.09 0.49 1.95 0.12 
PR interval rs470490 G 
C18orf20, 
LOC643448 
European 2,334 5.00E-06 2.45 0.39 0.95 0.10 0.16 
QT 
interval 
rs6845865 G ARHGAP10 European 2,325 7.00E-07 0.19 0.21 0.74 0.63 0.49 
PR interval rs7660702 T ARHGAP24 European 12,670 3.00E-17 8.46 0.74 0.6 0.65 0.44 
QT 
interval 
rs8015016 G TCL6 European 2,325 5.00E-07 -0.18 0.2 0.4 -1.90 0.22 
Heart rate rs885389 A GPR133 European 2,325 4.00E-08 -0.17 0.3 0.55 -0.51 0.3 
Ventricular 
conduction 
rs9912468 G PRKCA European 40,407 1.00E-08 0.39 0.43 0.97 0.02 0.32 
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Appendix J. Coded Allele Frequencies for GWAS-identified SNPs in African 
Americans compared to the original study population. We calculated allele frequencies 
for all GWAS-identified SNPs in African Americans after accounting for the coded allele. 
Original Study 
population 
 
Reference 
(PubMed ID) 
SNP 
Coded 
Allele 
CAF  
Original 
Study 
CAF 
African 
Americans 
European 20031603 rs1024020 A 0.21 0.38 
European 20031603 rs10488031 A 0.07 0.17 
Icelandic 20062063 rs10494366 G 0.39 0.60 
European 16648850 rs10496166 A 0.13 0.43 
European 20031603 rs10514995 G 0.36 0.48 
European 21076409 rs10850409 A 0.27 0.23 
European 19305409 rs10919071 A 0.87 0.97 
European 19305409 rs11129795 A 0.23 0.16 
European 20639392 rs11154022 A 0.33 0.17 
European 21076409 rs11710077 T 0.21 0.11 
European 21076409 rs11848785 G 0.27 0.09 
European 20062060 rs11897119 C 0.39 0.37 
European 19305409 rs11970286 T 0.44 0.24 
European 19305408 rs12029454 A 0.15 0.26 
European 19305408 rs12053903 C 0.34 0.77 
European 19305408 rs12143842 T 0.24 0.12 
European 19305409 rs12296050 T 0.20 0.50 
European 20031603 rs12476289 A 0.07 0.01 
European 20031603 rs12552736 G 0.06 0.22 
European 20031603 rs12554086 A 0.39 0.15 
European 19305408 rs12576239 T 0.13 0.15 
European 21076409 rs13165478 A 0.36 0.53 
Icelandic 20062063 rs1321311 T 0.21 0.39 
European 20031603 rs13300284 A 0.04 0.013 
European 20031603 rs1348582 G 0.18 0.34 
European 21041692 rs1371867 C 0.42 0.74 
Indian Asians 20062061 rs1415259 A 0.39 0.40 
European 20031603 rs1447537 A 0.31 0.60 
European 20031603 rs1484948 G 0.32 0.80 
European 20031603 rs1533317 A 0.46 0.82 
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European 20031603 rs1541010 A 0.28 0.31 
European 21076409 rs1733724 A 0.25 0.05 
European 20639392 rs174547 C 0.33 0.10 
European 21909110 rs17608766 C 0.16 0.02 
European 20031603 rs17706439 A 0.17 0.15 
European 19305409 rs17779747 T 0.35 0.09 
European 21041692 rs1937332 G 0.47 0.49 
Korsae 19389651 rs2070488 A 0.33 0.23 
European 19305408 rs2074518 T 0.46 0.18 
European 20639392 rs223116 A 0.24 0.76 
European 21076409 rs2242285 A 0.42 0.26 
Korsae 19389651 rs2461751 G 0.44 0.68 
European 20031603 rs2478333 A 0.33 0.08 
European 20062060 rs251253 C 0.40 0.64 
European 20031603 rs2650951 A 0.05 0.28 
European 20031603 rs2670321 C 0.27 0.63 
European 20031603 rs2717128 G 0.14 0.15 
European 20639392 rs281868 G 0.50 0.53 
European 20031603 rs2880058 G 0.32 0.70 
European 20031603 rs3110127 A 0.33 0.56 
European 20031603 rs3117035 A 0.48 0.22 
European 20639392 rs314370 C 0.19 0.07 
Icelandic 20062063 rs365990 G 0.34 0.61 
Icelandic 20062063 rs37062 G 0.24 0.47 
Icelandic 20062063 rs3807375 T 0.35 0.69 
European 20062060 rs3807989 A 0.40 0.62 
Icelandic 20062063 rs3825214 G 0.22 0.22 
European 21076409 rs4074536 C 0.29 0.44 
European 20031603 rs4132509 A 0.21 0.30 
European 20031603 rs4318720 A 0.09 0.12 
European 20031603 rs4352210 A 0.37 0.44 
European 20639392 rs452036 A 0.36 0.61 
European 19305409 rs4657178 T 0.33 0.37 
European 21076409 rs4687718 A 0.14 0.55 
European 21041692 rs470490 G 0.39 0.16 
European 20062061 rs4725982 T 0.22 0.23 
European 20062060 rs4944092 G 0.32 0.45 
European 20031603 rs652889 A 0.36 0.60 
Icelandic 20062063 rs6795970 A 0.36 0.08 
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Indian Asians 20062061 rs6795970 A 0.36 0.08 
European 20062060 rs6800541 C 0.40 0.09 
European 20031603 rs6845865 G 0.21 0.49 
Icelandic 20062063 rs727957 T 0.19 0.03 
European 20031603 rs7318731 A 0.48 0.37 
European 20031603 rs744016 A 0.20 0.12 
European 21076409 rs7562790 G 0.40 0.59 
European 20031603 rs7601713 A 0.23 0.14 
European 21041692 rs7602460 A 0.40 0.43 
Icelandic 20062063 rs7660702 T 0.74 0.44 
European 20031603 rs7728043 G 0.48 0.52 
European 21076409 rs7784776 G 0.43 0.38 
European 20031603 rs789852 A 0.08 0.96 
European 20031603 rs8015016 G 0.20 0.22 
European 19305408 rs8049607 T 0.46 0.45 
European 21076409 rs883079 C 0.29 0.31 
European 20031603 rs885389 A 0.30 0.30 
European 21076409 rs9851724 C 0.33 0.14 
European 21076409 rs991014 T 0.42 0.98 
European 21076409 rs9912468 G 0.43 0.32 
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Appendix K. Linkage Disequilibrium plots around the SCN5A/SCN10A region in YRI 
HapMap samples compared to CEU samples. 
A. CEU 
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A. CEU 
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Appendix L. Linkage Disequilibrium plots around the NOS1AP region in YRI 
HapMap samples compared to CEU samples. 
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Appendix M. Correlation matrix for fibrinogen and hematological traits for all NHANES III populations. Pair wise 
correlations (r
2
) of all traits tested in Chapter III (Section A) and IV (Section B) were performed to determine if multiple traits 
are correlated in all three NHANES III populations. A. non-Hispanic whites, B. non-Hispanic blacks, and C. Mexican 
Americans. 
  
A. NHANES III non-Hispanic whites 
Variable Fibrinogen 
Platelet 
Count 
ln Triglycerides 
Platelet 
Distribution 
Width 
Mean 
Platelet 
Volume 
White Blood 
Cell Count 
Fibrinogen 1.00 0.09 0.14 0.05 0.02 0.17 
Platelet Count 0.09 1.00 0.04 -0.27 -0.37 0.26 
ln Triglycerides 0.14 0.04 1.00 0.11 0.01 0.14 
Platelet Distribution Width 0.05 -0.27 0.11 1.00 0.10 -0.05 
Mean Platelet Volume 0.02 -0.37 0.01 0.10 1.00 0.03 
White Blood Cell Count 0.17 0.26 0.14 -0.05 0.03 1.00 
B. NHANES III non-Hispanic blacks 
Variable Fibrinogen 
Platelet 
Count 
ln Triglycerides 
Platelet 
Distribution 
Width 
Mean 
Platelet 
Volume 
White Blood 
Cell Count 
Fibrinogen 1.00 0.11 0.13 0.03 0.02 0.09 
Platelet Count 0.11 1.00 0.09 -0.26 -0.47 0.21 
ln Triglycerides 0.13 0.09 1.00 0.07 -0.05 0.16 
Platelet Distribution Width 0.03 -0.26 0.07 1.00 0.19 -0.08 
Mean Platelet Volume 0.02 -0.47 -0.05 0.19 1.00 0.02 
White Blood Cell Count 0.09 0.21 0.16 -0.08 0.02 1.00 
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C. NHANES III Mexican Americans 
Variable Fibrinogen 
Platelet 
Count 
ln Triglycerides 
Platelet 
Distribution 
Width 
Mean 
Platelet 
Volume 
White Blood 
Cell Count 
Fibrinogen 1.00 0.10 0.10 0.02 -0.04 0.21 
Platelet Count 0.10 1.00 0.06 -0.30 -0.46 0.32 
ln Triglycerides 0.10 0.06 1.00 0.04 -0.01 0.10 
Platelet Distribution Width 0.02 -0.30 0.04 1.00 0.22 -0.08 
Mean Platelet Volume -0.04 -0.46 -0.01 0.22 1.00 -0.01 
White Blood Cell Count 0.21 0.32 0.10 -0.08 -0.01 1.00 
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Appendix N. Coded allele frequencies across all three NHANES III study sub-populations. We selected the same coded 
allele across all three populations in our analysis. In some cases the major allele was coded as the effect allele in the regression 
model.Abbreviation: aoded allele frequency (CAF), 
SNP Alleles Coded Allele 
CAF 
Non-Hispanic 
white 
CAF 
Non-Hispanic 
black 
CAF 
Mexican 
Americans 
rs2070022 A/G G 0.67 0.87 0.67 
rs2070033 A/G G 0.99 0.93 0.99 
rs2070031 A/G G <0.001 0.007 <0.001 
rs6050 A/G G 0.25 0.37 0.25 
rs2070017 A/G G 0.99 0.90 0.99 
rs2070011 A/G G 0.63 0.75 0.63 
rs2070009 A/C C 0.39 0.54 0.39 
rs2070008 A/G G 0.13 0.11 0.13 
rs2070006 A/G G 0.62 0.51 0.62 
rs1800791 A/G G 0.72 0.88 0.72 
rs1800788 A/G G 0.76 0.90 0.76 
rs2227395 A/G G 0.86 0.90 0.86 
rs2227409 A/C C <0.001 <0.001 <0.001 
rs2227434 C/T T 0.99 0.99 0.99 
rs6058 A/C C 0.99 0.93 0.99 
rs4220 A/G G 0.86 0.91 0.86 
rs2227425 C/G G <0.001 0.02 <0.001 
rs2066879 C/T C 0.99 0.97 0.99 
rs1049636 C/T C 0.47 0.24 0.47 
rs2066861 A/G G 0.77 0.71 0.77 
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rs2066860 A/G G 0.99 0.49 0.99 
rs2066874 A/G G <0.001 0.02 <0.001 
rs6063 A/G G 0.99 0.99 0.99 
rs1800792 A/G G 0.27 0.05 0.27 
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Appendix O. Pair-wise linkage disequilibrium plots for fibrinogen SNPs across each 
study population.  Pair-wise LD (r 
2
) was calculated separately for each NHANES III 
sub-population (indicated by letter).   
 
 
A. Non-Hispanic whites 
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B. non-Hispanic blacks 
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C. Mexican Americans 
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Appendix P. Association results for all fibrinogen SNPs and traits tested in each 
NHANES III sub-population. We performed linear regression adjusting for age, sex, 
BMI and smoking status for 25 SNPs, assuming an additive model for six hematological 
traits. Note some tests of association were not performed in sub-populations with low 
minor allele frequencies and/or variants that were not in Hardy-Weinberg Equilibrium. 
Abbreviations: NHW= Non-Hispanic White, NHB= Non-Hispanic Black, MA= Mexican 
American, MPV= mean platelet count, FB = fibrinogen, PDW= platelet distribution 
width, PC = platelet count, WBC = white blood cell count, LN_Tri = natural logarithm of 
triglycerides. 
SNP Trait 
NHANES 
III 
Population 
N β SE p-value 95% CI 
rs1049636 FB NHW 1392 0.04 0.02 0.04 0, 0.08 
rs1049636 FB MA 664 0.04 0.03 0.08 -0.01, 0.09 
rs1049636 FB NHB 626 0.06 0.03 0.07 0, 0.13 
rs1800788 FB NHB 627 -0.02 0.05 0.64 -0.11, 0.07 
rs1800788 FB MA 659 0.00 0.03 0.91 -0.06, 0.06 
rs1800788 FB NHW 1389 0.04 0.02 0.11 -0.01, 0.09 
rs1800791 FB NHB 627 -0.08 0.04 0.07 -0.16, 0.01 
rs1800791 FB MA 661 -0.03 0.03 0.26 -0.09, 0.03 
rs1800791 FB NHW 1391 0.00 0.03 0.89 -0.05, 0.05 
rs1800792 FB MA 666 -0.03 0.03 0.36 -0.08, 0.03 
rs1800792 FB NHB 627 -0.01 0.04 0.71 -0.08, 0.06 
rs1800792 FB NHW 1395 0.01 0.02 0.72 -0.03, 0.04 
rs2066860 FB NHW 1393 -0.04 0.05 0.36 -0.13, 0.05 
rs2066860 FB NHB 627 0.05 0.18 0.79 -0.3, 0.4 
rs2066860 FB MA 665 0.12 0.10 0.26 -0.08, 0.31 
rs2066861 FB MA 663 0.04 0.03 0.24 -0.02, 0.1 
rs2066861 FB NHW 1393 0.05 0.02 0.01 0.01, 0.1 
rs2066861 FB NHB 625 0.05 0.03 0.12 -0.01, 0.11 
rs2066874 FB MA 666 Not tested 
rs2066874 FB NHB 626 -0.28 0.08 
6.78E-
04 
-0.45, -0.12 
rs2066874 FB NHW 1396 0.27 0.49 0.58 -0.69, 1.23 
rs2066879 FB NHW 1397 -0.38 0.34 0.28 -1.05, 0.3 
rs2066879 FB MA 666 -0.37 0.24 0.12 -0.84, 0.1 
rs2066879 FB NHB 627 -0.13 0.07 0.07 -0.26, 0.01 
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rs2070006 FB NHB 620 0.01 0.03 0.85 -0.05, 0.06 
rs2070006 FB NHW 1391 0.02 0.02 0.20 -0.01, 0.06 
rs2070006 FB MA 660 0.03 0.03 0.28 -0.02, 0.08 
rs2070008 FB MA 661 -0.02 0.04 0.57 -0.1, 0.05 
rs2070008 FB NHB 627 -0.01 0.05 0.75 -0.1, 0.08 
rs2070008 FB NHW 1390 0.01 0.03 0.61 -0.04, 0.07 
rs2070009 FB NHW 1387 -0.03 0.02 0.16 -0.06, 0.01 
rs2070009 FB MA 662 -0.03 0.03 0.22 -0.09, 0.02 
rs2070009 FB NHB 621 0.00 0.03 0.94 -0.06, 0.05 
rs2070011 FB NHB 626 0.02 0.03 0.45 -0.04, 0.09 
rs2070011 FB NHW 1387 0.03 0.02 0.14 -0.01, 0.07 
rs2070011 FB MA 663 0.03 0.03 0.29 -0.02, 0.08 
rs2070017 FB NHB 625 0.08 0.05 0.08 -0.01, 0.17 
rs2070017 FB MA 666 0.14 0.13 0.28 -0.11, 0.39 
rs2070017 FB NHW 1397 0.24 0.22 0.28 -0.19, 0.67 
rs2070022 FB NHB 623 -0.08 0.04 0.06 -0.17, 0 
rs2070022 FB MA 659 -0.07 0.03 0.01 -0.13, -0.02 
rs2070022 FB NHW 1393 -0.03 0.02 0.23 -0.08, 0.02 
rs2070031 FB NHW 1397 Not tested 
rs2070031 FB NHB 627 0.16 0.16 0.32 -0.16, 0.47 
rs2070031 FB MA 666 0.54 0.48 0.26 -0.41, 1.49 
rs2070033 FB MA 666 -0.16 0.15 0.26 -0.45, 0.12 
rs2070033 FB NHW 1395 -0.05 0.24 0.85 -0.52, 0.43 
rs2070033 FB NHB 627 0.07 0.05 0.16 -0.03, 0.17 
rs2227395 FB NHW 1391 -0.08 0.02 
6.94E-
04 
-0.13, -0.03 
rs2227395 FB MA 665 -0.02 0.04 0.58 -0.1, 0.05 
rs2227395 FB NHB 625 -0.02 0.05 0.61 -0.11, 0.07 
rs2227409 FB MA 666 Not tested 
rs2227409 FB NHB 627 Not tested 
rs2227409 FB NHW 1396 Not tested 
rs2227425 FB MA 666 Not tested 
rs2227425 FB NHW 1397 Not tested 
rs2227425 FB NHB 627 -0.03 0.10 0.78 -0.21, 0.16 
rs2227434 FB NHW 1396 0.16 0.20 0.42 -0.23, 0.55 
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rs2227434 FB NHB 627 0.27 0.50 0.59 -0.71, 1.25 
rs2227434 FB MA 666 0.50 0.28 0.07 -0.04, 1.04 
rs4220 FB NHW 1391 -0.08 0.02 
2.08E-
03 
-0.13, -0.03 
rs4220 FB MA 666 -0.04 0.04 0.36 -0.11, 0.04 
rs4220 FB NHB 625 0.08 0.05 0.10 -0.02, 0.18 
rs6050 FB NHW 1389 -0.04 0.02 0.04 -0.09, 0 
rs6050 FB MA 661 -0.04 0.03 0.19 -0.1, 0.02 
rs6050 FB NHB 624 0.02 0.03 0.52 -0.04, 0.08 
rs6058 FB MA 666 -0.17 0.20 0.38 -0.56, 0.21 
rs6058 FB NHW 1397 -0.05 0.24 0.85 -0.52, 0.43 
rs6058 FB NHB 627 0.07 0.05 0.18 -0.03, 0.17 
rs6063 FB NHB 627 Not tested 
rs6063 FB NHW 1397 -0.03 0.12 0.80 -0.26, 0.2 
rs6063 FB MA 666 0.11 0.21 0.60 -0.31, 0.53 
rs1049636 LN_Tri NHW 1459 -0.01 0.01 0.22 -0.04, 0.01 
rs1049636 LN_Tri NHB 1320 0.01 0.02 0.38 -0.02, 0.04 
rs1049636 LN_Tri MA 1004 0.02 0.01 0.15 -0.01, 0.04 
rs1800788 LN_Tri MA 1000 0.00 0.02 0.84 -0.03, 0.03 
rs1800788 LN_Tri NHW 1457 0.00 0.01 0.86 -0.03, 0.03 
rs1800788 LN_Tri NHB 1325 0.02 0.02 0.46 -0.03, 0.06 
rs1800791 LN_Tri NHB 1321 -0.03 0.02 0.19 -0.07, 0.01 
rs1800791 LN_Tri MA 1004 -0.02 0.01 0.15 -0.05, 0.01 
rs1800791 LN_Tri NHW 1459 0.01 0.02 0.48 -0.02, 0.04 
rs1800792 LN_Tri MA 1005 -0.03 0.01 0.03 -0.06, 0 
rs1800792 LN_Tri NHB 1325 -0.03 0.02 0.08 -0.06, 0 
rs1800792 LN_Tri NHW 1460 0.00 0.01 0.67 -0.02, 0.03 
rs2066860 LN_Tri NHW 1460 0.02 0.03 0.50 -0.04, 0.08 
rs2066860 LN_Tri NHB 1324 0.04 0.08 0.56 -0.1, 0.19 
rs2066860 LN_Tri MA 1005 0.13 0.06 0.02 0.02, 0.24 
rs2066861 LN_Tri MA 1000 -0.02 0.02 0.31 -0.05, 0.01 
rs2066861 LN_Tri NHW 1458 -0.01 0.01 0.56 -0.03, 0.02 
rs2066861 LN_Tri NHB 1319 -0.01 0.01 0.70 -0.03, 0.02 
rs2066874 LN_Tri NHB 1324 0.03 0.04 0.37 -0.04, 0.11 
rs2066874 LN_Tri MA 1006 0.34 0.30 0.25 -0.24, 0.92 
rs2066874 LN_Tri NHW 1462 0.37 0.30 0.22 -0.22, 0.96 
rs2066879 LN_Tri MA 1006 -0.06 0.11 0.59 -0.28, 0.16 
rs2066879 LN_Tri NHB 1325 -0.03 0.03 0.34 -0.09, 0.03 
rs2066879 LN_Tri NHW 1463 0.21 0.21 0.33 -0.21, 0.63 
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rs2070006 LN_Tri MA 998 -0.01 0.01 0.39 -0.04, 0.01 
rs2070006 LN_Tri NHW 1452 0.00 0.01 0.81 -0.02, 0.02 
rs2070006 LN_Tri NHB 1311 0.00 0.01 0.89 -0.02, 0.03 
rs2070008 LN_Tri NHW 1455 -0.02 0.02 0.18 -0.05, 0.01 
rs2070008 LN_Tri MA 1004 0.01 0.02 0.54 -0.03, 0.05 
rs2070008 LN_Tri NHB 1325 0.01 0.02 0.67 -0.03, 0.05 
rs2070009 LN_Tri NHW 1451 0.00 0.01 0.72 -0.03, 0.02 
rs2070009 LN_Tri MA 1000 0.01 0.01 0.41 -0.02, 0.04 
rs2070009 LN_Tri NHB 1319 0.01 0.01 0.64 -0.02, 0.03 
rs2070011 LN_Tri MA 1001 -0.01 0.01 0.56 -0.03, 0.02 
rs2070011 LN_Tri NHB 1325 0.00 0.01 0.86 -0.03, 0.03 
rs2070011 LN_Tri NHW 1455 0.01 0.01 0.50 -0.01, 0.03 
rs2070017 LN_Tri MA 1006 -0.11 0.08 0.19 -0.26, 0.05 
rs2070017 LN_Tri NHB 1322 0.02 0.02 0.46 -0.03, 0.06 
rs2070017 LN_Tri NHW 1462 0.37 0.21 0.09 -0.05, 0.78 
rs2070022 LN_Tri NHB 1323 -0.03 0.02 0.19 -0.06, 0.01 
rs2070022 LN_Tri MA 1002 -0.02 0.01 0.12 -0.05, 0.01 
rs2070022 LN_Tri NHW 1460 0.01 0.01 0.60 -0.02, 0.04 
rs2070031 LN_Tri NHW 1463 Not tested 
rs2070031 LN_Tri MA 1006 -0.50 0.30 0.10 -1.08, 0.09 
rs2070031 LN_Tri NHB 1325 0.05 0.08 0.52 -0.1, 0.2 
rs2070033 LN_Tri NHW 1462 -0.24 0.21 0.26 -0.66, 0.18 
rs2070033 LN_Tri NHB 1324 -0.02 0.03 0.54 -0.07, 0.03 
rs2070033 LN_Tri MA 1006 0.08 0.08 0.34 -0.08, 0.24 
rs2227395 LN_Tri NHW 1460 -0.01 0.01 0.37 -0.04, 0.02 
rs2227395 LN_Tri MA 1003 0.00 0.02 0.86 -0.03, 0.04 
rs2227395 LN_Tri NHB 1323 0.01 0.02 0.54 -0.03, 0.05 
rs2227409 LN_Tri MA 1006 Not tested 
rs2227409 LN_Tri NHW 1462 Not tested 
rs2227409 LN_Tri NHB 1325 0.04 0.19 0.84 -0.34, 0.42 
rs2227425 LN_Tri MA 1006 Not tested 
rs2227425 LN_Tri NHW 1463 Not tested 
rs2227425 LN_Tri NHB 1325 -0.02 0.04 0.59 -0.11, 0.06 
rs2227434 LN_Tri NHW 1460 -0.08 0.12 0.53 -0.32, 0.16 
rs2227434 LN_Tri MA 1006 0.00 0.15 0.98 -0.3, 0.29 
rs2227434 LN_Tri NHB 1323 0.01 0.34 0.98 -0.65, 0.67 
rs4220 LN_Tri NHW 1454 -0.02 0.01 0.29 -0.04, 0.01 
rs4220 LN_Tri MA 1004 0.01 0.02 0.72 -0.03, 0.04 
rs4220 LN_Tri NHB 1323 0.01 0.02 0.74 -0.04, 0.05 
rs6050 LN_Tri NHB 1317 0.00 0.01 0.81 -0.03, 0.02 
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rs6050 LN_Tri NHW 1454 0.01 0.01 0.50 -0.02, 0.03 
rs6050 LN_Tri MA 997 0.01 0.02 0.71 -0.02, 0.04 
rs6058 LN_Tri NHW 1463 -0.24 0.21 0.26 -0.66, 0.18 
rs6058 LN_Tri MA 1006 -0.11 0.11 0.34 -0.33, 0.11 
rs6058 LN_Tri NHB 1324 -0.03 0.03 0.26 -0.08, 0.02 
rs6063 LN_Tri MA 1006 -0.11 0.15 0.46 -0.4, 0.18 
rs6063 LN_Tri NHB 1325 0.05 0.19 0.79 -0.33, 0.43 
rs6063 LN_Tri NHW 1463 0.11 0.08 0.15 -0.04, 0.27 
rs1049636 MPV MA 1674 -0.04 0.03 0.27 -0.1, 0.03 
rs1049636 MPV NHW 2305 0.00 0.03 0.97 -0.05, 0.06 
rs1049636 MPV NHB 1652 0.02 0.04 0.56 -0.05, 0.1 
rs1800788 MPV MA 1668 -0.03 0.04 0.44 -0.11, 0.05 
rs1800788 MPV NHW 2302 0.00 0.03 0.93 -0.06, 0.07 
rs1800788 MPV NHB 1657 0.00 0.06 0.96 -0.12, 0.11 
rs1800791 MPV NHB 1652 -0.05 0.05 0.35 -0.15, 0.05 
rs1800791 MPV MA 1671 0.00 0.04 0.93 -0.07, 0.08 
rs1800791 MPV NHW 2304 0.01 0.04 0.78 -0.06, 0.08 
rs1800792 MPV NHB 1657 0.01 0.04 0.74 -0.07, 0.1 
rs1800792 MPV NHW 2308 0.01 0.03 0.82 -0.05, 0.06 
rs1800792 MPV MA 1679 0.01 0.04 0.88 -0.07, 0.08 
rs2066860 MPV NHB 1656 -0.14 0.20 0.47 -0.53, 0.25 
rs2066860 MPV NHW 2308 -0.08 0.07 0.28 -0.21, 0.06 
rs2066860 MPV MA 1679 -0.02 0.14 0.87 -0.31, 0.26 
rs2066861 MPV MA 1673 -0.06 0.04 0.13 -0.14, 0.02 
rs2066861 MPV NHB 1651 0.00 0.04 0.93 -0.07, 0.08 
rs2066861 MPV NHW 2307 0.01 0.03 0.74 -0.05, 0.07 
rs2066874 MPV NHW 2311 -0.66 0.91 0.47 -2.45, 1.13 
rs2066874 MPV NHB 1654 -0.12 0.10 0.27 -0.32, 0.09 
rs2066874 MPV MA 1680 0.02 0.99 0.99 -1.92, 1.95 
rs2066879 MPV NHB 1657 -0.10 0.09 0.24 -0.27, 0.07 
rs2066879 MPV NHW 2313 0.07 0.65 0.91 -1.19, 1.34 
rs2066879 MPV MA 1679 0.60 0.33 0.07 -0.04, 1.25 
rs2070006 MPV NHB 1642 -0.01 0.03 0.82 -0.08, 0.06 
rs2070006 MPV NHW 2300 0.00 0.03 0.88 -0.06, 0.05 
rs2070006 MPV MA 1665 0.00 0.03 0.95 -0.07, 0.07 
rs2070008 MPV MA 1673 -0.07 0.05 0.15 -0.17, 0.03 
rs2070008 MPV NHB 1657 -0.02 0.05 0.69 -0.13, 0.09 
rs2070008 MPV NHW 2301 0.03 0.04 0.50 -0.05, 0.11 
rs2070009 MPV NHB 1648 -0.02 0.03 0.59 -0.09, 0.05 
rs2070009 MPV MA 1669 0.00 0.03 0.98 -0.07, 0.07 
 207 
 
rs2070009 MPV NHW 2296 0.01 0.03 0.71 -0.04, 0.06 
rs2070011 MPV NHW 2299 -0.01 0.03 0.85 -0.06, 0.05 
rs2070011 MPV NHB 1656 0.01 0.04 0.74 -0.06, 0.09 
rs2070011 MPV MA 1672 0.01 0.03 0.75 -0.06, 0.08 
rs2070017 MPV NHW 2312 -0.41 0.41 0.31 -1.22, 0.39 
rs2070017 MPV NHB 1653 0.08 0.06 0.13 -0.03, 0.19 
rs2070017 MPV MA 1680 0.16 0.21 0.44 -0.25, 0.57 
rs2070022 MPV NHB 1651 -0.05 0.05 0.36 -0.15, 0.05 
rs2070022 MPV MA 1665 -0.01 0.04 0.73 -0.08, 0.06 
rs2070022 MPV NHW 2307 0.02 0.03 0.65 -0.05, 0.08 
rs2070031 MPV NHW 2313 Not tested 
rs2070031 MPV NHB 1657 0.11 0.20 0.59 -0.29, 0.5 
rs2070031 MPV MA 1680 0.71 0.99 0.47 -1.23, 2.65 
rs2070033 MPV MA 1680 -0.11 0.23 0.65 -0.56, 0.35 
rs2070033 MPV NHB 1656 -0.05 0.07 0.49 -0.18, 0.08 
rs2070033 MPV NHW 2311 0.35 0.35 0.31 -0.33, 1.03 
rs2227395 MPV NHB 1654 -0.07 0.05 0.20 -0.18, 0.04 
rs2227395 MPV MA 1676 0.02 0.05 0.68 -0.08, 0.11 
rs2227395 MPV NHW 2304 0.03 0.03 0.36 -0.04, 0.1 
rs2227409 MPV MA 1680 Not tested 
rs2227409 MPV NHW 2312 Not tested 
rs2227409 MPV NHB 1657 1.11 0.57 0.05 0, 2.22 
rs2227425 MPV NHW 2313 Not tested 
rs2227425 MPV NHB 1657 -0.12 0.12 0.32 -0.34, 0.11 
rs2227425 MPV MA 1680 0.11 0.99 0.91 -1.82, 2.05 
rs2227434 MPV MA 1680 -0.31 0.44 0.48 -1.17, 0.56 
rs2227434 MPV NHW 2310 0.25 0.31 0.42 -0.35, 0.85 
rs2227434 MPV NHB 1654 0.68 0.69 0.32 -0.67, 2.04 
rs4220 MPV NHW 2300 0.04 0.04 0.28 -0.03, 0.11 
rs4220 MPV MA 1676 0.04 0.05 0.41 -0.06, 0.14 
rs4220 MPV NHB 1655 0.04 0.06 0.56 -0.08, 0.15 
rs6050 MPV NHB 1649 -0.01 0.04 0.77 -0.08, 0.06 
rs6050 MPV NHW 2298 0.00 0.03 0.93 -0.06, 0.06 
rs6050 MPV MA 1667 0.03 0.04 0.39 -0.04, 0.11 
rs6058 MPV MA 1680 -0.38 0.31 0.23 -0.99, 0.23 
rs6058 MPV NHB 1656 -0.02 0.07 0.79 -0.15, 0.12 
rs6058 MPV NHW 2313 0.42 0.37 0.26 -0.32, 1.15 
rs6063 MPV NHW 2313 0.15 0.19 0.42 -0.22, 0.53 
rs6063 MPV MA 1680 0.19 0.33 0.56 -0.45, 0.84 
rs6063 MPV NHB 1657 0.47 0.49 0.34 -0.49, 1.43 
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rs1049636 PC NHB 1623 1.47 2.47 0.55 -3.38, 6.33 
rs1049636 PC NHW 2284 2.21 1.75 0.21 -1.21, 5.64 
rs1049636 PC MA 1658 3.27 2.06 0.11 -0.77, 7.3 
rs1800788 PC NHW 2281 -1.50 2.12 0.48 -5.66, 2.66 
rs1800788 PC MA 1652 -0.33 2.45 0.89 -5.14, 4.47 
rs1800788 PC NHB 1628 1.47 3.64 0.69 -5.67, 8.62 
rs1800791 PC NHB 1623 -3.20 3.28 0.33 -9.63, 3.23 
rs1800791 PC MA 1655 -1.50 2.33 0.52 -6.08, 3.07 
rs1800791 PC NHW 2283 -0.28 2.26 0.90 -4.72, 4.15 
rs1800792 PC MA 1663 -5.32 2.30 0.02 -9.83, -0.81 
rs1800792 PC NHW 2287 -2.20 1.64 0.18 -5.41, 1.02 
rs1800792 PC NHB 1628 1.11 2.79 0.69 -4.37, 6.58 
rs2066860 PC MA 1663 4.72 8.94 0.60 -12.82, 22.25 
rs2066860 PC NHW 2287 6.35 4.27 0.14 -2.03, 14.73 
rs2066860 PC NHB 1627 15.09 12.26 0.22 -8.96, 39.13 
rs2066861 PC NHW 2286 -0.36 1.91 0.85 -4.12, 3.39 
rs2066861 PC MA 1657 -0.27 2.49 0.91 -5.15, 4.6 
rs2066861 PC NHB 1622 2.45 2.31 0.29 -2.07, 6.98 
rs2066874 PC NHW 2290 -95.82 56.04 0.09 -205.71, 14.07 
rs2066874 PC MA 1664 -19.61 60.31 0.75 -137.9, 98.68 
rs2066874 PC NHB 1625 -4.86 6.58 0.46 -17.76, 8.04 
rs2066879 PC NHW 2292 -41.85 39.61 0.29 -119.52, 35.82 
rs2066879 PC MA 1663 -29.11 20.11 0.15 -68.56, 10.33 
rs2066879 PC NHB 1628 -3.08 5.40 0.57 -13.67, 7.5 
rs2070006 PC NHW 2280 -1.97 1.69 0.25 -5.29, 1.35 
rs2070006 PC MA 1649 -1.82 2.14 0.39 -6.01, 2.37 
rs2070006 PC NHB 1613 2.39 2.20 0.28 -1.92, 6.69 
rs2070008 PC NHB 1628 0.35 3.45 0.92 -6.41, 7.11 
rs2070008 PC MA 1657 2.06 3.13 0.51 -4.08, 8.2 
rs2070008 PC NHW 2282 2.47 2.45 0.31 -2.34, 7.27 
rs2070009 PC NHB 1619 -1.61 2.17 0.46 -5.87, 2.65 
rs2070009 PC MA 1653 1.59 2.13 0.45 -2.58, 5.77 
rs2070009 PC NHW 2276 1.86 1.69 0.27 -1.47, 5.18 
rs2070011 PC NHW 2278 -1.91 1.70 0.26 -5.24, 1.43 
rs2070011 PC MA 1656 -1.81 2.14 0.40 -6.02, 2.39 
rs2070011 PC NHB 1627 0.73 2.43 0.77 -4.05, 5.5 
rs2070017 PC MA 1664 -15.32 12.67 0.23 -40.17, 9.53 
rs2070017 PC NHB 1624 -8.12 3.47 0.02 -14.93, -1.31 
rs2070017 PC NHW 2291 19.29 25.11 0.44 -29.94, 68.53 
rs2070022 PC MA 1649 -1.83 2.22 0.41 -6.17, 2.52 
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rs2070022 PC NHW 2286 -0.71 2.14 0.74 -4.91, 3.48 
rs2070022 PC NHB 1622 -0.60 3.17 0.85 -6.82, 5.63 
rs2070031 PC NHW 2292 Not tested 
rs2070031 PC MA 1664 -68.26 60.53 0.26 -186.99, 50.47 
rs2070031 PC NHB 1628 -11.92 12.50 0.34 -36.45, 12.6 
rs2070033 PC NHW 2290 -10.37 21.22 0.63 -51.97, 31.24 
rs2070033 PC MA 1664 -6.50 14.29 0.65 -34.52, 21.53 
rs2070033 PC NHB 1628 2.10 4.18 0.62 -6.1, 10.29 
rs2227395 PC MA 1660 -1.17 2.97 0.69 -7, 4.66 
rs2227395 PC NHW 2284 1.05 2.13 0.62 -3.12, 5.22 
rs2227395 PC NHB 1625 2.40 3.36 0.47 -4.18, 8.99 
rs2227409 PC MA 1664 Not tested 
rs2227409 PC NHW 2291 Not tested 
rs2227409 PC NHB 1628 -43.77 35.16 0.21 -112.73, 25.18 
rs2227425 PC NHW 2292 Not tested 
rs2227425 PC MA 1664 6.23 60.34 0.92 
-112.12, 
124.58 
rs2227425 PC NHB 1628 7.07 7.29 0.33 -7.22, 21.36 
rs2227434 PC NHB 1625 -37.06 43.04 0.39 -121.48, 47.35 
rs2227434 PC NHW 2289 -19.33 18.72 0.30 -56.05, 17.38 
rs2227434 PC MA 1664 5.31 27.02 0.84 -47.68, 58.3 
rs4220 PC NHB 1626 -5.91 3.73 0.11 -13.23, 1.41 
rs4220 PC MA 1660 -1.80 3.04 0.55 -7.75, 4.16 
rs4220 PC NHW 2279 1.79 2.21 0.42 -2.55, 6.13 
rs6050 PC NHB 1620 -1.89 2.21 0.39 -6.22, 2.44 
rs6050 PC NHW 2277 0.81 1.90 0.67 -2.91, 4.53 
rs6050 PC MA 1651 1.05 2.44 0.67 -3.73, 5.84 
rs6058 PC NHW 2292 0.33 22.92 0.99 -44.61, 45.27 
rs6058 PC NHB 1628 3.29 4.30 0.44 -5.13, 11.72 
rs6058 PC MA 1664 35.76 20.13 0.08 -3.72, 75.24 
rs6063 PC NHB 1628 -27.15 30.44 0.37 -86.85, 32.54 
rs6063 PC MA 1664 -18.24 20.14 0.37 -57.74, 21.27 
rs6063 PC NHW 2292 2.36 11.74 0.84 -20.66, 25.38 
rs1049636 PDW MA 1656 -0.02 0.02 0.33 -0.05, 0.02 
rs1049636 PDW NHB 1623 0.00 0.02 0.93 -0.05, 0.04 
rs1049636 PDW NHW 2277 0.01 0.01 0.34 -0.01, 0.04 
rs1800788 PDW MA 1649 -0.01 0.02 0.51 -0.06, 0.03 
rs1800788 PDW NHW 2274 0.01 0.02 0.53 -0.02, 0.04 
rs1800788 PDW NHB 1628 0.04 0.03 0.23 -0.03, 0.11 
rs1800791 PDW NHW 2276 -0.01 0.02 0.54 -0.05, 0.02 
rs1800791 PDW NHB 1623 0.02 0.03 0.55 -0.04, 0.08 
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rs1800791 PDW MA 1652 0.03 0.02 0.14 -0.01, 0.07 
rs1800792 PDW NHB 1628 -0.01 0.03 0.62 -0.06, 0.04 
rs1800792 PDW MA 1660 -0.01 0.02 0.76 -0.05, 0.03 
rs1800792 PDW NHW 2280 0.01 0.01 0.40 -0.01, 0.04 
rs2066860 PDW NHB 1627 -0.08 0.11 0.49 -0.3, 0.14 
rs2066860 PDW MA 1660 -0.03 0.08 0.68 -0.19, 0.12 
rs2066860 PDW NHW 2280 -0.01 0.03 0.77 -0.08, 0.06 
rs2066861 PDW MA 1654 -0.04 0.02 0.09 -0.08, 0.01 
rs2066861 PDW NHB 1622 -0.04 0.02 0.09 -0.08, 0.01 
rs2066861 PDW NHW 2279 0.03 0.02 0.07 0, 0.06 
rs2066874 PDW NHW 2283 -0.56 0.45 0.21 -1.44, 0.32 
rs2066874 PDW MA 1661 -0.14 0.54 0.79 -1.21, 0.92 
rs2066874 PDW NHB 1625 0.08 0.06 0.16 -0.03, 0.2 
rs2066879 PDW NHB 1628 -0.02 0.05 0.63 -0.12, 0.07 
rs2066879 PDW MA 1660 0.06 0.18 0.75 -0.3, 0.41 
rs2066879 PDW NHW 2285 0.77 0.32 0.02 0.15, 1.39 
rs2070006 PDW MA 1646 -0.03 0.02 0.09 -0.07, 0.01 
rs2070006 PDW NHB 1613 -0.01 0.02 0.50 -0.05, 0.03 
rs2070006 PDW NHW 2272 0.01 0.01 0.27 -0.01, 0.04 
rs2070008 PDW NHB 1628 0.00 0.03 0.98 -0.06, 0.06 
rs2070008 PDW NHW 2273 0.02 0.02 0.35 -0.02, 0.06 
rs2070008 PDW MA 1654 0.02 0.03 0.41 -0.03, 0.08 
rs2070009 PDW NHW 2268 -0.02 0.01 0.25 -0.04, 0.01 
rs2070009 PDW NHB 1619 0.00 0.02 0.94 -0.04, 0.04 
rs2070009 PDW MA 1650 0.04 0.02 0.07 0, 0.07 
rs2070011 PDW MA 1653 -0.03 0.02 0.08 -0.07, 0 
rs2070011 PDW NHB 1627 -0.01 0.02 0.73 -0.05, 0.04 
rs2070011 PDW NHW 2271 0.02 0.01 0.21 -0.01, 0.04 
rs2070017 PDW NHW 2284 -0.01 0.20 0.97 -0.4, 0.39 
rs2070017 PDW NHB 1624 0.05 0.03 0.11 -0.01, 0.11 
rs2070017 PDW MA 1661 0.06 0.11 0.59 -0.16, 0.29 
rs2070022 PDW NHW 2279 -0.01 0.02 0.69 -0.04, 0.03 
rs2070022 PDW NHB 1622 -0.01 0.03 0.75 -0.07, 0.05 
rs2070022 PDW MA 1646 0.03 0.02 0.09 -0.01, 0.07 
rs2070031 PDW NHW 2285 Not tested 
rs2070031 PDW MA 1661 -0.16 0.54 0.76 -1.23, 0.9 
rs2070031 PDW NHB 1628 0.17 0.12 0.16 -0.07, 0.41 
rs2070033 PDW NHW 2283 -0.04 0.17 0.80 -0.38, 0.29 
rs2070033 PDW NHB 1627 -0.02 0.04 0.61 -0.09, 0.06 
rs2070033 PDW MA 1661 0.09 0.13 0.49 -0.16, 0.34 
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rs2227395 PDW NHW 2276 -0.01 0.02 0.68 -0.04, 0.03 
rs2227395 PDW MA 1657 -0.01 0.03 0.80 -0.06, 0.05 
rs2227395 PDW NHB 1625 0.02 0.03 0.56 -0.04, 0.08 
rs2227409 PDW MA 1661 Not tested 
rs2227409 PDW NHW 2284 Not tested 
rs2227409 PDW NHB 1628 0.52 0.32 0.11 -0.11, 1.14 
rs2227425 PDW NHW 2285 Not tested 
rs2227425 PDW NHB 1628 -0.08 0.07 0.22 -0.21, 0.05 
rs2227425 PDW MA 1661 1.14 0.54 0.03 0.08, 2.21 
rs2227434 PDW NHW 2282 -0.25 0.16 0.11 -0.56, 0.06 
rs2227434 PDW MA 1661 0.02 0.24 0.94 -0.46, 0.5 
rs2227434 PDW NHB 1625 0.36 0.39 0.36 -0.41, 1.13 
rs4220 PDW NHW 2272 0.00 0.02 0.83 -0.04, 0.03 
rs4220 PDW MA 1657 0.01 0.03 0.84 -0.05, 0.06 
rs4220 PDW NHB 1626 0.04 0.03 0.20 -0.02, 0.11 
rs6050 PDW NHW 2270 -0.03 0.02 0.04 -0.06, 0 
rs6050 PDW NHB 1620 -0.01 0.02 0.52 -0.05, 0.03 
rs6050 PDW MA 1649 0.04 0.02 0.09 -0.01, 0.08 
rs6058 PDW NHB 1627 -0.03 0.04 0.40 -0.11, 0.04 
rs6058 PDW NHW 2285 -0.02 0.18 0.93 -0.38, 0.34 
rs6058 PDW MA 1661 0.19 0.17 0.26 -0.14, 0.53 
rs6063 PDW MA 1661 0.05 0.18 0.80 -0.31, 0.4 
rs6063 PDW NHW 2285 0.06 0.09 0.54 -0.13, 0.24 
rs6063 PDW NHB 1628 0.61 0.28 0.03 0.06, 1.15 
rs1049636 WBC MA 1680 -0.04 0.07 0.58 -0.17, 0.1 
rs1049636 WBC NHW 2307 -0.02 0.07 0.82 -0.16, 0.13 
rs1049636 WBC NHB 1654 0.02 0.08 0.78 -0.14, 0.18 
rs1800788 WBC NHB 1659 -0.10 0.12 0.42 -0.34, 0.14 
rs1800788 WBC MA 1674 0.02 0.08 0.80 -0.14, 0.18 
rs1800788 WBC NHW 2304 0.11 0.09 0.22 -0.07, 0.29 
rs1800791 WBC NHB 1654 -0.14 0.11 0.20 -0.35, 0.08 
rs1800791 WBC MA 1677 0.01 0.08 0.93 -0.15, 0.16 
rs1800791 WBC NHW 2306 0.01 0.10 0.93 -0.18, 0.2 
rs1800792 WBC NHB 1659 -0.01 0.09 0.89 -0.2, 0.17 
rs1800792 WBC MA 1685 0.07 0.08 0.34 -0.08, 0.22 
rs1800792 WBC NHW 2310 0.09 0.07 0.19 -0.04, 0.23 
rs2066860 WBC NHB 1658 0.01 0.41 0.97 -0.8, 0.82 
rs2066860 WBC NHW 2310 0.04 0.18 0.81 -0.31, 0.4 
rs2066860 WBC MA 1685 0.07 0.30 0.81 -0.51, 0.65 
rs2066861 WBC NHB 1653 -0.03 0.08 0.71 -0.18, 0.12 
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rs2066861 WBC MA 1679 0.02 0.08 0.82 -0.14, 0.18 
rs2066861 WBC NHW 2309 0.11 0.08 0.19 -0.05, 0.27 
rs2066874 WBC NHW 2313 -3.38 2.38 0.16 -8.06, 1.29 
rs2066874 WBC NHB 1656 0.06 0.22 0.77 -0.37, 0.49 
rs2066874 WBC MA 1686 2.19 2.03 0.28 -1.8, 6.18 
rs2066879 WBC NHB 1659 0.29 0.18 0.11 -0.07, 0.64 
rs2066879 WBC NHW 2315 0.33 1.69 0.84 -2.97, 3.63 
rs2066879 WBC MA 1685 0.48 0.68 0.48 -0.85, 1.81 
rs2070006 WBC NHB 1644 -0.05 0.07 0.53 -0.19, 0.1 
rs2070006 WBC NHW 2302 0.03 0.07 0.68 -0.11, 0.17 
rs2070006 WBC MA 1671 0.03 0.07 0.71 -0.11, 0.17 
rs2070008 WBC MA 1679 -0.04 0.11 0.72 -0.24, 0.17 
rs2070008 WBC NHB 1659 0.05 0.11 0.66 -0.17, 0.27 
rs2070008 WBC NHW 2303 0.07 0.10 0.52 -0.14, 0.27 
rs2070009 WBC NHW 2298 -0.05 0.07 0.52 -0.19, 0.09 
rs2070009 WBC MA 1675 -0.02 0.07 0.74 -0.16, 0.12 
rs2070009 WBC NHB 1650 0.06 0.07 0.42 -0.08, 0.2 
rs2070011 WBC NHB 1658 -0.11 0.08 0.20 -0.26, 0.05 
rs2070011 WBC MA 1678 0.02 0.07 0.75 -0.12, 0.16 
rs2070011 WBC NHW 2301 0.03 0.07 0.67 -0.11, 0.17 
rs2070017 WBC NHW 2314 -0.66 1.07 0.54 -2.75, 1.44 
rs2070017 WBC NHB 1655 0.10 0.12 0.40 -0.13, 0.33 
rs2070017 WBC MA 1686 0.40 0.43 0.35 -0.44, 1.24 
rs2070022 WBC NHB 1653 0.02 0.11 0.85 -0.19, 0.23 
rs2070022 WBC NHW 2309 0.05 0.09 0.58 -0.13, 0.23 
rs2070022 WBC MA 1671 0.06 0.07 0.45 -0.09, 0.2 
rs2070031 WBC NHW 2315 Not tested 
rs2070031 WBC MA 1686 -0.59 2.04 0.77 -4.6, 3.41 
rs2070031 WBC NHB 1659 -0.28 0.42 0.51 -1.1, 0.55 
rs2070033 WBC NHB 1658 -0.12 0.14 0.40 -0.39, 0.15 
rs2070033 WBC NHW 2313 -0.09 0.90 0.92 -1.86, 1.68 
rs2070033 WBC MA 1686 -0.04 0.48 0.94 -0.98, 0.91 
rs2227395 WBC MA 1682 -0.23 0.10 0.02 -0.43, -0.04 
rs2227395 WBC NHW 2306 0.01 0.09 0.87 -0.16, 0.19 
rs2227395 WBC NHB 1656 0.10 0.11 0.37 -0.12, 0.32 
rs2227409 WBC MA 1686 Not tested 
rs2227409 WBC NHW 2314 Not tested 
rs2227409 WBC NHB 1659 -1.27 1.18 0.28 -3.6, 1.05 
rs2227425 WBC NHW 2315 Not tested 
rs2227425 WBC NHB 1659 -0.05 0.24 0.84 -0.53, 0.43 
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rs2227425 WBC MA 1686 0.85 2.04 0.68 -3.14, 4.84 
rs2227434 WBC NHW 2312 -0.25 0.80 0.75 -1.81, 1.31 
rs2227434 WBC NHB 1656 0.23 1.45 0.87 -2.61, 3.08 
rs2227434 WBC MA 1686 0.39 0.91 0.67 -1.4, 2.17 
rs4220 WBC MA 1682 -0.28 0.10 0.01 -0.48, -0.08 
rs4220 WBC NHW 2302 -0.03 0.09 0.73 -0.22, 0.15 
rs4220 WBC NHB 1657 0.07 0.13 0.58 -0.18, 0.31 
rs6050 WBC NHW 2300 -0.08 0.08 0.32 -0.24, 0.08 
rs6050 WBC MA 1673 -0.01 0.08 0.88 -0.17, 0.15 
rs6050 WBC NHB 1651 0.00 0.07 0.98 -0.15, 0.14 
rs6058 WBC MA 1686 -0.66 0.65 0.31 -1.92, 0.61 
rs6058 WBC NHB 1658 -0.05 0.14 0.75 -0.32, 0.23 
rs6058 WBC NHW 2315 0.54 0.97 0.58 -1.37, 2.45 
rs6063 WBC MA 1686 0.25 0.68 0.72 -1.09, 1.58 
rs6063 WBC NHW 2315 0.43 0.50 0.39 -0.55, 1.41 
rs6063 WBC NHB 1659 0.64 1.03 0.53 -1.37, 2.65 
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Appendix Q. Candidate SNPs list for replication of GWAS-identified variants in 
combined NHANES dataset. Below is a list of SNPs proposed for genotyping for 
section B in Chapter III. Candidate SNPs had to be either previously identified by a 
genome-wide association study or well-characterized in the literature by candidate gene 
studies. SNPs also had to be associated with fibrinogen or hematological related traits. 
Abbreviations: MPV= mean platelet count, FB = fibrinogen, MCH = mean corpuscular 
hemoglobin concentration, RBC = red blood cell count, MPC = mean platelet count, PC 
= platelet count, WBC = white blood cell count, AfAms= African Americans, GWAS = 
genome-wide association study, CG = candidate gene study, NR= not reported, CAF= 
Coded Allele Frequency. 
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SNP Gene Phenotype Population CAF p-value Study 
design 
PubMed 
ID 
rs7961894 WDR66 MPV Europeans 0.12 7.24x10-
48 
GWAS 19110211 
rs12485738 ARHGEF3 MPV Europeans 0.36 3.81x10-
27 
GWAS 19110211 
rs2138852 TAOK1 MPV Europeans 0.49 7.19x10-
28 
GWAS 19110211 
rs2070016 FGA FB Europeans NR 1.00E-
03 
CG 16706972 
rs1800790 FGB FB Europeans NR <0.001 CG 16706972 
rs2227421 FGB FB Europeans NR 4.00E-
03 
CG 16706972 
rs2070017 FGA FB AfAms NR 3.00E-
03 
CG 16706972 
rs1800792 FGB FB AfAms NR 2.00E-
02 
CG 16706972 
rs2066874 FGG FB AfAms NR 6.00E-
03 
CG 16706972 
rs1800789 FGB FB Europeans NR 1.75E-
30 
GWAS 20031576 
rs2522056 IRF1 FB Europeans NR 1.30E-
15 
GWAS 20031576 
rs511154 PCCB FB Europeans NR 5.99E-
10 
GWAS 20031576 
rs1539019 near NLRP3 FB Europeans NR 1.00E-
08 
GWAS 20031576 
rs342293 Intergenic MPV Europeans 0.46 1.08E-
24 
GWAS 19221038 
rs5756506 TMPRSS6 MCH Europeans NR 1.2E-6 GWAS 19820697 
rs11970772 BYSL/CCND3 RBC Europeans NR 4.7E-7 GWAS 19820697 
rs1800562 HFW RBC Europeans NR 5.9E-11 GWAS 19820697 
rs9609565 FBX07 RBC Europeans NR 8.2E-7 GWAS 19820697 
rs9402686 HBS1L-MYB RBC Europeans NR 9.1E-17 GWAS 19820697 
rs7385804 TFR2 RBC Europeans NR 4.7E-6 GWAS 19820697 
rs10914144 DNM3 MPC Europeans NR 2.9E-7 GWAS 19820697 
rs11071720 TPM1 MPC Europeans NR 6.5E-7 GWAS 19820697 
rs11602954 BET1L MPC Europeans NR 1.9E-6 GWAS 19820697 
rs12485738 ARHGEF3 MPC Europeans NR 1.5E-8 GWAS 19820697 
rs1668873 TMCC2 MPC Europeans NR 3.3E-10 GWAS 19820697 
rs2138852 TAOK1 MPC Europeans NR 2.5E-9 GWAS 19820697 
rs2393967 JMJD1C MPC Europeans NR 2.3E-8 GWAS 19820697 
rs342293 PIK3CG MPC Europeans NR 6.8E-13 GWAS 19820697 
rs6136489 SIRPA MPC Europeans NR 1.3E-6 GWAS 19820697 
rs674316 EHD3 MPC Europeans NR 7.4E-8 GWAS 19820697 
rs7961894 WDR66 MPC Europeans NR 8.2E-19 GWAS 19820697 
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rs893001 CD226 MPC Europeans NR 8.3E-8 GWAS 19820697 
rs11065987 ATXN2 PC Europeans NR 8.3E-9 GWAS 19820697 
rs11066301 PTPN11 PC Europeans NR 2.3E-9 GWAS 19820697 
rs210135 BAK1 PC Europeans 0.12 2.6E-7 GWAS 19278955 
rs385893 AK3 PC Europeans NR 5.6E-7 GWAS 19820697 
rs17609240 GSDMA WBC Europeans NR 1.2E-6 GWAS 19820697 
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Appendix R. Minor allele frequency comparison for SCN5A SNPs in NHANES III 
populations and Jackson Heart Study To compare allele frequencies, we calculated Fst 
for all SCN5A SNPs, comparing each NHANES III sub-population studied and African 
Americans to the Jackson Heart Study. Abbreviations: minor allele frequency (MAF), 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP Alleles 
Minor 
Allele 
MAF 
Jackson 
Heart 
Study 
(n = 
3054) 
MAF 
non-
Hispanic 
whites 
(n~1150) 
MAF 
Mexican 
Americans 
(n~620) 
JHS 
vs. 
NHW 
Fst 
JHS 
vs. 
MA 
Fst 
rs7374138 C/G G 0.23 0.16 0.19 0.045 0.050 
rs7637849 G/A A 0.21 <0.01 0.03 0.019 0.004 
rs11129796 C/T T 0.15 0.05 0.04 0.051 0.037 
rs7629265 C/T T 0.08 0.003 0.01 0.015 0.125 
rs6768664 A/C C 0.36 0.46 0.45 0.061 0.053 
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